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Abstract 
Melanin concentrating hormone (MCH) is an orexigenic neuropeptide 
expressed centrally in the zona incerta and lateral hypothalamus.   Evidence 
from rodent studies implicates hypothalamic MCH in the modulation of varied 
and diverse physiological functions most notably in energy homeostasis but 
also emerging as a candidate mediator in reproductive activities.  These two 
aspects of normal physiology are intimately related though the pathways 
through which they integrate are only just being explored.  Currently little is 
known about the actions, sources or targets of peripheral or circulating MCH.  
This study is the first to describe normal physiological concentrations of 
circulating MCH in humans.  Particular emphasis has been devoted to 
aspects which might further understanding of the dual roles of circulating 
MCH in energy balance and reproductive function.  A primary objective was 
to develop and validate a tool with which to quantifiably measure circulating 
MCH concentrations since previous work in this area has failed to reconcile 
this objective. Following the successful validation of a radioimmunoassay 
(RIA), three studies were undertaken with human subjects drawn from 3 
distinct sample populations. The chief objectives were 1) to detect changes in 
circulating MCH post-prandial in association with other metabolic markers of 
energy homeostasis; 2) to determine associations between circulating MCH 
concentrations and resting metabolic rate (RMR); and 3) to detect changes in 
circulating MCH concentrations during the menstrual cycle.  The results 
indicate that circulating MCH concentrations may be involved in glucose 
homeostasis since there were associations between the post-prandial MCH 
and the post-prandial insulin response.  Circulating MCH may also convey 
information regarding the nutritional status of the individual, though this 
appears to be influenced by a combination of gender and adiposity status. 
Circulating MCH concentrations remained stable over the course of the 
menstrual cycle and were not strongly aligned to RMR. Whilst there were 
emergent patterns and trends there were also inconsistencies between the 
sample populations.  This initial characterisation may be constructive for 
future exploration of the physiological relevance of circulating MCH in 
humans. 
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1.   Introduction 
 
1.1 Aims of the research 
The original research presented in the thesis was designed to develop and 
validate a novel radioimmunoassay with which to measure and hence 
describe normal circulating MCH concentrations in discrete human 
populations under both similar and differing conditions.  This preliminary 
characterisation of the normal patterns of MCH in circulation may serve as a 
prelude to the further exploration of the physiological relevance of circulating 
MCH in humans. 
These aims were addressed by the following objectives: 
1. To confirm that MCH is quantifiably and reliably measurable in human 
plasma. 
2. To establish normal reference ranges for circulating MCH 
concentrations in humans. 
3. To determine whether circulating MCH is a bio-marker of adiposity in 
humans.  
4. To explore associations between circulating MCH concentrations and 
energy expenditure and energy intake. 
5. To determine associations between circulating MCH concentrations 
and circulating metabolic markers of energy homeostasis and 
reproductive function.  
 
1.2 Structure of the thesis 
The thesis comprises one chapter which describes the development and 
validation of a radioimmunoassay to measure circulating MCH concentrations 
in humans (Chapter 4), and three chapters (5, 6, & 7) which describe 3 
studies undertaken with 3 different populations of human subjects.  The key 
objectives of the study described in Chapter 5 were to establish a reference 
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range for circulating MCH concentrations in young healthy adults and to 
determine associations between circulating MCH concentrations and RMR.  
The key objective of the study described in Chapter 6 was to investigate the 
post-prandial MCH response to feeding in association with circulating blood 
glucose and plasma insulin and leptin concentrations in an older cohort of 
subjects (40+ yrs).  In the study described in Chapter 7 changes in circulating 
MCH concentrations were investigated in association with circulating 
progesterone and leptin concentrations over the course of one menstrual 
cycle in a group of normally cycling women.  The findings of all four studies 
are synthesised in Chapter 8.   
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2.   Review of the literature 
 
2.1 Abstract 
Melanin concentrating hormone (MCH) is a comparatively recently 
discovered anabolic neuropeptide with multiple and diverse physiologic 
functions including a key role in energy homeostasis. Rodent studies have 
shown that ablation of functional MCH results in a lean phenotype, increased 
energy expenditure and resistance to diet-induced obesity.  These findings 
have generated interest amongst pharmaceutical companies vigilant for 
potential anti-obesity agents.  Nutritional status impacts on reproductive 
physiology and behaviours thereby optimising reproductive success and the 
ability to meet energetic demands.  This complex control system entails 
integration of direct or indirect peripheral stimuli with central effector systems 
and involves numerous mediators.  Recently a role for MCH in the 
reproductive axis has emerged giving rise to the premise that MCH may 
serve as an integratory mediator between those discrete systems which 
regulate energy balance and reproductive function. Hence this review 
focuses on published evidence concerning a) the role of MCH in energy 
homeostasis  b) the regulatory role of MCH in the reproductive axis.  The 
question as to whether the MCH system mediates the integration of energy 
homeostasis with the neuroendocrine reproductive axis and if so by what 
means has received limited coverage in the literature, evidence to date and 
current theories are summarised here.   
2.2 Introduction 
Energy balance is inextricably linked to reproduction: the ability to monitor 
both internal and external energy availability and consequently to modulate 
reproductive behaviours confers a species-wide reproductive advantage 
(Schneider, 2004). In times of energetic scarcity survival of the individual 
takes precedence over an essentially deferrable and energy costly activity, 
such as  reproduction.  Suppressed ovulatory cycles may be evidenced in 
female mammals and in humans self-imposed severe food restriction may 
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result in persistent amenorrhea (Wade and Jones, 2004). The deleterious 
consequences of obesity on reproductive function both in terms of ovulatory 
dysfunction and prenatal complications have been well documented 
(Loveland et al., 2001; Pasquali et al., 2003; Lashen et al., 2004).  These 
manifestations of impaired reproductive function both in the obese and in the 
under-nourished are unsurprising from an evolutionary point of view which 
propounds survival of the fittest.  Hence those mechanisms which control 
reproductive function and nutritional status must be functionally linked 
(Schneider, 2004). Nevertheless in mammals these links are complex and 
incompletely understood (Gosman et al., 2006), though it has been argued 
that it is energy balance and the availability of oxidisable fuels rather than fat 
mass per se which are the critical determinants of fertility status (Wade and 
Jones, 2004).   
Understanding of the central regulation of energy homeostasis has advanced 
considerably since Stellar’s (1954) identification of hypothalamic satiety and 
hunger centres more than half a century ago.  The discovery of leptin in the 
early 1990s (Zhang et al., 1994) was hailed as a breakthrough in the 
regulation of body weight. Originally characterised as an anti-obesity 
hormone (Hamman and Matthaei, 1996), the precise physiological role of 
leptin is now known to be more complex and its interactions with numerous 
metabolic modulators are widespread (Moschos et al., 2002).  A consenus 
viewpoint has arisen in which peripheral signals relating to the nutritional 
status of the individual are centrally integrated and efferent pathways (such 
as, the neuropeptide Y and agouti related protein (NPY/AGRP) system) 
respond to maintain energy homeostasis via modulation of appetite and 
energy expenditure (for review see Schwartz et al., 2000). Recently several 
hormones and neuropeptides with the potential to link energy balance to 
reproductive function have been identified (Schneider, 2004).  One such 
neuropeptide is melanin concentrating hormone . 
Originally characterised as a circulating hormone modulating the skin colour 
of teleost fish (Kawauchi et al., 1983), mammalian MCH was subsequently 
identified in rat hypothalamic tissue (Vaughan et al., 1989).  The amino acid 
sequence of MCH has been found to be identical in all mammals analysed 
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thus far, notably humans, rats and mice (Nahon et al., 1989; Thompson and 
Watson, 1990; Presse et al., 1990; Breton et al., 1993).  Centrally the 
neuropeptide is expressed primarily in the lateral hypothalamic area and 
rostral zona incerta/incerto-hypothalamic area (Bittencourt et al., 1992; Sita 
et al., 2007): two areas known to be critically involved in the regulation of 
feeding behaviours (for review see Schwartz et al., 2000).   The orexigenic 
properties of MCH were first proposed in 1996 (Qu et al., 1996), although the 
findings of a number of subsequent studies suggest that  the anti-obesogenic 
effects of MCH antagonism are mediated through its impact on appetite 
regulation secondary to its effects on energy expenditure and altered 
metabolism (Shimada et al., 1998; Chen et al., 2002; Marsh et al., 2002; 
Segal-Lieberman et al., 2003).   
The physiological functions of MCH are not restricted to energy metabolism. 
MCH and its receptors are implicated in the modulation of complex 
behaviours such as those involved in motivation and reward (Saito et al., 
1999; Saito et al., 2001; Saper et al., 2002), stress response, affective states 
(Smith et al., 2006), anxiety and depression (for review see Dyck, 2005).  Of 
particular interest to this review are the effects of MCH on the female 
reproductive axis.  To date the known effects are largely those associated 
with the central effects of MCH on the regulation of luteinising hormone (LH) 
release (Gonzalez et al., 1997; Murray et al., 2000a; Chiocchio et al., 2001; 
Williamson-Hughes et al., 2005; Murray et al., 2006).  Little is known about its 
impact on target reproductive organs though disruption of normal 
gonadotrophin releasing hormone (GnRH) activity produces a cascade of 
effects throughout the entire reproductive axis (for review see Schneider, 
2004).  There are conflicting reports in the literature regarding the 
reproductive consequences of deletion of either MCH or its receptor 
(Shimada et al., 1998; Alon and Friedman, 2006).  Hence this review will 
focus on published evidence concerning the dual roles of MCH in those 
discrete yet overlapping systems which modulate energy balance and 
reproductive function. The intriguing question as to whether the MCH system 
plays a role in the integration of energy homeostasis with the neuroendocrine 
reproductive axis and if so by what means has received limited coverage in 
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the literature (Smith and Grove, 2002, Williamson-Hughes et al., 2005; Yang 
et al., 2005) and current theories/evidence to date will be summarised here.   
 
2.3 MCH, appetite regulation and energy expenditure 
The pharmaceutical industry is currently very interested in targeting the MCH 
system as a potential therapeutic in the treatment of obesity because of its 
regulatory role on eating behaviours and energy expenditure.  Of particular 
relevance are studies which report that deletion of either the MCH gene or 
the MCH receptor (MCHR-1) results in resistance to diet-induced obesity 
(Chen et al., 2002; Kokkotou et al., 2005; Mashiko et al., 2005;).  Although 
two MCH receptor sub-types have been identified in humans (designated 
MCHR-1 and MCHR-2), research to date has focussed on MCHR-1 since 
MCHR-1 has not been detected in rodents (Tan et al., 2002).  Consequently 
research into the physiological relevance of MCHR-1 has been limited.  The 
majority of preliminary intervention studies have been undertaken using 
rodent models and their relevance to human populations remains to be seen.  
For a review of factors pertinent to the interpretation and extrapolation of the 
results of rodent experiments see Young and Kirkland (2007). A summary of 
the results of the key studies is presented in Table 1.  
Whilst the MCH system is unquestionably involved in the control of food 
intake, the specific effects of MCH administration or ablation are somewhat 
diverse depending upon empirical methods.  Variations in diet, genetic 
background and environment may all contribute to the miscellaneous effects 
of MCH on eating behaviours and phenotype which have been reported in 
the literature.  Chronic intracerebroventricular (ICV) infusion of MCH 
produced no difference in food intake and slightly increased body weight in 
mice maintained on a regular diet, whilst hyperphagia and substantially 
increased body weight were observed in those maintained on a high fat diet 
(Gomori et al., 2002).  Chronic ICV infusion of an MCHR-1 antagonist 
produced differing effects on food intake and phenotype depending on the 
genetic background of the animal (Mashiko et al., 2005).  Kokkotou and 
colleagues (2005), also reported that the effects of MCH ablation were strain-
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specific.  MCH-/- mice generated from an obesity-prone strain and from an 
obesity-resistant strain gained less weight and exhibited reduced fat mass on 
both high fat diets and regular chow than their wild-type counterparts.  These 
results were amplified in the obesity-resistant strain which gained 
substantially less weight and exhibited increased energy expenditure when 
maintained on a high fat diet.   
In agreement with the proposed influence of MCH on the reward aspect of 
feeding, Morens and colleagues (2005) reported that an MCHR-1 antagonist 
significantly reduced consumption of highly palatable food.  This 
phenomenon may be partly explained by evidence of MCHR-1 expression in 
the arcuate nucleus, olfactory pathway and nucleus of the solitary tract of the 
CNS, suggesting a role for MCH in the integration of gustatory and olfactory 
sensory input (Kokkotou et al., 2001; Saito et al., 2001).  Sakamaki et al. 
(2005) reported enhanced sucrose though not saccharin intake in MCH-
treated rats (ICV injection). In contrast Baird and colleagues (2008) found 
that hindbrain administration of MCH produced no increase in licking for 
water, sucrose or saccharin. Similarly Zheng and colleagues (2005) reported 
that hindbrain infusions of MCH produced no effect on either food or water 
intake. Therefore it would appear that the orexigenic properties of MCH 
require forebrain input and that the MCH response to palatable food is 
related to the nutritive value of the food as well as to the hedonic aspects of 
feeding.  Taken together these studies serve to illustrate the modal diversity 
through which MCH may exert its control on eating behaviours. They also 
exemplify the complexities of the neural control of ingestive behaviours and 
the essential contribution to energy homeostasis of indirect controls of 
feeding behaviours as first proposed by Smith (1996).   
Results of genetic studies appear to consolidate the putative contribution of 
the MCH system to energy balance. Mice over-expressing the MCH gene in 
the lateral hypothalamus displayed a tendency to hyperphagia, obesity and 
impaired glucose homeostasis (Ludwig et al., 2001).  Ablation of the MCH 
gene led to hypophagia, increased metabolic rate and reduced body mass 
(Shimada et al., 1998). In contrast disruption of the MCH receptor resulted in 
hyperphagia with a lean phenotype due to increased energy expenditure 
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(Chen et al., 2002).  It has been suggested that these differences in feeding 
behaviour may be attributable to ablation of NEI and NGE (in the MCH 
knockout (k/o) model), two distinct peptides which are cleaved from prepro-
MCH (Pissios and Flier, 2003; Segal-Lieberman et al., 2003).  Whether or not 
this is the case commonality in these studies is manifest in the reported 
effects of MCH on energy expenditure.  A lack of consistency in terms of the 
effect of MCH administration/ablation on eating behaviours contrasts with the 
reported uniformity of its effects on energy expenditure.  In those studies 
reporting on energy expenditure where functional MCH or its receptor were 
ablated, all report that the animals demonstrated increased energy 
expenditure, some resulting from increased metabolic rate, others from 
increased locomotor activity or both.  This property of MCH was clearly 
demonstrated by Segal-Lieberman and colleagues (2003).  MCH expression 
is up-regulated in ob/ob mice lacking the leptin gene. Reasoning that MCH 
ablation in these mice would lead to reduced feeding and attenuate the 
obese phenotype, double-null animals were bred. Interestingly feeding 
behaviour was not affected: hyperphagia persisted in these animals even 
though body weight and fat mass were notably reduced.  Increased energy 
expenditure was evidenced by elevated oxygen consumption and locomotor 
activity, improved thermogenesis and an increase in the expression of 
uncoupling protein-1 (UCP-1).  The characteristic lean phenotype induced by 
functional MCH ablation is noteworthy since this property appears to be 
atypical of other orexigenic mediators such as the orexins (Hara et al., 2005), 
NPY and AGRP (for reviews see Lin et al., 2004; Flier, 2006) and serves to 
underline the distinctive role of MCH in energy conservation. 
The propensity to conserve energy is more vigorously defended by the 
human organism than are those responses that resist obesity. In recent years 
our understanding of the mechanisms which control energy balance has 
deepened and the role of the hypothalamus as an integrative centre of both 
centrally and peripherally derived signals reflecting energy intake and stores 
has become apparent (for review see Schwartz et al., 2000).  Whilst initial 
studies have generated a solid body of evidence implicating a key position for 
MCH in the systemic regulation of energy homeostasis, specifically as a 
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promoter of positive energy balance, the specific molecular pathways through 
which it mediates its effects are yet to be fully elucidated.   Evidence that 
MCH may be a modulator of autonomic nervous system activity has been 
reported (Astrand et al., 2004; Messina and Overton, 2007).   Increased 
basal heart rate which was independent of increased dark-phase body 
temperature and locomotor activity were observed in MCH-/- mice.  These 
mice were also leaner and more resistant to diet-induced obesity than their 
wild-type counterparts.  A switch to predominance of sympathetic over 
parasympathetic activity in MCHR-1 deficient mice lead to speculation that 
MCH is a significant regulator of autonomic nervous system control (Astrand 
et al., 2004).  In broad concord with these findings two recent studies found 
that centrally administered MCH induced bradycardia and reduced mean 
arterial pressure in rodents (Brown et al., 2007; Messina and Overton, 2007).  
In the former study MCH was injected into the Nucleus Tractus Solitarius 
(NTS) whilst in the latter chronic ICV infusion not only induced the 
bradycardic and hypotensive response but the customary tachycardia which 
occurs in the dark-phase feeding was suppressed by acute infusion of MCH 
at a dose which would normally promote hyperphagia for 2 – 4 hours.  
Therefore the tandem consequences of acute MCH administration would 
appear to be consistent with energy conservation. Taken together these 
studies suggest that MCH is involved in the tonic suppression of sympathetic 
nervous system activity, though these results were inconsistent with earlier 
similar chronic infusion work with sheep (Parkes, 1996). 
The production of uncoupling proteins in skeletal muscle and adipose tissue 
increases metabolic rate by inhibiting adenosine triphosphate (ATP) 
production thereby enhancing the rate of cellular respiration. There is some 
evidence that the production of uncoupling proteins in adipose tissue may be 
associated with MCH activity.  Uncoupling protein-1, expressed in brown 
adipose tissue (BAT) in rodents stimulates thermogenesis by increased 
cellular respiration and heat production (Nicholls and Locke, 1984).  Reports 
of reduced UCP-1 mRNA activity following chronic MCH ICV infusion and 
elevated UCP-1 expression in MCH-/- models may provide mechanistic 
evidence of the metabolic effects of MCH (Ito et al., 2003; Segal-Lieberman 
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et al., 2003).  In cold-exposed rats blockade of MCH lead both to increased 
BAT mass and UCP-1 expression; the magnitude of those increases were 
significantly greater than those induced by cold in intact rats.  Hence in these 
conditions loss of functional MCH appears to result in the dysregulation of 
thermogenic mechanisms involved in energy expenditure (Pereira-da-Silva et 
al., 2003).  Consistent with these observations sympathetic innervation of 
BAT originates in particular hypothalamic regions including the MCH-rich 
LHA (Oldfield et al., 2002).  Presumed MCH-mediated lipogenesis in liver 
and white adipose tissue  following chronic MCH infusion, in addition to 
reduced expression of 2 key enzymes in the beta-oxidation pathway (Ito et 
al., 2003) would appear to augment the obesity-inducing effects of  MCH. 
Given the reported impact of MCH on both autonomic nervous activity and 
uncoupling activity in adipose tissue it would seem logical to investigate the 
presence of any neurochemical link between the MCH system and the 
adrenergic system, the latter being responsible for lipolysis in adipose tissue.  
However there is little published work in this area. In rat hypothalamic slices 
Bayer and colleagues (2005) report a hyperpolarising effect of noradrenaline 
on MCH neurones.  Since the MCH-rich lateral hypothalamus receives inputs 
from noradrenergic neurones this group speculates that this inhibitory effect 
may be responsible for decreased energy expenditure due to diminished 
arousal and activity.  More recently Kerman and colleagues (2007) mapped a 
group of pre-sympathetic premotor neurons which project polysynaptically to 
both skeletal muscle and adrenal gland and were thus hypothesised to have 
both autonomic and somatomotor functions.  This group identified a distinct 
population of neurons which express MCH giving rise to the premise that 
MCH may be active in the co-ordinated response between skeletal muscles 
and autonomic activity in stress situations.  This hypothesis is similar to the 
one proposed by Brown and colleagues (2007), (study discussed earlier), 
their finding that microinjections of MCH into the NTS induced bradycardic 
and depressor responses but that injection of a potent antagonist alone 
produced no response provoked the suggestion that MCH may only be 
released into the NTS in particular conditions, such as in stress situations 
when MCH would increase parasympathetic activity in order to negate the 
Chapter 2. Review of the literature 
11 
 
deleterious effects of stress.  Clearly such lines of enquiry require further 
investigation before more robust conclusions can be drawn but studies like 
these serve to highlight the extent of understanding yet to be gained 
regarding the MCH system.  
Somewhat surprisingly given the metabolic significance of the MCH system 
only one study to date has examined the role of this peptide in the thyroid 
axis.  In vivo plasma thyroid stimulating hormone (TSH) concentrations were 
reduced following ICV injection of MCH.  In vitro both MCH and NEI were 
reported to inhibit release of thyrotropin releasing hormone (TRH) from 
hypothalamic explants.  MCH did not affect basal TSH release from 
dispersed pituitary cell cultures though it did significantly inhibit TRH 
stimulated release of TSH from these cell lines (Kennedy et al., 2001).  
Without further investigation the significance of these findings is limited 
though initial conjecture would point to a role for MCH in the maintenance of 
energy homeostasis via this circuit.    
Although MCH is centrally expressed, there is some evidence that it 
circulates both in rodent (Bradley et al., 2000; Stricker-Krongrad et al., 2001) 
and in humans (Gavrila et al., 2005).  However there has been some 
published debate concerning the validity of detection methods in the latter 
(Waters and Krause, 2005; Takahashi, 2005).  The physiological role of 
circulating MCH is unknown at present.  Prepro-MCH mRNA and MCH have 
also been reported in various peripheral tissues; for example, rodent 
stomach, intestine and testis (Hervieu and Nahon, 1995).  The MCH receptor 
(MCHR-1) has been detected in a limited range of tissues including skeletal 
muscle, eye, ovary and testis (for review see Schlumberger et al., 2002).  In 
humans, the MCH precursor has been identified in immune cells (Verlaet et 
al., 2002; Sandig et al., 2007) and MCH and its receptors transcripts have 
been detected in skin endothelia (Hoogduijn et al., 2002).  However the 
physiological relevance of peripherally derived MCH is largely unknown. Of 
particular relevance to this review, and in accord with the known effects of 
MCH on feeding behaviours, a growing body of evidence implicates both 
central and peripheral MCH in glucose homeostasis (Ludwig et al., 2001; 
Pereira-da-Silva et al., 2005; Pissios et al., 2007).   Short-term acute ICV 
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administration of MCH produced a dysregulation of glucose homeostasis; 
specifically, glucose intolerance, reduced glucose-stimulated insulin secretion 
and insulin resistance.  These phenomena were unrelated to fluctuations in 
body weight though they were accompanied by modulation of insulin signal 
transduction (Pereira-da-Silva et al., 2005).  Perhaps less compelling, aging 
MCH -/- mice did not develop insulin resistance and impaired glucose 
tolerance compared to wild-type controls but this effect may well have been 
secondary to their sustained lean phenotype, increased locomotor activity 
and basal metabolic rate (Jeon et al., 2006).  Enhanced insulin sensitivity 
was also observed in double null mice (MCHR-1 knockout ob/ob) compared 
to ob/ob controls (Bjursell et al., 2006), although both strains demonstrated 
comparable body weight gain, food intake, lipoprotein profile and energy 
expenditure.  Both were severely obese. However the double null animals 
had higher locomotor activity, lower percentage body fat and increased lean 
body mass which could partly explain the improved insulin and glucose 
response in the double null animals. Nevertheless the fact that both types 
were severely overweight and differences in body composition were relatively 
modest would suggest a role for the MCH receptor in the regulation of 
glucose homeostasis.  This conjecture is supported by a recent study which 
detected both MCH and its receptor in mouse and human pancreatic islets 
and in clonal β-cell lines (Pissios et al., 2007).  MCHR-1 was detected both in 
human and mouse islets though at comparatively low concentrations to that 
found in brain tissue, whilst substantially higher expression levels were 
detected in the β-cell line.  MCH was also detected and localised in both 
human and mouse islets. Although the authors do not report expression of 
MCH and MCHR-1 specifically from β-cells the inference is clearly 
suggestive of the presence of MCH on those cells.  Two further findings from 
this study are that: MCH k/o mice fed a high-fat diet demonstrated reduced β-
cell mass compared to controls, this is in contrast to mice over-expressing 
MCH which demonstrated islet hyperplasia (Ludwig et al., 2001); and 
exogenous MCH provoked increased insulin secretion both in cultured 
mouse and human islets and in mouse β-cell lines.  Taken together these 
findings indicate a broader physiological role for MCH in the systemic 
regulation of energy homeostasis which invites further scrutiny. 
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Table 2.1 Key mammalian MCH energy studies   
Reference Species/model Intervention 
Effect on 
food 
intake* 
 
Effect on 
energy 
expenditure 
(EE)/metabolic 
rate* 
Effect on 
phenotype* 
Increased availability of physiological MCH concentrations 
Qu et al., 
1996 
 
Long Evans Rat 
 
Acute ICV MCH 
infusion Hyperphagia NR NR 
Ludwig et al., 
2001 
Male MCH-OE mice 
(MCH 
overexpression) 
Genetic 
disruption, high 
fat diet 
Hyperphagia NR 
Increased body 
mass and 
adiposity 
Gomori et al, 
2002 
Male C57BL/6J 
mice 
Chronic ICV 
infusion of MCH 
(a) regular diet  
(b) high fat diet 
 
 
 
(a) 
No effect 
(b) 
Hyperphagia 
 
NR 
          (a) 
Slightly 
increased body 
weight 
(b) Substantially 
increased body 
weight and fat 
mass 
Santollo and    
Eckel, 2008 
Male/female Long 
Evans rats 
Chronic ICV 
infusion of MCH 
Hyperphagia 
greater in 
males than 
females 
↓ locomotor activity NR 
Decreased availability of physiological MCH concentrations 
Marsh et al., 
2002 
Male/female 
MCHR-1 -/-mice 
Genetic 
disruption Hyperphagia 
↑ EE secondary to ↑ 
motor activity 
Reduced fat 
mass, 
increased lean 
mass 
Chen et al., 
2002 
Male/female 
MCHR-1 -/-mice 
Genetic 
disruption Hyperphagia 
↑ EE in males, no 
difference in 
females 
Reduced fat 
mass, constant 
lean mass 
Mashiko et 
al., 2005 
Male diet-induced 
obese mice 
 
Chronic 
ICV infusion of 
MCHR-1 
antagonist 
Hypophagia NR 
Reduced body 
weight and 
adiposity 
Pereira-da-
Silva et al., 
2003 
Male Wistar rats 
MCH protein 
synthesis 
blockade, cold 
exposure 
No effect None 
Reduced body 
weight, 
increased fat  
mass, 
decreased lean 
mass 
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Reference Species/model Intervention 
Effect on 
food 
intake* 
Effect on 
energy 
expenditure 
(EE)/metabolic 
rate* 
Effect on 
phenotype* 
Bjursell et al., 
2006 
Male MCHR-1-/- 
ob/ob mice (double-
null) 
Genetic 
disruption 
Hyperphagia 
compared to 
WT but not 
to ob/ob 
↑locomotor activity 
but not EE 
compared to ob/ob 
Lower fat mass, 
increased lean 
mass compared 
to ob/ob but not 
to WT 
Kowalaski et 
al., 2006 
 
Male/female diet-
induced obese mice 
 
 
 
Short-term oral 
administration of 
MCHR-1 
antagonist 
 
Chronic oral 
administration of 
MCHR-1 
antagonist 
 
 
Hypophagia 
 
 
 
Hypophagia 
 
 
 
 
 
 
NR 
 
 
NR 
 
 
 
 
 
 
 
Reduced  body 
weight and fat 
mass 
 
Reduced  body 
weight and fat 
mass 
 
 
 
Endogenous MCH absent 
Shimada et 
al., 1998 
Male/female 
MCH-/- mice 
Genetic 
disruption Hypophagia ↑metabolic rate 
Reduced body 
weight and 
adiposity 
Segal-
Lieberman et 
al., 2003 
Male MCH-/- ob/ob 
mice (double-null) 
Genetic 
disruption 
Hyperphagia 
compared to 
WT no diff to 
ob/ob 
↑ EE compared to 
ob/ob 
Reduced body 
weight and 
adiposity 
Alon and 
Friedman, 
2006 
Male/female 
MCH/ataxin-3 
transgenic mice 
Genetic 
disruption None 
↑ EE in males, not 
females 
Late onset 
reduced body 
weight, 
adiposity 
length, lean 
mass 
Jeon et al., 
2006 
Male/female 
C57BL/6 MCH-/- 
mice 
Genetic 
disruption 
No 
significant 
difference 
↑ REE + locomotor 
activity 
Attenuation of 
weight gain 
Reduced fat 
mass 
* in comparison to controls, NR: Not reported, ICV: Intracerebroventricular, EE: Energy Expenditure, REE: resting 
energy expenditure WT: wild-type mice, ↑ increased, ↓ decreased 
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2.4 MCH and reproductive function 
Whilst the orexigenic effects of MCH have been well-documented, reports 
concerning the role of MCH in the reproductive axis have been less prolific.  
The female reproductive cycle is critically dependent on GnRH which 
stimulates the pulsatile release of LH.    Over the last decade several groups 
have investigated a potential role for MCH in the regulation of LH release 
either directly at the level of the pituitary or indirectly via stimulation of 
hypothalamic GnRH.  Early work indicated a stimulatory role for MCH on LH 
secretion when the peptide was injected into the hypothalamic medial 
preoptic area or median eminence of ovariectomised rats (Gonzalez et al., 
1997; Murray et al., 2000a).  However injection into the third ventricle using a 
different rat model inhibited LH release (Tsukamura et al., 2000).  Disparity in 
empirical methods including diverse oestrogenic milieu and sampling 
methods were proposed as possible explanations for the conflicting results 
(Tsukamura et al., 2000). Subsequent studies indicate that this neural control 
of LH release would appear to be both site-specific (within the hypothalamus) 
and oestrogen-status dependent.  Murray and colleagues (2006) report that 
MCH administration induced either a stimulatory or inhibitory effect on LH 
release depending on both the injection site and endocrine milieu of the rat 
model. 
In support of this work a potential neuroanatomical framework through which 
MCH may act to link energy balance to reproductive behaviours has been 
proposed and evidenced by the close apposition of MCH fibres to 
hypothalamic GnRH neurones (Smith and Grove, 2002; Williamson-Hughes 
et al., 2005), and by the detection of the MCH receptor mRNA in GnRH 
neurones (Williamson-Hughes et al., 2005).  The latter group reported that 85 
– 90% of GnRH neurones were in contact with MCH immuno-positive 
projections.  This is in agreement with a recent study, albeit in males, which 
reported 86% of hypothalamic GnRH neurones were in close apposition with 
MCH-immunoreactive fibres.  Some anatomical overlap was also observed 
between MCH-immunoreactive projections and GnRH neuroterminals in the 
median eminence (Ward et al., 2009).  In vitro Yang and others (2005) 
reported detection of MCHR-1 mRNA on GT1-7 cell lines (cell model of 
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hypothalamic GnRH neurones) indicating a functional role for MCH at GnRH 
nerve terminals though the stability of cultured lines should be considered.   
Chiocchio and colleagues (2001) reported a stimulatory effect on both LH 
and Follicle Stimulating Hormone  from pituitary explants but only in 
proestrous pituitaries.  MCH has also been reported to moderate production 
of other pituitary hormones in vitro, namely human and rodent growth 
hormone  (Segal-Lieberman et al., 2006) and rodent TSH (Kennedy et al., 
2001).  The detection of MCHR-1 in both human and rodent pituitary tissue 
further supports the significance of the MCH system in the hypothalamic-
pituitary-gonadal axis (Saito et al., 1999; Takahashi et al., 2001; Segal-
Lieberman et al., 2006).   
Speculation concerning a potential feedback loop involving oestrogen and 
MCH has been strengthened by the results of several recent studies. 
Conjecture that an oestrogen sensitive mechanism may be involved in the 
regulation of MCH gene expression has been investigated.  Murray and 
others (2000b) report that oestrogen treatment inhibited the expression of 
prepro-MCH cell bodies specifically in the medial zona incerta of 
ovariectomised female rats.  Similarly administration of 17-β estradiol 
depressed hypothalamic MCH gene expression in male rats (Mystkowski et 
al., 2000).  In ovariectomised primates oestrogen exposure provoked 
fluctuations in the synthesis of hypothalamic MCH and NEI which were 
coincidental with the LH surge indicating that MCH expression in the 
hypothalamus may be oestrogen dependent (Viale et al., 1999).  This notion 
of oestrogen/MCH cross-talk is also supported by evidence from in vitro 
studies which suggest that MCH activity is involved in cyclical GnRH release 
specifically at proestrous; that is, an oestrogen-rich milieu (Chiocchio et al., 
2001, Gallardo et al., 2004). However Murray and colleagues (2000b) report 
no difference in prepro MCH mRNA expression between ovariectomised and 
intact rats at either proestrous or dioestrous suggesting that the impact of 
other ovarian products in this context should also be evaluated.   Although 
MCH neurones do not express the oestrogen receptor there is considerable 
anatomical overlap in the distribution of oestrogen receptor (ERα) labelled 
cells and MCH neurones in the paraventricular nucleus, zona incerta and 
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lateral hypothalamus, which is suggestive of an indirect regulatory 
mechanism, possibly via an intermediary neurone or ligand which 
consequently modulates MCH neuronal activity (Muschamp and Hull, 2007).  
Speculation that MCH may be involved in the regulation of peripheral 
reproductive organ function is supported by the detection of the MCH 
receptor in human ovary, human testis  (Mori et al., 2001) and mouse testis 
(Kokkotou et al., 2001).  Additionally retrograde viral transneuronal tracing 
from the rat ovary resulted in the detection of virus-infected neurones in the 
MCH-rich lateral hypothalamus and zona incerta though with less intensive 
labelling than that observed in the paraventricular nucleus  (Gerandai et al., 
1998).  Whilst there appears to be a neuronal connection between MCH-
producing areas of the brain and the ovary and MCH mRNA has been 
detected in human and rat testis (Viale et al., 1999; Hervieu and Nahon, 
1995) a potential role for circulating MCH in the reproductive system has not 
been investigated.  
Clearly the neurocircuitry controlling the hypothalamic-pituitary-gonadal axis 
is complex and other neuromodulators are known to be involved: leptin, 
serotonin, dopamine and recently kisspeptin and NEI (cleaved from MCH 
precursor) for example have all been reported to stimulate gonadotropin 
release (Yu et al., 1997; Vitale et al., 1993; Mackenzie et al., 1984; Messager 
et al., 2005; Attademo et al., 2006).  Precisely where MCH fits into this 
neurocircuitry is yet to be defined though it has been proposed that leptin 
may act through MCH, since administration of MCH antisera into the medial 
preoptic area (mPOA) prevented an expected leptin-induced rise in LH.  
Additionally melanocortin 5-R antagonists previously shown to prevent the 
stimulatory effect of MCH on LH release exerted a similar effect on leptin 
when injected into the zona incerta (Murray et al., 2000c). 
To date the role of MCH in male reproductive physiology has been largely 
neglected.  Early work reported the detection of MCH mRNA at the periphery 
of testicular rat seminiferous tubules and in isolated mice Sertoli cells 
(Hervieu and Nahon, 1995), whilst a subsequent study localised these 
products in rodent immature germ cells, spermatagonia and early 
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spermatocytes (Hervieu et al., 1996). The latter group report similar staining 
in spermatagonia and early spermatocytes in the testicular tissue of a human 
adult (Hervieu et al., 1996). This line of enquiry however has not been 
pursued.   
 
2.5 MCH, energy balance and fertility 
The threat to human health imposed by the obesity epidemic continues to 
grow in England and the UK (NHS Information Centre, 2010) whilst both 
under and over-nutrition in developing and developed countries impacts 
negatively on reproductive health (ESHERE Capri Workshop Group, 2006).  
In the case of over-nutrition this applies to both male and female fertility.  
Adipose tissue is no longer regarded as merely an energy depot, rather it has 
emerged as an endocrine organ with an important regulatory function in 
energy homeostasis (Bradley et al., 2001; Ahima, 2006).  Dysregulation of 
adipose tissue (obesity) is a major risk factor in the development of chronic 
and potentially fatal health conditions, such as certain cancers, 
cardiovascular disease, hypertension, stroke and type 2 diabetes (WHO, 
2003).  On the other hand menstrual dysfunction, poor fecundity and 
pregnancy complications are consequences of malnutrition at either end of 
the energy balance spectrum whilst obesity is a risk factor for miscarriage 
(ESHERE Capri Workshop Group, 2006). 
To date the dual roles of MCH in energy homeostasis and reproductive 
function have been explored principally via animal models and in vitro work.  
The focus has been on hypothalamic MCH; the role of circulating MCH 
remains largely unexplored though as previously noted there is evidence that 
the peptide circulates both in rodent and in humans.  As discussed in 
Sections 2.3 and 2.4 it would appear that hypothalamic MCH is well placed to 
act as an interneurone participating in both energy and reproductive 
pathways since a) it lies downstream of mediobasal hypothalamic neurones 
responsive to changes in peripheral energy stores and b) may act directly or 
indirectly on GnRH (Gonzalez et al., 1997, Murray et al., 2000a; Williamson-
Hughes et al., 2005; Ward et al., 2009).  However little is known about the 
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role of circulating MCH in mammals or in humans in either context and since 
evidence suggests that MCH is active in the periphery it is now important to 
fully understand whether its peripheral actions are reflective of or dissociated 
from its central actions.     
Nutritional status impacts on reproductive physiology and in many mammals 
on reproductive behaviours thereby optimising both reproductive success 
and the ability to meet energetic demands.  The complex control system 
entailing integration of direct or indirect peripheral stimuli with central effector 
systems involves numerous hormonal and chemical mediators, 
neuropeptides, neural pathways and detection systems.  Hormones and 
neuropeptides, such as MCH, may act in this domain in one of two ways: a) 
by operating as mediators between feeding behaviours and reproductive 
function (that is, when variability in metabolic fuel availability induces altered 
hormonal response and the consequent modulation of feeding behaviours 
and reproductive function) and b) by operating as modulators affecting the 
availability of oxidisable fuels thereby influencing reproductive behaviours 
(Schneider, 2004).  Though MCH is active both in the ingestive and in the 
reproductive contexts, investigation into the metabolic pathways through 
which it may integrate these dual functions has been limited.  The tendency 
to favour male models in energy balance research (Ludwig et al., 2001; 
Siegal-Lieberman et al., 2003; Mashiko et al., 2005; Bjursell et al., 2006) and 
female models in reproductive studies (Murray et al., 2000b; Garcia et al., 
2003; Williamson-Hughes et al., 2005; Messina et al., 2006) may be 
problematic for intergender extrapolation of results. In metabolic studies 
where both genders have been subject to the same protocol, some sexual 
dimorphism has been reported.  For example increased energy expenditure 
was observed in both male MCHR-1-/- and male transgenic mice with 
temporal loss of MCH though not in their female counterparts ( Chen et al., 
2002; Alon and Friedman, 2006). Since in most species the energy cost of 
procreation for females far exceeds that of males a potential gender 
difference in MCH action would merit investigation. 
The anorectic consequences of oestrogen treatment are well substantiated 
(Wade, 1986; Geary, 2000; Eckel, 2004).  Expanding on earlier work 
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investigating the modulatory link between oestrogen and hypothalamic MCH 
expression (Murray et al., 2000b, Mystkowski et al., 2000), a potential 
interaction between oestrogen and MCH which may modulate ingestive 
behaviours has recently been investigated with somewhat conflicting results 
(Tritos et al., 2004; Messina et al., 2006).  Whilst Tritos and colleagues 
(2004) report that oestradiol-induced anorexia is not mediated via leptin or 
MCH, Messina and colleagues (2006) found that oestradiol treatment 
decreased MCH-induced food intake.  Santollo and Eckel (2008) also report 
both exogenous and endogenous estradiol exerts a reductive effect on MCH-
induced feeding via decreased meal size.  They also report a difference in 
the magnitude of the orexigenic effect of MCH between differing stages of the 
oestrous cycle, these effects being attenuated in oestrous rats (following high 
oestradiol secretion) compared to dioestrous rats.  Morton and colleagues 
(2004) reported that pharmacological doses of oestrogen block the increase 
in hypothalamic MCH expression customarily induced by caloric restriction.  
The interesting hypothesis raised by the results of these recent studies, is 
that the characteristic changes in feeding behaviours at different stages of 
the oestrous cycle in female rats may partly be mediated by altered MCH 
signalling (Messina et al., 2006).  The conclusion by Tritos and others (2004), 
that MCH is not involved in oestrogen-induced anorexia since MCH k/o mice 
displayed significant hypophagia and weight loss in response to oestrogen 
treatment does not take into account the effects of the multiple anorexigenic 
mediators which also work in concert with oestrogen to induce anorexia 
(Messina et al., 2006).  Additionally it is unclear as to what extent 
compensatory mechanisms are initiated in transgenic animals. 
Pregnancy and lactation present considerable physiological challenges to the 
organism. Lactation in particular is characterised by substantially increased 
energy demands and a marked increase in food intake in rats (Oftedal, 
2004).  The exaggerated feeding response in the rat model (compared to 
humans) (Dewey, 1998) may provide valuable insights into the framework in 
which MCH and other metabolic modulators may operate within the context 
of hyperphagia, increased energy demands and negative energy balance.  
Investigation into this area has been limited and has produced somewhat 
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diverse results.  Sun and colleagues (2004) report increased hypothalamic 
MCH expression in lactating rats 11 – 12 days postpartum though no 
demonstrable increase in circulating MCH.  Conversely Garcia and others 
(2003) report decreased hypothalamic MCH mRNA expression in pregnant 
and lactating rats. More recently mice in whom a time-dependent ablation of 
MCH neurones was orchestrated were not capable of rearing their offspring 
(Alon and Friedman, 2006), indicating a role for MCH in lactation though 
MCH-/- mice are fertile, at least when crossed with wt/C57BL/6 mice 
(Shimada et al., 1998). These observations along with the observation by 
Knollema and others (1992) that MCH expression is transiently induced in 
the preoptic area (POA) of the hypothalamus 8 – 21 days postpartum and at 
no other time pose some interesting questions as to the scope of MCH in the 
regulation of energy balance during lactation.   
 
2.6 Summary 
MCH is a comparatively recently discovered anabolic neuropeptide. The 
portfolio of its multiple and diverse physiological functions; both metabolic 
and behavioural, continues to expand.  Over the last decade or so its role as 
a crucial mediator of energy balance has become apparent.  The property of 
central MCH to stimulate food intake is shared by a number of other effector 
molecules, however this property appears to be secondary to its role in 
energy conservation.  Ablation of functional MCH or its receptor leads to a 
lean phenotype regardless of inconsistency in its reported effects on feeding 
behaviours though remarkably the lean phenotype is often accompanied by 
hyperphagia.  The lean phenotype is attributed to increased energy 
expenditure, manifest as increased locomotor activity, metabolic rate or both.  
Hence the development of specific MCH antagonists is an attractive 
proposition for pharmaceutical companies.  Whilst a solid body of evidence 
implicates MCH as a key regulator of energy balance the precise 
mechanisms and molecular pathways through which it operates are yet to be 
fully defined.  Additionally the functionally distinct and overlapping roles of 
MCH and its two co-precursor molecules, NEI and NGE are not yet fully 
delineated.  Whereas the role of central MCH has received considerable 
Chapter 2. Review of the literature 
22 
 
scrutiny, the source, targets, expression and functional roles of peripheral 
and circulating MCH are largely unexplored though emerging evidence 
suggests a role for the peptide in the hypothalamic-pancreatic, hypothalamic-
pituitary-thyroid and hypothalamic-pituitary-gonadal axes.   
The known activities of MCH in the reproductive axis are chiefly those 
associated with the regulation of LH release and the impact of oestrogen on 
MCH expression.  MCH may stimulate or inhibit LH release depending on 
oestrogenic milieu and MCH expression in the hypothalamus may be 
oestrogen dependent.  Furthermore in female rats cyclic modulation of 
feeding behaviours may be partially mediated by altered MCH signalling.  
The complexities of the inter-relationship between ingestive and reproductive 
behaviours are slowly being unravelled and MCH is undoubtedly a key 
component of this neurocircuitry, though the extent and scope of its 
molecular interactions are still being documented.   As the MCH story unfolds 
questions are both answered and posed, manipulation of the availability of 
MCH and its receptor in different animal models has provided some 
important insights into its physiological relevance.  Based on evidence to 
date it is feasible that the MCH system may provide a link between 
behavioural aspects of ergotropic vigilance, trophotropic impulse and 
pleasure drive. The behavioural aspects of energy balance/reproduction in 
free-living situations may be importantly impacted upon by MCH.  Clearly in 
order to understand these complex phenomena, it is now essential to explore 
the precise and comprehensive biological role of the MCH system in humans, 
with particular reference to its largely uncharacterised peripheral and 
circulatory roles.   
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3.   Materials, Subjects  and Methods 
 
3.1 Radioimmunoassay (RIA) to measure MCH in plasma  
3.1.1   Reagents for MCH RIA 
The following reagents were used in the MCH RIA: 
- Buffer 1:  see formula in Section 3.1.1.1 
- Buffer 2:  see formula in Section 3.1.1.2 
- Purified MCH, # H1482, Lot 1006273, Bachem, Switzerland 
- ([I125]-MCH), # NEX373010UC, PerkinElmer Inc., USA 
- Primary antibody: Anti-MCH Antibody, # M8440, Sigma-Aldrich, UK 
- Normal Rabbit Serum (NRS), #S-5000, Vector Laboratories Ltd, 
UK  
- Secondary antibody: Anti-Rabbit Sac-Cel, #AA-SAC1, IDS Ltd, UK 
- Bovine Serum Albumin: # A3294, Lot 045K0662 Sigma-Aldrich, UK 
3.1.1.1 Buffer 1 
 Add the following reagents to 1L distilled water: 
- 0.114 g  NaH2PO4 H20 
- 1.30 g    Na2HPO4  
-  9.00 g   NaCl 
- 1.00 g    Na azide 
Stir until all reagents are fully dissolved then add 1.00 g Bovine Serum 
Albumin, stir until fully dissolved, adjust pH  to 7.4 
3.1.1.2 Buffer 2 
 Add  9.306 g ethylene diamine tetraacetic acid (EDTA) to 1L Buffer 1 ,  
 stir until fully dissolved, adjust  pH to 7.4 
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3.1.2  RIA Protocol 
The development and validation of a RIA to measure MCH in human plasma 
is described in Chapter 4.  Following establishment/optimisation standard 
curves were derived from a 3 day protocol as follows:   
 
Day 1: A stock solution of MCH was serially diluted with Buffer 1 to give a 
range of concentrations (12.5 pg/ml – 10 ng/ml).  The standard curve was 
prepared in triplicates and included total count (TC), non-specific binding 
(NSB) and Bo tubes.  As outlined in Table 3.1, Buffer 1 was added to all 
tubes except the TCs.  A 1:300 Buffer 1:Normal Rabbit Serum (NRS; v:v) 
solution was prepared.  This solution was added to each of the NSB tubes 
(100 µl/tube) and then used to prepare the primary antibody solution.  An 
initial dilution of 1:30,000 Buffer 1 with NRS:MCH antibody solution was 
prepared and 100 μl added to each tube except TC and NSB.  After vortexing 
all tubes were incubated overnight at 4°C. 
 
Day 2:  Radio-labelled MCH (I125MCH) was diluted with assay Buffer 2 to 
produce 10,000 counts per minute in 100 µl (cpm). The prepared 
radiolabelled MCH was added to all tubes which were then vortexed and 
incubated overnight at 4°C. 
 
Day 3: One hundred microlitres of a cellulose suspension coated with anti-
rabbit IgG (secondary antibody) was added to all tubes, except the TCs, and 
incubated at room temperature for 30 mins.  Deionised water (1000 μl) was 
added to all tubes, except the TCs, and then all the tubes were immediately 
centrifuged at 1000 rpm for 10 minutes at 4°C.  The supernatant was 
aspirated and the radioactivity of the remaining pellet measured by gamma 
counter (Wallac Wizard 1470, PerkinElmer Inc, USA). 
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Table-3.1 RIA Protocol: Summary of volume of reagents and/or unknown 
added to each tube per day 
 Day 1 Day 2 Day 3 
Tubes MCH 
standard 
Unknown Buffer 1 NRS AB 1 in 
NRS 
I125 
MCH 
AB 2 
TC - - - - - 100 μl - 
NSB - - 200 μl 100 µl - 100 μl 100 μl 
B0 - - 200 μl - 100 μl 100 μl 100 μl 
Standards 100 μl - 100 μl - 100 μl 100 μl 100 μl 
Unknowns - 100 μl 100 μl - 100 μl 100 μl 100 μl 
AB: antibody, TC: total count,  NSB: non-specific binding, B0: total binding, NRS: normal 
rabbit serum 
 
 
Standard Curves were plotted using Assayzap software (Biosoft, 
Cambridge). Assayzap is a flexible programme which selects the most 
appropriate fitting method for the shape of a specific standard curve. 
   
3.2   Subjects and experimental protocol  
Conditions for experimental procedures were standardised for all studies as 
follows: 
3.2.1 Ethical Approval 
All experimental protocols described in Chapters 4, 5, 6 and 7 were approved 
by the University of Westminster Ethics Committee, (Ethics Application 
Number 06/07/29) in January 2007 (Appendix 1).  All participants were 
volunteers and received no financial incentive to participate. All volunteers 
received a copy of an Informed Consent Form and a Subject Information 
Sheet (examples Appendices 2 & 3) prior to attendance in the laboratory to 
ensure full participant awareness of all experimental procedures.  All 
volunteers signed a copy of the Informed Consent Form prior to participation 
which was counter-signed by a witness.  Data collected by other researchers 
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at the University of Westminster has been included in the present analyses 
(Chapters 4 and 7), for which separate ethical approval was obtained. 
3.2.2  Pre-test 
 
Male and female subjects were recruited by advertisement in London 
morning and evening newspapers and by posters.  All subjects completed a 
pre-test Medical Screening Questionnaire (Appendix 4) which was checked 
by researchers.  Any volunteer whose completed Medical Screening 
Questionnaire indicated that they were not medically suitable to be involved 
in the research was not allowed to participate.   
 
3.2.3  Anthropometric measurements 
 
Subjects were weighed without shoes in indoor clothing on digital scales, 
measurement accuracy ± 0.1 kg, (Seca 780 231 7008, Gmbh & Co, 
Germany).  Standing height was measured by stadiometer (Holtain Limited, 
Crymych, Dyfed, UK) and recorded to the nearest 0.1 cm. Waist and hip 
circumference were measured at the narrowest part of the torso and widest 
part of the buttocks and the waist-hip ratio (WHR) was calculated.  Body 
Mass Index (BMI) was calculated using the equation weight (kg) / [height 
(m)]2.   
 
3.2.4 Resting metabolic rate  
 
Subjects were fasted and instructed not to take exercise before attendance at 
the laboratory at 09.00am. Resting metabolic rate (RMR) was measured 
using an open system indirect calorimeter (Deltatrac II Metabolic Monitor, 
Datex Instrumentarium Corp., Helsinki).  After standard calibration, subjects 
were required to lie prone on a bed for 40 minutes having a ventilated hood 
placed over head and shoulders to facilitate the measurement of pulmonary 
gas exchange.  The ratio of oxygen consumed to carbon dioxide produced 
was used to calculate energy expenditure and hence metabolic rate.  Once 
prone subjects were instructed to limit movement and to remain awake.  The 
following conditions were observed: 
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- Noise in the laboratory was kept to a minimum and subjects listened to 
 meditation music (Sleep, Nukarma) via headphones. 
- Screens were placed around the beds in order to limit visual stimuli. 
- Laboratory lights were turned off. 
RMR expressed as kcal/day was calculated using the Weir equation (1949): 
((3.941 x VO2 ) + (1.11 x VCO2)) x 1.44 
To allow for acclimatisation the first 20 minutes of the continuous 
measurements were excluded.  Data collected in the last 20 minutes of the 
collection period were used to calculate RMR. 
 
3.2.5  Body composition measurements  
 
Total body fat mass and total body lean mass were measured by air 
displacement plethysmography (Bod Pod: Version 4.1, Body Composition 
System; Life Measurement Instruments, Concord, CA). After standard 
calibration subjects were weighed on the Bod Pod electronic scales wearing 
swim-wear or tight fitting underwear.  Hair was covered in a close fitting cap 
and jewellery removed.  Subjects were then required to sit in the Bod Pod 
chamber whilst 3 x 40 second tests were conducted during which subjects 
were instructed to limit movement and breathe normally.  The Bod Pod 
calculates body fat percentage using the Siri equation (Siri, 1956).  Body 
density is derived from body volume measured in the chamber and body 
weight in air. 
 
3.2.6 Blood collection 
 
All blood samples were taken by a trained phlebotomist.  Venous blood 
samples were collected into 10 ml vacutainers™  primed with EDTA (unless 
otherwise stated), (Becton Dickinson Medical, UK) and immediately 
centrifuged for 12 minutes, 3000 rpm, at room temperature to obtain plasma. 
Each plasma sample was aliquotted into 3, decanted into 5ml sterilin tubes 
(Z5PE, Sterlin Ltd, UK) and frozen at -20°C. Fingerprick blood samples were 
obtained and immediately analysed for blood glucose concentrations using 
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the Hemocue Glucose 201+ Analyser (Hemocue AB, Sweden),   
measurement range 0 – 22.2 mmol/l.  The intra-assay coefficient of variation 
(CV), calculated using EurotrolGlucoTrol-NG control solution was < 1.8% at a 
range of concentrations (Rajashekar, 2009). 
 
 3.2.7  Plasma hormone measurements 
 
All plasma samples were frozen (-20ºC) at time of collection and were 
defrosted at room temperature for 10 – 15 minutes prior to assay. 
 
3.2.7.1  MCH RIA 
 
Where possible plasma samples were used which had not previously been 
thawed and refrozen.  Plasma MCH concentrations were measured using the 
in-house competitive radioimmunoassay described in Section 3.1.2  
 
3.2.7.2  Insulin RIA 
 
Plasma insulin concentrations were measured using a commercially available 
insulin RIA kit (DSL-1600, Diagnostic Systems Inc, USA).  The assay 
sensitivity was 1.3 µIU/ml, the intra-assay CV was 8.3% at 4.8 µIU/ml and 
6.4% at 54.6 µIU/ml. 
 
3.2.7.3  Leptin RIA 
 
Plasma leptin concentrations were measured using a commercially available 
leptin RIA kit (HL-81HK, Millipore, USA). The assay sensitivity was 0.5 ng/ml, 
the intra-assay CV was 8.3% at 4.9 ng/ml and 3.4% at 25.6 ng/ml. 
 
3.2.7.4 Progesterone RIA  
 
Plasma progesterone concentrations were measured using a commercially 
available progesterone RIA kit (Progesterone double antibody 125I kit, # 
170102,  MP Biomedicals, USA).   The assay sensitivity was 0.2 ng/ml, the 
intra-assay CV was 11.9% at 0.79 ng/ml and 2.3% at 17.6 ng/ml. 
 
The above commercially available assays i.e. leptin, insulin and progesterone 
RIAs were performed as per manufacturer’s instructions except for the 
following modification: recommended volumes of all reagents and unknowns 
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were halved, e.g. where manufacturer’s instructions indicated that 100 µl 
volume should be used, 50 µl volume was substituted.   
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4.  Development and validation of a radioimmunoassay to measure 
MCH in plasma 
 
4.1 Introduction 
 
Although circulating MCH has been detected in both rodent (Stricker-
Krongrad et al., 2001) and human plasma (Gavrila et al., 2005), the 
physiological relevance of circulating MCH remains largely unexplored at 
present.  The requirement for further investigation into the role of circulating 
MCH has been publicly acknowledged (Pissios et al., 2007). There has been 
published debate concerning the validity of detection methods in the only 
human study to describe circulating MCH (Mantzoros, C., 2005; Waters and 
Krause, 2005). Specifically a discrepancy in reported serum MCH 
concentrations between their cross-sectional (97.8 ± 22.8 pg/ml) and 
intervention studies (~ 20 pg/ml) and their failure to validate the commercially 
available RIA for plasma and serum samples were causes for concern 
(Takahashi, 2005; Waters and Krause, 2005).  Therefore the first objective of 
this study was to develop and validate a competitive radioimmunoassay 
(RIA) for the detection of MCH in human plasma.  A series of experiments 
were carried out to establish the optimal conditions for a RIA for MCH; 
including determining the optimal primary antibody concentration, range of 
sensitivity of the curve, specificity of detection, the effects of anti-coagulants 
in plasma collection containers and the effects of storage conditions on the 
stability of MCH in plasma.  Once satisfactory results had been achieved a 
sample population was recruited in order to establish a reference range. 
 
4.2 Material and Methods 
Unless otherwise specified all reagents were described in Section 3.1. 
4.2.1 Antibody concentration 
Approximately 30% total binding affords the best competitive conditions for 
peptide hormones in a RIA. To determine the optimal antibody concentration, 
which yields ~ 30% total binding in the RIA, a series of antibody titre curves 
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were performed.   The initial antibody titre curves were derived from antibody 
concentrations ranging from 1:100,000 to 1:320,000.  After refinement 
antibody concentrations ranging from 1:20,000 to 1:50,000 were assessed 
(n=5). The titre curves were prepared in triplicate and included TC and NSB 
tubes.  Day 1: As outlined in Table 4.1, a 1:300 NRS: Buffer 1 (v:v) solution 
was prepared.  This solution was then used to prepare serial dilutions of the 
MCH antibody (ASB) to give a range of concentrations.  Buffer 1 (200 µl) was 
added to all tubes except TCs.  NRS:Buffer 1 solution (100 µl) was added to 
NSB tubes.  Serially diluted ASB (100 µl) was then added to all tubes except 
TCs and NSBs.  Radiolabelled MCH (125MCH) was diluted with assay Buffer 
2 to produce 10,000 cpm in 100 µl.  The prepared radiolabelled MCH was 
added to all tubes which were then vortexed and incubated overnight at 4ºC. 
Day 2: As Day 3 RIA Section 3.1.2.  The resultant anti-body titre curves were 
plotted (software as per section 3.1.2) and were used to determine the 
optimal antibody concentration.   
Table 4.1  Antibody Titre Protocol: Summary of volume of reagents added 
to each tube per day 
Tube Day 1 Day 2 
 Buffer 1 NRS:Buffer 
1 
ASB I125 MCH Antibody 2 
TC - - - 100 μl - 
NSB 200 μl 100 μl - 100 μl 100 μl 
Serial 
dilutions 
200 μl - 100 μl 100 μl 100 μl 
TC: total count, NSB: non-specific binding, NRS: normal rabbit serum, ASB: antisera buffer 
 
4.2.2 Sensitivity of the RIA 
A series of dilution curves of purified MCH in Buffer 1 were run to establish 
the minimal detection limit and range of MCH concentrations (n=15).  The 
protocol and range of concentrations were as described in Section 3.1.2. 
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4.2.3. Specificity of detection 
 
To determine possible cross-reactivity, a series of dilution curves (range 0.1 
pg – 0.1 mg) of biomolecules reported to have a competitive or agonistic 
relationship with MCH were assayed: namely, human atrial natriuretic peptide 
(ANP: #A1663, Lot 066K4805, Sigma-Aldrich, UK) (Hervieu et al., 1996); 
human α-melanocyte-stimulating hormone (α-MSH: #H1075, Lot 1008241, 
Bachem, Switzerland) (Barber et al., 1987; Ludwig et al., 1998); human 
adrenocorticotrophin (ACTH: #H1160, Lot 1003985, Bachem, Switzerland) 
(Baker et al.,1985) and Neuropeptide–E-I-MCH (NEI-MCH: #H4714, Lot 
0561279, Bachem, Switzerland) (Maulon-Feraille et al., 2002).  A standard 
curve for MCH was run with the biomolecule dilutions treated as unknowns 
and plotted for comparison (n=2). 
 
4.2.4  Dilution curve of plasma 
 
Non-fasting human blood was collected from 2 sources and immediately 
centrifuged to obtain plasma. The plasma was added to a series of dilution 
curves (0.49 – 125 pg/ml) to determine whether the curves with plasma 
paralleled the standard curve (n=4).  The dilution curves were obtained using 
the same method as for the RIA standard curves (Section 3.1.2) except 100 
µl of plasma was substituted for Buffer 1 in the standard tubes and the NSB 
and B0 tubes received 100 µl Buffer 1 + 100 µl plasma instead of 200 µl 
Buffer 1. 
 
4.2.5 Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) 
and Mass Spectrometry (MS)  (performed by Tania Murphy, PhD) 
 
Cross–validation was conducted by RP-HPLC using a modified version of the 
method described by Maulon-Ferraille et al., (2002).  A series of plasma: 0.1 
N HCl dilutions were subject to RP-HPLC to determine the optimum dilution 
for detection (n=1). The optimum dilution for detection was 1:9 plasma: 0.1 N 
HCl (v:v).  The mixture was then centrifuged at 4°C and 1000 rpm for 10 
minutes. The supernatant was removed and subjected to HPLC in a RP 
column (C18 Phenomenex, UK) with a gradient 20 – 60% (0.1% 
Chapter 4. Validation of the assay 
33 
 
trifluoroacetic acid in HPLC water: acentonitrile) for 60 minutes at a flow rate 
of 0.5 ml/min. Purified MCH was serially diluted and treated similarly for 
comparison.  MCH was detected using UV absorbance at 230 nm.  Protein 
fragments obtained by RP-HPLC were subject to MS for determination of 
analyte mass. Mass analysis was performed by single quadropole mass 
spectrometric detector (Dionex MSQ Plus, Dionex Corp., Massachusetts, 
USA) and MS data analysis was performed by Chromeleon LC/MS software 
(Dionex Corp., Massachusetts, USA).    
 
4.2.6  RP-HPLC and RIA 
 
To consolidate immunodetection of MCH in plasma by RIA, plasma collected 
in EDTA tubes and diluted in the ratio 1:9 plasma:0.1 N HCl (v:v),  a 1:9 
dilution of buffer:HCl in EDTA (v:v) and purified MCH were subject to RP-
HPLC as described in Section 4.2.5.  Fractions were collected at 1 minute 
intervals and the aliquots analysed by RIA as described in Section 3.1 (n=1). 
 
4.2.7 Stability of MCH in plasma 
 
Plasma was subjected to a number of storage conditions to test the stability 
of MCH in plasma determined by RP-HPLC.  Briefly before plasma samples 
were processed by RP-HPLC as described in Section 4.2.5, they were left at: 
a) room temperature for 1 hour; b) 4°C for 1 hour; c) room temperature 
overnight; d) 4°C overnight; e) -20°C overnight; and f) -20°C before being 
thawed, refrozen and thawed again (n=1).  Samples were checked against a 
freshly prepared sample.   
 
4.2.8 Collection Methods 
 
To determine the effects of different reagents customarily found in blood 
collection tubes on the detection of MCH in plasma by RP-HPLC, non-fasting 
blood samples from the same individuals were collected in vacutainers™ 
containing: 
a) lithium heparin: anti-coagulant (green cap)    
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b) silica + gel: clot activator + gel for serum separation (orange cap) 
c) fluoride oxalate: anti-coagulant and enzyme inhibitor (grey cap) 
d) EDTA: anti-coagulant (lilac cap) 
e) sodium citrate: reversible anti-coagulant (light blue cap) 
 
The samples were processed as described in Section 4.2.5 (n=2). 
 
4.2.9  Subjects 
 
In order to establish a reference range for circulating MCH, fasting blood 
samples collected by other researchers at the University of Westminster were 
included in the present analyses.  The researchers were Fawaz Alzaid, (MSc 
2008/09), Barbora Doslikova (BSc (Hons) 2008/09) and Marcela Brito (BSc 
(Hons) 2009/10). Anthropometric measurements and fasting blood samples 
were collected from 197 volunteers in addition to those described in Chapter 
6.  Data from volunteers who participated in the studies described in 
Chapters 5 and 7 were not included. The recruitment methods for volunteers 
were similar to those described in Section 3.2.2.   Blood collection, treatment 
and plasma storage methods were the same as those described in Section 
3.2.6.  Plasma MCH concentrations were measured using the in-house 
competitive radioimmunoassay described in Section 3.1.2. Anthropometric 
measurement methods were the same as those described in Sections 3.2.3 
and 3.2.5.  In total 242 male and female subjects were tested, of these 10 
were excluded since it was not possible to obtain a fasting blood sample from 
them, 1 was excluded as his plasma MCH concentration was > 4 SD from 
the mean. 
 
4.3 Statistical analyses 
 
The inter-assay coefficient of variation was calculated using the following  
formula:  CV = SD/[mean] x 100.  Independent samples t-tests were used to  
establish inter-gender differences between anthropometric characteristics  
and circulating MCH concentrations.  A one way between groups ANOVA  
was conducted to determine if there was an effect of body composition on  
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plasma MCH concentrations.  The post-hoc test was performed using 
Tukey’s adjustment for multiple comparisons. Associations between fasting 
plasma MCH concentrations and body composition parameters were 
determined by Pearson product-moment correlational analysis. Data were 
analysed using the Statistical Package for the Social Sciences (SPSS 
version 16.0 for Windows; Chicago, IL, US). 
 
4.4 Results  
 
4.4.1 Antibody concentration 
 
The optimal antibody concentration which yielded ~30% binding was 
established as 1:30,000 (Figure 4.1).  This concentration was used in the 
MCH RIAs described in Chapters 4, 5, 6 and 7.  
 
Figure 4.1: Example of antibody titre curve illustrating optimal antibody concentration 
 
 
4.4.2 Sensitivity and repeatability of the RIA 
 
The effective range was established as 19.5 – 1248 pg MCH/ml. This was 
taken as the level of detection in the assays that were used to measure MCH 
described in Chapters 4, 5, 6 and 7 (Figure 4.2). At 39 pg/ml and 156 pg/ml 
the inter-assay coefficient of variation was approximately 3.7%. 
1:1000     1:5000   1:10000   1:20000   1:40000  1:80000    1:160000  1:32000 
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Figure 4.2: An example of a typical standard curve for MCH using 1:30000 antibody 
concentration: range 19.5 – 1248 pg/ml  
 
4.4.3  Specificity of detection  
Serial dilutions of ANP, α-MSH and ACTH failed to displace the MCH 
antibody.  Only NEI-MCH at supraphysiological concentrations showed any 
potential for cross-reactivity with the MCH antibody (Figure 4.3).  
 
Figure 4.3:  Standard curve for MCH     + dilution curves for ANP       α-MSH      
ACTH      NEI-MCH 
 
 
4.4.4  Dilution curve of plasma  
Serial dilutions of two human plasma samples confirmed that the curves were 
parallel to the standard curve (Figure 4.4).   
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Figure 4.4: Standard curve for MCH + standard curve for MCH with plasma 
MCH        Plasma A       Plasma B 
 
4.4.5  Reverse Phase-High Performance Liquid Chromatography and Mass 
Spectrometry 
Purified MCH was detectable in the range 1 μg/ml - 1 mg/ml (see calibration 
curve, Figure 4.5). The retention time for MCH was 22.3 minutes on a 
RP C18 column, with a gradient of 20 - 60% (0.1% trifluoroacetic acid in 
HPLC water: acetonitrile) for 60 minutes, at a flow rate of 0.5 ml/min (Figure 
4.6).  In the example shown in Figure 4.6, the area under the curve for the 
peak eluted at 22.3 mins, was 6.4498 mAU (milli-absorption units) and from 
the calibration curve this corresponds to an MCH concentration of 14.87–
15.32 μg/ml.  
 
Figure 4.5: Calibration curve for MCH covering the range 1 - 20μg/ml 
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Figure 4.6: Chromatogram of purified MCH, retention time 22.3 minutes, area 6.4498 
mAU,14.87–15.32 μg/ml. The peak labelled 1 – 22300 indicates the retention time at which 
the analyte (MCH) elutes from the column. The retention time is specific to MCH. 
 
 
Mass spectrometry was used to detect and identify MCH in human plasma 
samples.  An MCH standard calibration curve (1 µg/ml – 100 µg/ml) was 
generated by RP-HPLC/MS.  It was predicted that product ions of m/z 796 
and 2 of m/z 1194 would be generated specifically for MCH.  Product ions at 
m/z 796 and m/z 1194 were detected at the correct elution time when purified 
MCH was analysed by MS (Figure 4.7a). 
 
Figure 4.7a: Product ion mass spectrum obtained from purified MCH.  The arrows indicate 
peaks at m/z 796 and 1194 
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Once purified MCH had been successfully analysed and detected by RP-
HPLC and MS, human plasma samples were analysed for MCH content.  
Product ion mass spectra were generated from human plasma samples 
which displayed peaks with identical relative masses to those generated from 
purified MCH (Figures 4.7b & c). 
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Figure 4.7b & c: Product ion mass spectrum obtained from the same plasma sample.  The 
arrows indicate identical product ions to those presented in Figure 4.7a.  Note that a different 
scale on the x axes has been used in Figures 4.7b & c compared to Figure 4.7a. 
 
 
B 
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4.4.6 RP-HPLC and RIA 
 
Purified MCH eluted from the column at 22.3 minutes.  Immunoreactivity of 
purified MCH determined by RIA was detected between 20 – 24 minutes 
(Figure 4.8).  MCH in a plasma sample was detected in the RP-HPLC 
fractions by RIA at 22 minutes at a concentration of 27.76 pg/ml which is 
within the established physiological reference ranges (Sections 4.4.9.2 and 
5.4.2.1).  An arbitrary value of 19.4 pg/ml was allocated to samples which 
were below the level of detection. 
 
  
Figure 4.8:  MCH immunoreactivity  of samples fractionated by RP-HPLC. Purified MCH 
eluted at 22.3 minutes. Immunoreactivity of purified MCH determined by RIA was detected 
between 20 – 24 minutes 
       Plasma collected in EDTA tubes with HCl        Purified MCH (μg/ml)         
        Buffer:HCl in EDTA 
 
4.4.7 Stability of MCH in plasma 
 
Results indicate that plasma MCH is not labile and that storage conditions do 
not affect recovery.  There were no detectable differences between 
concentrations of MCH in plasma which had been subject to the storage 
conditions described in 4.2.7 and a freshly prepared sampled when 
measured by RP-HPLC.  There was however a discrepancy between the 
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concentrations detected in plasma by RIA and by HPLC: this discrepancy is 
still being investigated.  
 
4.4.8 Collection Methods 
 
When plasma was run through the HPLC column a peak was detected at 
22.3 mins.  However MCH was only detected by HPLC in samples collected 
in the lithium heparin, EDTA and silica + gel vacutainers™.  The area under 
the curve ranged from 0.0569-0.0859 mAU which is approximately 1.7 – 1.8 
μg MCH/ml (see an example in Figure 4.9: sample collected with a silica + 
gel vacutainer™ (serum tube). Based on these results blood samples were 
only collected in lithium heparin or EDTA tubes in the studies described in 
Chapters 4, 5, 6 and 7. 
 
.  
Figure 4.9: Chromatogram of plasma sample, retention time 22.3 minutes, area 0.0859 
mAU, 1.7 – 1.8  µg/ml.  The peak labelled 1 – 22300 indicates the retention time at which the 
analyte (MCH) elutes from the column. 
 
4.4.9  Plasma MCH concentrations  determined by in-house RIA 
4.4.9.1 Demographic and anthropometric characteristics of study participants 
Mean female and male ages were similar (p=0.150).  The age range was 
from 18.0 – 76.0 years.  Mean BMI was in the normal range for both males 
and females although males had significantly higher BMI than females 
(p<0.001).  As expected males were significantly taller, (p<0.001), heavier 
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(p<0.001) and leaner (p<0.001) than females.  Females had significantly 
greater percent fat mass (p<0.001) but not fat mass weight (kg) than males 
(Table 4.2; independent samples t-tests: p=0.521).   
Table 4.2  Demographic, anthropometric and hormonal variables of 
study participants 
 Female (n = 135) Male (n = 96) 
 Mean ± SD Range Mean ± SD Range 
Age (yrs) 36.9±13.6 18.0–76.0 39.5±13.2 19.0–70.0 
Height (m) 1.66±0.07 1.42–1.86 1.78±0.07*** 1.56– 2.0 
Weight (kg) 61.3± 9.8 42.1–98.5 80.1±12.7*** 52.4–117.8 
Fat mass (%) 27.7±8.9*** 10.5–54.8 20.2±8.6 2.3–41.8 
Lean mass (%) 72.2±8.9 45.2–89.5 79.8±8.6 58.2–97.7 
Fat mass (kg) 17.6±8.3 6.1–51.2 16.8±9.2 1.3–45.4 
Lean mass (kg) 43.7±5.1 28.4–55.6 79.8±8.6*** 44.1–94.4 
BMI (kg/m2) 22.3±3.9 16.5–39.7 24.7±3.3*** 19–35.1 
Fasting MCH 
(pg/ml) 
37.3±9.2 19.51–70.4 36.0±9.1 21.0–63.0 
*** Significantly greater than the other gender (p<0.001) 
4.4.9.2  Fasting plasma MCH concentrations  
Fasting plasma MCH concentrations were detected in the range 19.51 – 70.4 
pg/ml, though 1 subject had fasting MCH concentrations in excess of 150 
pg/ml. This subject’s sample was assayed several times and it was 
consistently high.  Mean fasting plasma MCH concentrations were 36.7 ± 9.3 
pg/ml (all individuals excluding the outlier). Within this assay 95% of the 
sample population would be expected to have fasting MCH concentrations 
between 19.4 and 55.4 pg/ml.  There were no significant differences in mean 
fasting plasma MCH concentrations between males and females. When the 
sample population was grouped by gender and fat mass: male lean (ML): 
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body fat % < 21%; male excess fat (ME): body fat % ≥ 21%; female lean 
(FL): body fat % < 31%; female excess fat (FE): body fat % ≥ 31% (ACSM, 
1996), there were no significant differences in plasma MCH concentrations 
between the groups (one-way between-groups ANOVA; p>0.05).  Fasting 
plasma MCH concentrations were not significantly correlated with percent fat 
mass, percent lean mass, fat mass weight (kg), lean mass weight (kg), height 
or age. Circulating MCH concentrations did not change significantly with 
increasing age. There were however significant correlations between fasting 
plasma MCH concentrations and (a) body weight in females with excess fat, 
(b) male BMI, (c) BMI in females with excess fat, (d) BMI in males with 
excess fat (Table 4.3, Figure 4.10).  Female correlations were inverse, that is 
higher plasma MCH concentrations were associated with lower body weight 
and BMI.  Male correlations were in the positive direction. 
Table 4.3: Associations between fasting MCH concentrations and body 
composition parameters  
Gender/adiposity group Body weight (kg) BMI (kg/m2) 
Female EF (n=41) r=-0.360, (p=0.021)* - 
Male all (n=90) - r=0.230, (p=0.030)* 
Female EF (n=41) - r=-0.368, (p=0.018)* 
Male EF (n=38) - r=0.472, (p=0.003)** 
 Values represent Pearson product-moment correlations. ** significant at 0.01 level (2-tailed), 
* significant at 0.05 level (2-tailed), EF: excess fat. Significant associations only reported. 
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Figure 4.10:  Plasma MCH concentrations and BMI in a) males with excess fat (n=38; 
r=0.472) and b) females with excess fat (n=41; r=-0.368), (Pearson product-moment 
correlations) 
 
4.5  Discussion 
A sensitive and specific RIA for the quantifiable measurement of MCH in 
human plasma has been successfully developed using antisera raised in 
rabbit.  The only previous published attempt to detect circulating human MCH 
using a commercially available assay (Gavrila et al., 2005) has been publicly 
criticised (Waters and Krause, 2005; Takahashi, 2005).  Takahashi (2005) 
contends that MCH is not detectable in peripheral blood or tissue, due to the 
failure of his laboratory to detect circulating MCH in humans or rats with an 
in-house RIA using antisera against salmon MCH.  Nevertheless results of 
A 
B 
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the current study confirm that  MCH is detectable in human plasma by both 
RIA and RP-HPLC/MS. The effective range was established as 19.5 – 1248 
pg/ml and the inter-assay coefficient of variation was 3.7% indicating this 
assay is highly reproducible. 
The antisera’s affinity for MCH and not other peptides reported to have a 
competitive or agonistic relationship with MCH was tested.  Evidence of a 
competitive relationship between MCH and ANF (Hervieu et al., 1996), α-
MSH (Barber et al., 1987; Ludwig et al., 1998) and ACTH (Baker et al.,1985) 
has emerged from rodent and fish studies.  Additionally there is evidence to 
suggest that a pro-MCH derived peptide (NEI-MCH) acts as a super-agonist 
to MCH (Maulon-Feraille et al., 2002). Therefore to determine possible cross-
reactivity, dilution curves substituting the above peptides for MCH standard 
were run.  As expected the only molecule showing evidence of cross-
reactivity was NEI-MCH though only at supraphysiological concentrations 
(Figure 4.3). Currently there is little evidence to suggest that NEI-MCH 
circulates therefore at physiological concentrations this assay is specific for 
MCH.  Furthermore parallelism of the dilution curves of plasma to the 
standard curve confirms that other plasma components have no adverse 
effects on the curve. It should be noted here that Waters and Krause (2005) 
questioned the specificity of the Sigma antisera in a letter to an editor.  
However this comment was never followed up in a peer reviewed publication. 
Specifically the authors claim that MCH antisera obtained from Sigma (St 
Louis, MO) reacted with an immunoreactive substance in MCH knock-out 
mice.  In response to this critique it was countered that leptin knock-out mice 
can carry a truncated leptin molecule which reacts with leptin antisera 
therefore even though the animal is leptin deficient specificity is not 
compromised (Mantzoros, 2005).  In the current study the polyclonal MCH 
antisera (Sigma-Aldrich, UK) was raised in rabbit using synthetic human 
MCH as immunogen conjugated to keyhole limpet hemocyanin (KLH). The 
manufacturers state that at 50% binding, cross-reactivity with α-MSH, β-
MSH, γ-MSH, β-endorphin, α-endorphin, ACTH (1-39), ACTH (1-24) is 
≤0.01%. As discussed above the results of the current study are in 
agreement with the manufacturers. 
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To confirm that MCH is detectable and measurable in human plasma cross-
validation was performed by RP-HPLC and MS.  A peak was detected at 
22.3 mins when plasma was run through the HPLC column which 
corresponds exactly to the elution time of purified MCH.  Additionally when 
human plasma was subject to MS product ions of identical mass to those 
generated by purified MCH were observed.  There was however a 
discrepancy between concentrations of plasma MCH detected by HPLC and 
those detected by RIA.  The range of the standard curve for MCH generated 
by HPLC was 1 – 20 µg/ml.  MCH was not detectable at lower concentrations  
whereas the MCH plasma samples measured by RIA mostly fell into the 
range 19.5 – 1249 pg/ml.  Since these two analytical tools are entirely 
different this outcome is perhaps unsurprising.  Whereas HPLC identifies the 
analyte based on hydrophobic and polar interactions, RIA measures 
immunoreactivity.  RIAs are more sensitive than HPLC (Buice et al., 1987; 
Granich et al., 1989), as evidenced for instance by the results reported herein 
and the detection range of the aforementioned commercially available assay 
which has a similar lower detection limit (17 pg/ml vs 19.5 pg/ml).  
Concentration differences between plasma components measured by RIA 
and by HPLC are not uncommon (Carruthers et al., 1983; Buice et al., 1987; 
Chen et al., 2008).  Discrepancies of this nature are not particularly pertinent 
so long as there is consistency between the results (Caruthers et al., 1983).  
Furthermore results of RIA and HPLC measurements have been reported to 
correlate well (Wolf et al., 1989; De-Remer et al., 1997; Lips et al., 1999).  
Therefore in order to consolidate the RIA results human plasma samples 
were fractionated by HPLC, collected at one minute intervals and quantified 
by RIA.  Purified MCH eluted from the HPLC column at 22.3 minutes. In the 
RIA immunoreactivity in plasma samples was detected at 22 minutes.  This 
combination of HPLC and RIA methods is recommended to improve the 
molecular specificity of the analysis (Desiderio, 1984). With regard to the 
discrepancy in the magnitude of the detected concentrations it could be that 
the RIA cannot recognise the molecular configuration of bound MCH whilst 
the HPLC acidification process may cleave bound MCH which would then be 
detectable in addition to free MCH accounting for the higher concentrations 
detected by HPLC. 
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HPLC was also used to examine the stability of MCH and the effects of 
collection methods.  Plasma MCH retains stability under various conditions 
and even being left at room temperature overnight did not interfere with 
detection levels.  Nor did freeze thaw cycles impact on detection.  In contrast 
different collection methods produced variable results, MCH was detected in 
plasma collected in vacutainers primed with anti-coagulants lithium heparin 
or EDTA, or in serum tubes containing a clotting agent.  Other anti-
coagulants, namely sodium citrate and fluoride oxalate interfered with 
detection.  These results indicate that collection methods for plasma MCH 
should be standardised.   Also whilst it is desirable that storage conditions 
should be standardised, if on occasion it is not possible to adhere to standard 
practice the consequences should not be detrimental.  Furthermore since it is 
impractical to recruit volunteers each time a plasma sample is required for 
analysis the finding that freeze/thaw does not affect detection levels permits 
optimal utilisation of resources. 
Fasting blood samples from 135 female and 96 male volunteers were 
obtained in order to establish a reference range.  It was the intention to 
obtain samples from a diverse population therefore volunteers were recruited 
from a range of ethnicities, ages and phenotype.  The mean fasting plasma 
MCH concentration was 36.7 ± 9.3 pg/ml, therefore within this assay 95% of 
the population would be expected to have plasma MCH concentrations 
between 19.4 and 55.4 pg/ml though one subject had a fasting plasma MCH 
concentration of more than double the upper limit of the range.  This was not 
an anomaly since his sample was assayed several times and, in a separate 
study a female sample also showed a consistently similarly high value.  The 
physiological significance (if any) of these excessive values is not known 
though the male subject had a BMI and fat mass % greater than 2SD from 
the mean, and the female’s height was more than 2SD from the mean.   
However neither physical attribute was unique within their own populations.   
In rodents increased availability of hypothalamic MCH is associated with 
adiposity (Ludwig et al., 2001; Gomori et al., 2002) whilst decreased 
availability is associated with leanness (Marsh et al., 2002; Kowalski et al., 
2006), therefore it was hypothesised that circulating MCH concentrations 
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would also be aligned to phenotype.  In the current study whilst there were no 
associations between percent fat mass, percent lean mass, fat mass weight, 
lean mass weight, age or height there were significant correlations between 
circulating MCH concentrations and BMI in both males and females with 
excess fat (r=0.472, p=0.003; r=0.368, p=0.018 respectively).  Also a modest 
correlation between circulating MCH concentrations and body weight in 
females with excess fat (r=0.360, p=0.021).  These results indicate that 
circulating MCH may not be a marker of adiposity in humans since BMI and 
body weight measurements do not represent adiposity per se.  Body weight 
and BMI, which is a product of the weight/height ratio are possessed of other 
components such as muscle, bone tissue, fluids et cetera therefore an effect 
of these constituents cannot be excluded. However the outcome that these 
relationships are only observed in those with excess fat is indicative of some 
altered signalling in the presence of adiposity. Throughout this series of 
studies associations between circulating MCH concentrations and the same 
body composition parameters were examined; the current results do not 
completely synchronise with results of the other studies in this series.  Whilst 
there were associations between circulating MCH concentrations and certain 
body composition parameters the associations appeared to be gender and 
phenotype specific within the different populations examined.  This subject is 
discussed more fully in Chapter 8. Nevertheless circulating MCH 
concentrations have consistently been associated with body composition 
parameters in all studies though only in sub-groups of the sample 
populations. 
In agreement with the other studies in this series there were no differences 
between male and female fasting circulating MCH concentrations.  In this 
respect current results agree with the only other study to date to measure 
circulating MCH in humans (Gavrila et al., 2005); which found only a non-
significant gender difference in serum MCH concentrations.  Age-related 
changes in body composition did not appear to impact on circulating MCH 
concentrations since there were no differences in circulating MCH 
concentrations between those who were 40 +, 50 + or 60 + years and their 
younger co-subjects.  Nor was there a significant correlation between age 
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and absolute circulating MCH concentrations.  That said it is not known 
whether age-associated changes in health or nutritional status impact on 
circulating MCH concentrations and a longitudinal study would be required to 
further explore age-related changes in this respect. 
 
4.6 Summary, limitations and future work 
A sensitive and specific RIA for the measurement of circulating MCH in 
humans has been successfully developed and validated.  By use of this 
assay a profile of normal circulating MCH in humans is emerging.  In contrast 
to earlier published work where 1) circulating MCH was not detectable by RIA 
(Takahashi et al., 2005) and 2) where MCH was detectable by RIA but the 
validity of the RIA was questioned (Gavrila et al., 2005); results of the current 
study confirmed that MCH is detectable in human plasma by RP-HPLC/MS 
and by RIA, and that MCH concentrations in human plasma have been 
reliably measured by a radioimmunoassay. 
 Although not a cause for concern the discrepancy between concentrations of 
plasma MCH measured by HPLC and those measured by RIA should be 
investigated and there are ongoing plans for this work to be undertaken. 
Waters and Krause (2005) comments are noted.  In conclusion current 
results indicate that this assay is sensitive, specific and sufficiently reliable  
for use in future research.   
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5.  Circulating MCH concentrations and their association with resting 
metabolic rate, body composition and parameters of glucose 
homeostasis in young adults 
 
5.1 Introduction 
No reference ranges exist for concentrations of circulating human MCH and 
since it was confirmed that MCH is quantifiably measurable in human plasma 
(reported in Chapter 4), a cross-sectional study was undertaken in order to 
determine inter- and intra-subject variations of plasma MCH concentrations 
and their correlation with resting metabolic rate (RMR) and body composition, 
as empirical evidence from animal studies supports a strong role for MCH in 
appetite control and energy conservation (Shimada et al., 1998; Ludwig et 
al., 2001; Seigal-Liberman et al., 2003).  The pattern of release of circulating 
MCH has not been established therefore a further aim was to investigate 
whether circulating MCH concentrations were acutely responsive to food 
stimuli.  Furthermore since both hypothalamic and peripheral MCH have 
been implicated in glucose homeostasis (Ludwig et al., 2001; Pereira-da-
Silva et al., 2005; Pissios et al., 2007) plasma MCH concentrations in both 
the fasted and fed states were examined in association with circulating 
concentrations of glucose, insulin and leptin. The sample population was 
tightly controlled for age and body mass since being the first study to 
characterise circulating MCH concentrations in humans, it was the intention 
to eliminate potential confounding factors such as age, increased fat mass 
and associated changes in health.  
The objectives of this study were: 
• To establish a reference range for circulating concentrations of MCH 
in young healthy humans.  
• To describe associations between circulating MCH concentrations and 
a) RMR and b) body composition. 
• To track the acute response of circulating concentrations of MCH in 
response to feeding in relation to glucose, insulin and leptin 
concentrations. 
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5.2. Subjects and experimental protocol 
 
5.2.1 Participants 
 
Thirty two male and female subjects were recruited as Section 3.2.2. The 
inclusion criteria for females were: pre-menopausal; non-oral contraceptive 
using; aged 18 – 30 years; and with a body mass index (BMI) of < 24.9.  The 
inclusion criteria for males were: aged 18 – 30 years; BMI < 24.9.  Those on 
medication for chronic illnesses, lactating females, recently lactating (within 
the last 12 months) and pregnant women were excluded.   
 
5.2.2 Pre-test 
 
Prior to attendance in the laboratory subjects were provided with and 
instructed how to complete a 3-day Food Diary.  This diary was kept for  two 
weekdays and  one weekend day immediately prior to attendance in the 
laboratory to establish habitual food intake (Appendix 5). The Food Diaries 
were analysed using Dietplan 6 Personal P3 software (Forestfield Software 
Limited, Horsham, UK).  Subjects also received a Subject Information Sheet 
(Appendix 3) and completed an Informed Consent Form and pre-test Medical 
Screening Questionnaire (Appendices 2 & 4). 
 
5.2.3 Experimental protocol 
 
Subjects arrived in the laboratory fasted at 09.00am and were tested in a four 
hour protocol.  Upon arrival subjects were verbally familiarised with 
experimental procedures after which anthropometric measurements were 
taken as Section 3.2.3.  Following this RMR was measured using the 
procedure described in Section 3.2.4. One fasting venous blood sample and 
3 post-prandial blood samples were collected at designated intervals and 
nine fingerprick samples were also obtained at 15 minute intervals. See 
Figure 5.1 for timings.  Venous blood samples were collected, treated and 
the plasma stored as Section 3.2.6. Plasma samples were subsequently 
assayed for MCH, leptin and insulin as described in Section 3.2.7.  The 
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fingerprick blood samples were immediately quantified for tracking pre and 
post-prandial blood glucose concentrations.  After RMR was measured 
subjects consumed a controlled meal of mixed macronutrient content. The 
calorific content of the meal was 510 k/cal for males and 388 k/cal for 
females. This represents the recommended percentage daily intake for 
breakfast (20%) of the Estimated Average Daily Requirements for Energy 
(Food Standards Agency, 1996; Department of Health, 1991).  The 
macronutrient content of the meal was based on the Dietary Reference 
Values for protein, carbohydrate and fat for adult males and females 
(Department of Health, 1991).   The glycaemic index for this meal was 59.45.  
After blood sampling was completed volunteers’ total body fat and lean 
masses were measured by air displacement plethysmography (Bod Pod), as 
Section 3.2.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1:  Schematic representation of experimental protocol  
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5.3 Statistical analyses 
Normality of data was assessed by Shapiro-Wilk’s W test and by examination 
of skewness and kurtosis values. Square root or log-transformed data was 
used where necessary.  Homogeneity of variance was determined by 
Levene’s Test for Equality of Variances.  Independent samples t-tests were 
used to establish inter-gender differences between anthropometric 
characteristics and circulating hormone concentrations. Differences in pre- 
and post-prandial circulating hormone concentrations were assessed by 
paired samples t-tests. Comparisons between circulating hormone 
concentrations at the pre- and post-prandial sampling time-points were 
assessed by repeated measures design ANOVA.  Post-hoc tests were 
performed using Bonferroni adjustment for multiple comparisons.  One way 
between-groups ANOVAs were conducted to determine if there was an effect 
of body composition on plasma hormone concentrations.  Post-hoc tests 
were performed using Tukey’s adjustment for multiple comparisons.  The 
group effect of size was calculated using partial eta squared or eta squared.  
The guidelines for interpretation were those proposed by Cohen (1988).  
Relationships between fasted and post-prandial plasma MCH concentrations, 
RMR and body composition were also determined by linear multiple 
regression. The incremental area under the curve (AUC) was calculated for 
MCH, leptin, insulin and glucose using the trapezoidal method (Matthews et 
al., 1990). The strength of the associations between plasma MCH, leptin and 
insulin concentrations, RMR and body composition parameters were 
determined by Pearson product-moment correlational analysis. Partial 
correlation was used to control for compounding variables. Values are 
presented as mean ± standard deviation (SD) or mean ± standard error of 
the mean (SEM).  Data were analysed using the Statistical Package for the 
Social Sciences (SPSS version 16.0 for Windows; Chicago, IL, US). 
Statistical significance was set at p<0.05. 
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5.4. Results 
5.4.1. Subject characteristics 
Demographic and anthropometric characteristics of the study participants are 
presented in Table 5.1. Males and females were of similar ages (p=0.130) 
and BMI (p=0.421).  As expected males were significantly taller, (p<0.001), 
heavier (p<0.001) and had a greater lean mass % (p<0.001) than females.  
Females had significantly greater fat mass % than males (p<0.001). 
Table 5.1 Demographic and anthropometric characteristics of  study 
participants 
 Female (n = 21) Male (n = 11) 
 Mean ± SD Range Mean ± SD Range 
Age (yrs) 27.5±2.8 21.7–30.7 25.7±3.3 21.5–30.1 
Height (m) 1.66±0.1 1.57–1.8 1.78±0.1*** 1.65–1.9 
Weight (kg)  61.4±6.3 46.0–72.5 72.4±9.2*** 51.5–90.2 
Fat Mass (%) 26.6±5.4*** 16.7–37.9 15.5±6.6 7.9–29.6 
Lean Mass (%) 73.3±5.4 62.1–83.3 84.4±6.6*** 70.4–92.1 
BMI (kg/m2) 22.1±2.2 16.7–24.9 22.8±2.0 18.9–25.5 
*** p<0.001 significantly greater than opposite sex 
 
5.4.2  Plasma hormone concentrations 
 
5.4.2.1 Pre- and post-prandial plasma hormone and blood glucose 
concentrations  
The four sampling timepoints were designated F=fasted; PP1=30 minutes 
after feeding; PP2=60 minutes after feeding; and PP3=120 minutes after 
feeding. 
MCH:  In all individuals mean fasted plasma MCH concentrations (45.3 ± 
11.0 pg/ml) were not different to mean post-prandial plasma MCH 
concentrations (45.2 ± 8.6 pg/ml). The ranges were 26.3 – 71.2 pg/ml and 
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33.0 – 74.2 pg/ml in fasted and post-prandial individuals respectively. There 
were no significant differences in plasma MCH concentrations at any of the 
four time-points (one-way repeated measures ANOVA; p=0.772).   The intra-
subject CV was 1.98% for fasted plasma MCH concentrations and 1.01% for 
post-prandial plasma MCH concentrations.  The inter-subject CV for plasma 
MCH concentrations was 2.44%. The range in which 95% of plasma MCH 
concentrations fell was 28.02 – 62.38 pg/ml. 
Male and female plasma MCH concentrations are presented in Table 5.2 and 
Figure 5.1a.  There were no significant differences between male and female 
plasma MCH concentrations at any of the four sampling time-points 
(independent samples t-test; F: p=0.464; PP1: p=0.638; PP2: p=0.545; PP3: 
p=0.181). Similarly there was no effect of gender on mean MCH 
concentrations when fasted or after feeding (independent samples t-test; 
p=0.694 and p=0.716 respectively).  
Leptin:  Male and female plasma leptin concentrations are presented in 
Table 5.2 and Figure 5.1b. Circulating leptin concentrations decreased 
significantly in both males and females post-prandial.  However there was a 
gender difference in the pattern of the response.  Female circulating leptin 
concentrations had decreased significantly by the 1 hour sampling time-point 
but returned to near fasting by 2 hours post-prandial.  Male circulating leptin 
concentrations did not decrease significantly until two hours post-prandial 
(one-way repeated measures ANOVA; p=0.037, p=0.028 respectively).   
Mean female leptin concentrations were significantly greater than mean male 
leptin concentrations at every sampling time-point (independent samples t-
test; p<0.05). 
Insulin:  Male and female plasma insulin concentrations are presented in 
Table 5.3 and Figure 5.1c.  Plasma insulin concentrations were significantly 
different at each sampling time-point: being lowest in the fasting samples and 
peaking at 30 mins post-prandial, they had not returned to fasting 
concentrations 2 hours post-prandial (all individuals, one-way repeated 
measures ANOVA: p<0.005; with a large effect of size, multivariate partial 
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eta squared=0.849). Male and female plasma insulin concentrations were not 
different at any sampling time-point.  
Table 5.2: Fasted and mean post-prandial plasma MCH and leptin 
concentrations  
MCH (pg/ml) Leptin (ng/ml) 
Female 
(n=19) 
Male 
(n=10) 
Female 
(n=18) 
Male 
(n=10) 
F PP F PP F PP F PP 
44.18 
±10.93 
46.24 
±10.32 
47.40 
±11.41 
43.66 
±5.73 
7.58 
±3.88a 
6.84 
±3.46b 
2.63 
±1.88c 
2.53 
±1.91c 
Mean ± SD, F: fasted, PP: mean post-prandial, values with different superscripts are 
significantly different from each other (paired samples t-test; p<0.05)  
 
Table 5.3: Fasted and mean post-prandial blood glucose and plasma 
insulin concentrations  
Glucose (mmol/l) Insulin (ng/ml) 
Female 
(n=21) 
Male 
(n=10) 
Female 
(n=20) 
Male 
(n=10) 
F PP F PP F PP F PP 
4.33 
±0.64 
5.60 
±0.70 
4.60 
±0.62 
5.60 
±0.75 
0.28 
±0.13a 
1.80 
±0.78b 
0.34 
±0.14a 
1.66 
±0.71b 
Mean ± SD, F: fasted, PP: mean post-prandial, values with different superscripts are 
significantly different from each other (paired samples t-test; p<0.05)  
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Figure 5.1:  fasting and post-prandial a) MCH, b) leptin and c) insulin concentrations in 
young healthy males (n=10) and females (n=19, 18, 20 respectively) (mean ± SEM) 
         Male        Female    p: post-prandial   
 
  A 
 B 
  C 
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Glucose: Male and female blood glucose concentrations are presented in 
Table 5.3 and Figure 5.2.  All subjects had fasted and 2 hr post-prandial 
blood glucose concentrations in the normal range, the customary peak 15 – 
30 minutes post-prandial followed by  a rapid return to near fasting values 
was observed. There were no differences between male and female blood 
glucose concentrations (independent samples t-test; p>0.05). 
 
Figure 5.2: fasting and post-prandial blood glucose concentrations in young healthy males 
(n=10) and females (n=21)   (mean ± SEM)        Male        Female  p: post-prandial  
 
           
5.4.2.2  Associations between pre-and post-prandial plasma MCH, leptin, 
insulin and blood glucose concentrations 
 
The MCH AUC was correlated with the insulin AUC in individuals with excess 
fat only (r=0.862, p=0.012, n=6).  The insulin AUC was also correlated with 
mean plasma MCH concentrations in those with excess fat (r=0.891, 
p=0.009).  There was a significant correlation between the MCH AUC and 
glucose AUC only in males (r=-0.836, p=0.019, n=7).  At the one hour and 
two hour sampling time-points plasma leptin concentrations were correlated 
with plasma insulin concentrations in individuals with excess fat (r=0.818, 
p=0.047; r=0.894, p=0.016 respectively).  Plasma leptin concentrations were 
correlated with blood glucose concentrations at the 2 hour sampling time-
point in males only (r=-0.730, p=0.040). 
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5.4.3  Associations between plasma MCH and leptin concentrations and 
body composition parameters 
In males, fasting plasma MCH concentrations were positively correlated with 
body lean mass weight (kg) and mean post-prandial plasma MCH 
concentrations were positively correlated with BMI.   Mean concentrations of 
plasma leptin were strongly significantly correlated with fat mass percent, 
lean mass percent, fat mass weight (kg) and BMI in both males and females 
(Pearson product-moment correlation) (Table 5.4). 
Table 5.4 Associations between mean plasma MCH and leptin 
concentrations and body composition parameters 
 MCH (pg/ml) Leptin (ng/ml) 
 F 
(n=19) 
M 
(n=11) 
F 
(n=19) 
M 
(n=10) 
Fat mass (%) 0.040 0.072 0.769** 0.856** 
Lean mass (%) 0.238 0.005 -0.769** -0.856** 
Fat mass (kg) 0.004 0.497 0.766** 0.832** 
Lean mass (kg) -0.148 0.639# 
(p=0.034)* 
0.072 0.022 
BMI (kg/m2) 0.030 0.662Ϯ  
(p=0.037)* 
0.566* 0.842** 
Body weight (kg) -0.043 0.584 0.415 0.394 
Values represent Pearson product-moment correlations, * *significant at 0.01 level (2 tailed),  
* significant at 0.05 level (2 tailed),  # fasted MCH concentrations, Ϯ  mean post-prandial 
concentrations. All other comparisons based on mean value of all four sampling time-points. 
 
To explore the impact of body composition on circulating MCH and leptin 
concentrations subjects were sub-divided into four groups based on the 
American College of Sports Medicine’s cut-off point between individuals 
assigned to a lean or excess fat category: male lean (ML)=body fat % < 21%; 
male excess fat (ME)=body fat % ≥ 21%; female lean (FL)= body fat % < 
31%; female excess fat (FE)=body fat % ≥ 31% (ACSM, 1996).  MCH: There 
were no significant differences in mean concentrations of plasma MCH 
between any of the groups (p=0.928). Leptin: Circulating concentrations of 
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leptin were significantly different from each other for ML, FL and FE 
individuals (one-way between groups ANOVA with a large effect of size 
which was calculated as 0.599 using eta squared). 
5.4.4 Associations between plasma MCH and leptin concentrations and 
resting metabolic rate  
RMR was significantly higher in males than in females when expressed in 
absolute terms (kcal/day), though not when adjusted for lean body mass. 
RMR data presented immediately below were adjusted for lean body mass. 
RMR was negatively correlated with lean body mass weight (kg) in all 
individuals (r=-0.499, p=0.05) and in females only when split by gender (r=-
0.450, p=0.046).  Both male and female RMR were negatively correlated with 
body weight (r=-0.674, p=0.046; r=-0.479, p=0.002 respectively).   The CV for 
RMR was 0.82% and 0.85% in males and females respectively. There were 
no significant correlations between fasted or mean plasma MCH 
concentrations and RMR in either males or females. 
The group was further sub-divided based on % of predicted RMR. Predicted 
RMR (kcal/day) was calculated as the mean of the Fleisch and Harris-
Benedict equations (Fleisch, 1951; Harris and Benedict, 1919). A RMR of ± 
10% predicted is considered normal (McKardle et al., 2001). Therefore the 
groups were N= ≥ 90% predicted RMR; L= < 90% predicted RMR. There 
were no significant correlations between RMR and fasted or post-prandial 
mean plasma MCH concentrations in either group.  However when those with 
the highest metabolic rate were assigned to a separate category, that is, 
where RMR was ≥ 100% predicted, there was a significant correlation 
between fasted plasma MCH concentrations and females whose RMR was 
between 90 – 99.9% predicted (Table 5.5: r=-0.798, p=0.018). RMR, per cent 
fat-free mass, fat-free mass (kg), per cent fat mass and gender did not 
contribute significantly to the variance in fasted or post-prandial plasma MCH 
concentrations (linear multiple regression; p>0.05).  Leptin: Fasting and 
mean post-prandial plasma leptin concentrations were significantly correlated 
with RMR in all individuals, however there was no effect when leptin was 
controlled for fat mass.  
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Table 5.5  Associations between plasma MCH concentrations and RMR 
 Fasted MCH 
concentrations 
Post-prandial MCH 
concentrations 
 
RMR mH (n=2) 
 
 
NC 
 
NC 
 
RMR fH (n=5) 
 
0.802   
(p=0.102) 
 
 
-0.645 
(p=0.240) 
 
RMR mM (n=5) 
 
-0.185 
(p=0.766) 
 
 
-0.822 
(p=0.088) 
 
RMR fM (n=8) 
 
-0.798  
(p=0.018)* 
 
 
-0.257 
(p=0.538) 
 
RMR mL (n=2) 
 
NC 
 
 
NC 
 
RMR fL (n=5) 
 
-0.335 
(p=0.582) 
 
 
-0.328 
(p=0.525) 
Values represent Pearsons product-moment correlations, * significant at 0.05 level (2-tailed), 
m: male, f: female, H: high, M: medium, L: low, NC: not computed  
 
 
5.4.5  Associations between plasma MCH concentrations, energy intake and 
RMR 
Eighteen 3-day food diaries were analysed (male n=9, female n=9).  Male 
and females did not differ in total caloric intake per kg bodyweight or in the 
percentage of total daily energy intake provided by carbohydrate, protein or 
fat (independent samples t-test; p>0.05). Alcohol intake contributed 2.9% of 
total daily energy intake across the group.  Total caloric intake was not 
associated with fasted or mean post-prandial plasma MCH concentrations.  
Neither were there significant associations between specific macronutrient  
intake and plasma MCH concentrations. RMR (per kg lean mass) was not 
associated with caloric intake in either males or females (Pearson product-
moment correlation; p>0.05).   
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5.5  Discussion 
5.5.1  Circulating MCH concentrations 
A reference range for circulating MCH in humans has not been established. 
Therefore a primary objective of the current study was to determine normal 
values for circulating MCH in young, healthy individuals.  To this end a tightly 
controlled population was chosen; age-group 18 – 30 yrs, BMI not in excess 
of 25 kg/m2 and free of chronic health problems.  The rationale for this 
constraint was to minimise confounding factors which may have been 
introduced by a more diverse sample population.  Concurrently blood 
samples from a less stringently controlled sample population were collected 
in order to establish a broader-based reference range.  The results of this 
concurrent study were reported in Chapter 4.   
There were no differences between fasted and mean post-prandial plasma 
MCH concentrations.  Male and female plasma MCH concentrations were not 
significantly different, although there was a trend for female concentrations to 
rise after eating whereas male concentrations decreased.  The current 
findings are somewhat at odds with values reported in the only other study to 
measure circulating MCH in humans (Gavrila et al., 2005).  This cross-
sectional study reported mean values which were significantly higher (97.8 ± 
22.8 pg/ml) than those in the current study.  Whilst their sample population 
was younger than the ones reported here, there were no direct associations 
between plasma MCH concentrations and age in the current study (Chapter 
4).  Confusingly in a separate intervention study the same authors reported 
baseline mean values which were inconsistent with the ones they reported in 
their cross-sectional study, therefore clearly it was important to establish a 
reference range with reproducible values.  Results indicate that within this 
assay 95% of the population (young, healthy) would be expected to have 
plasma MCH concentration values falling into the range 19.5 - 62.4 pg/ml. 
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5.5.2  MCH and RMR 
A putative role for MCH in energy conservation has been validated by 
findings from genetic studies which have consistently shown that ablation of 
functional hypothalamic MCH results in increased energy expenditure and in 
some cases increased locomotor activity (Shimada et al., 1998; Marsh et al., 
2002; Segal Lieberman et al., 2003; Jeon et al., 2006).  Furthermore some 
studies have shown this phenomena to be gender specific with males only 
demonstrating this trait (Chen et al., 2002; Alon and Friedman, 2006).  In one 
study locomotor activity was decreased following MCH administration 
(Santollo and Eckel, 2008).  An interesting finding resulting from this rodent 
work is that increased energy expenditure resulting from decreased 
availability of physiological hypothalamic MCH may be accompanied either 
by hyper- or hypophagia.  Whether these consummatory behaviours are 
compensation driven, that is, increased ingestion to compensate for 
increased energy output or a result of reduced MCH-induced food intake is 
not known.  However in humans there is no evidence to support a role for 
circulating MCH in energy homeostasis, therefore in the first instance it was 
deemed important to describe associations between RMR and circulating 
MCH concentrations in young, healthy individuals.   Fat-free mass has 
customarily been considered to be one of the strongest predictors of RMR in 
both male and females (Cunningham, 1991; Astrup et al., 1992; Weinsier et 
al., 1992),  and whilst it is acknowledged that the practice of presenting RMR 
as a function of lean mass or  fat-free mass is simplistic (Illner et al., 2000, 
Wang et al., 2000; Heymsfield et al., 2002), it is nonetheless considered 
satisfactory to facilitate inter-gender comparisons in energy expenditure 
(McArdle et al., 2001).  In the current analyses RMR has been presented 
after adjusting for lean mass unless otherwise indicated. 
As expected higher RMR was observed in males (absolute values) though 
there was no inter-gender difference in RMR when adjusted for lean mass.  
Neither were there differences in circulating MCH concentrations between 
males and females in this population. We found no evidence of a relationship 
between fasted or fed plasma MCH concentrations and RMR.  In rodent 
studies manipulation of the availability of physiological MCH has a profound 
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effect on energy expenditure but the relevance of circulating MCH to 
metabolic rate in the absence of intervention has not been described.  The 
results of this study indicate that circulating concentrations of MCH remain 
stable in the absence of energetic flux.  However if up-regulation of MCH 
results in energy conservation (Santollo and Eckel, 2008), then it may be 
expected that individuals with lower metabolic rates be possessed of higher 
circulating concentrations of MCH.  Therefore the sample population was 
sub-divided into 2 groups based on their RMR as a percentage of predicted 
(standard) RMR.   Those with a measured RMR ≤ 89.9% predicted were 
designated L (low) and those with a measured RMR ≥  90% predicted were 
designated N (normal) since any value within ± 10% of standard is 
considered normal.  There were no differences in fasted or post-prandial 
circulating MCH between the groups and RMR was not correlated with 
plasma MCH concentrations in either group.  Curiously when the normal 
group was further sub-divided in an effort to determine whether there were 
any associations between circulating MCH and those with the highest 
metabolic rates, that is, ≥ 100% predicted RMR, a significant negative 
correlation was observed between females with normal but not high RMR (90 
– 99.9% predicted) and fasted circulating MCH.  Whilst this relationship is in 
the direction one would expect, that is higher RMR values associated with 
lower MCH concentrations, the small sample size (n=8) makes meaningful 
conclusions difficult. If circulating MCH concentrations are involved in a 
feedback mechanism conveying metabolic information it would be expected 
that those individuals with lower and higher metabolic rates would also 
display a relationship between RMR and circulating MCH concentrations.  
To further explore the relationship between metabolic rate and circulating 
MCH regression analyses were performed.   Results indicate that factors 
associated with variance in RMR, that is percent fat-free mass, percent fat-
mass, fat-free mass (kg) and gender, aswell as RMR do not contribute 
significantly to the variance in fasted or post-prandial MCH concentrations.  
Furthermore in a separate model fasting MCH concentrations did not 
contribute significantly to the variance in RMR. These results suggest that 
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circulating MCH cannot be considered a biomarker of resting energy 
expenditure in young, healthy adults.   
 
5.5.3  MCH and body composition 
A further objective of this study was to determine whether there were any 
associations between body composition and circulating MCH concentrations 
since body composition undeniably impacts on metabolic rate and, as will 
also be discussed in Chapter 7, in rodents the MCH system appears to have 
the capacity to impact strongly on phenotype.  Briefly a lean or obese 
phenotype can be induced by  decreasing or increasing  the availability of 
physiological hypothalamic MCH.  The characteristic phenotype of an MCH 
knock-out model, whether lacking the peptide or the receptor, is one of 
leanness with increased energy expenditure, some studies have also 
reported resistance to diet-induced obesity (Chen et al., 2002; Mashiko et al., 
2005; Kokkotou et al., 2005); a trait which makes MCH antagonism attractive 
to pharmaceutical companies. In the current study mean circulating plasma 
MCH concentrations were not significantly correlated with percent body fat 
mass, percent body lean mass, body fat weight, lean mass weight, body 
weight or BMI in males or females.  However in males only there were 
significant correlations between fasted MCH and BMI (r=0.662, p=0.037) and 
between mean post-prandial MCH and body lean mass weight (kg) (r=0.639, 
p=0.034).  It is generally assumed that a higher BMI indicates a fatter 
individual but this is not true as a higher BMI can also be indicative of a 
greater lean mass.  Therefore these results are not contradictory to each 
other but do not support the  results of earlier rodent work where increased 
MCH has been associated with increased adiposity (Ludwig et al., 2001, 
Gomori et al., 2002).  
If these results are reproducible and not anomalies then a further point 
arising from the current analysis is the question as to why the observed 
associations were so temporally specific, that is, only  fasted MCH 
concentrations were correlated with BMI and only mean post-prandial MCH 
concentrations were correlated with lean body mass weight.  Clearly body 
composition did not change measurably over the course of 2 hours and 
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fasted MCH concentrations were not significantly different to mean post-
prandial concentrations in males or females.  In the current study the sample 
size was modest (n=10) and further work is required.  The studies described 
in Chapters 4, 6 and 7 examined the same parameters and since differing 
results were observed in each Chapter a full discussion in light of all the 
results is reserved for Chapter 8. 
 
5.5.4  MCH response to feeding 
Earlier work with rodents has consistently shown that administration or 
ablation of functional hypothalamic MCH impacts on feeding behaviours.  
This subject is discussed more fully in Section 5.5.5.  In rodents central MCH 
expression is up-regulated after fasting (Qu et al., 1996; Tritos et al., 2001) 
though food restriction does not affect MCH mRNA or MCHR-1 mRNA (Elliott 
et al., 2004).  In humans serum MCH concentrations were increased to 127% 
of base-line after 2 days fasting (Gavrila et al., 2005).  However it has not 
been determined whether or not feeding acutely affects circulating MCH 
concentrations.  Therefore circulating MCH concentrations both in the fasted 
state and in the acute period after feeding were measured; to this end blood 
samples were obtained at 30, 60 and 120 minutes post-prandial.  Circulating 
leptin and insulin concentrations were also tracked since the post-prandial 
plasma leptin response is linked to insulin (Saad et al., 1998; Romon et al., 
1999) though differences have been reported regarding the time-course for 
the leptin response (Dallongeville et al., 1998; Romon et al., 1999; Teff et al., 
2004).  Since it was the aim to examine the normal physiological response to 
feeding subjects were fed a combination of foods which may typically have 
been consumed for breakfast.  The caloric and macronutrient contents were 
in line with Department of Health recommendations as described in Section 
5.2.3. 
Feeding did not appear to affect circulating MCH concentrations in the short 
term as there were no differences between fasted and fed MCH 
concentrations measured at any of the sampling time-points, nor was there a 
gender difference in the MCH response to feeding.  In contrast circulating 
leptin concentrations had decreased significantly by the 1 hour post-prandial 
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sampling time-point in females only whilst males displayed a non-significant 
decrease in circulating leptin concentrations.  The rapid female response is 
unlike that reported in previous studies in which the leptin response to 
feeding was not evident until 4hrs + post-prandial (Dallongeville et al., 1998; 
Romon et al., 1999; Romon et al., 2003), though one study with both lean 
and obese men reported a response within 2 hours (Imbeault et al., 2001). 
Differences in the leptin response seem to be influenced by gender, body 
composition and type of meal consumed.  A difference in the magnitude of 
the leptin response has been observed following either high fat or high 
carbohydrate meals, the response being greater following the high 
carbohydrate meal (Romon et al., 1999).  Females displayed an elevated 
leptin response following a high fat meal whereas males did not (Romon et 
al., 1999).  In the current study the meal content was 60% carbohydrate/ 20% 
fat and this ratio has been designated high carbohydrate/low fat in other 
studies (Havel et al., 1999) so a perceptible leptin response would have been 
expected.  The direction of the leptin response also appears to be affected by 
body composition, Imbeault and colleagues (2001) reported an increase in 
post-prandial plasma leptin concentrations in lean men and a decrease in 
obese men which was thought to be related to a dysregulated leptin 
response to insulin in the obese.  However most studies commonly report an 
increase in circulating leptin which commences several hours after eating.  
Since in this study the final sampling time-point was 2 hours post-prandial, it 
could be the lack of male response was entirely predictable, and what was 
observed may have been related to the morning nadir of leptin (Sinha et al., 
1996).  Daily fluctuations in circulating MCH concentrations in humans have 
not yet been established, so at present it cannot be determined whether or 
not they impacted on current results. 
A further objective of this study, aligned with the MCH response to feeding 
was to compare fasted and fed circulating MCH concentrations with blood 
glucose and plasma insulin concentrations since both hypothalamic and 
peripheral MCH has been implicated in glucose homeostasis and there is 
some evidence of local production of MCH in the endocrine pancreas 
(Pissios et al., 2007).  This was the major objective in the study described in 
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Chapter 6 with older adults.  However by way of assessing the 
generalisability of the results across the studies albeit in different populations, 
the same parameters were examined here.  The results of the current study 
are suggestive of an association between the post-prandial insulin response 
and the post-prandial MCH response since the AUC for insulin was positively 
correlated with the AUC for MCH and with mean plasma MCH concentrations 
in individuals with excess fat (r=0.862, p=0.012; r=0.891, p=0.009 
respectively).  Additionally the AUC’s for MCH and glucose were negatively 
correlated in males only (r=-0.836, p=0.019).   Two points arise from these 
results; first it appears that the circulating MCH and insulin response to food 
stimuli moves in the same direction but only in those with excess fat which 
could be a consequence of some insulin resistant state.  In rodents there is 
evidence that MCH may be involved in insulin secretion and normal β-cell 
physiology (Pissios et al., 2007).  Hyperinsulinemia has been observed in a 
transgenic mouse model over-expressing MCH (Ludwig et al., 2001).  Pissios 
and colleagues (2007) suggest that this phenomena may be the result of 
MCH-driven insulin production.  The results reported above are not 
incompatible with this framework.  Secondly associations between the post-
prandial MCH, glucose and insulin response are only evident in discrete sub-
groups of the sample population and not across the group as a whole.  
However since the sample sizes were small robust conclusions cannot be 
drawn though the results are reported since they are in broad agreement with 
the results reported in Chapter 6.  
 
5.5.5  MCH and energy intake 
As noted above, in rodents the MCH system appears to have the capacity to 
impact strongly on feeding behaviours.  Hyper- or hypophagia can be 
induced by manipulating the availability of physiological hypothalamic MCH 
concentrations. Whilst increased availability results in hyperphagia (Ludwig et 
al., 2001, Gomori et al., 2002, Santollo and Eckel, 2008), decreased 
availability can result in either hyperphagia (Chen et al., 2002; Marsh et al., 
2002) or hypophagia (Mashiko et al., 2005; Kowalaski et al., 2006).   This 
discrepancy may be attributed to whether a genetic or pharmacological 
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rodent model was used. Compensatory hyperphagia in response to reduced 
adiposity has been proposed as the cause of consummatory behaviours in 
MCHR-1 knockout models whilst antagonism of the MCHR-1 generally 
results in hypophagia (for review see Pissios, 2009).   Accumulating evidence 
from behavioural and anatomical studies also supports a role for MCH 
activity in the hedonic aspect of feeding.  Antagonism of the MCH receptor 
reduced consumption of highly palatable food (Morens et al., 2005), whilst 
infusion of MCH resulted in increased alcohol, sucrose and saccharin intake 
(Duncan et al., 2005; Sakamaki et al., 2005; Furudono et  al., 2006). An 
apparent preference for fatty foods has also been observed following chronic 
ICV infusion of MCH in mice (Gomori et al., 2002). MCH treatment also 
seems to be able to affect meal size, being increased following MCH 
administration (Santollo and Eckel, 2008), or decreased following antagonism 
of the MCH receptor (Kowalski et al., 2004).  Extra-hypothalamic sites are 
also involved in the MCH effect on ingestive behaviours.  In a recent study 
food intake though not energy expenditure increased after injection of an 
MCH agonist into the nucleus accumbens shell (Guesdon et al, 2009), an 
area involved in motivation and reward (Grace et al., 2007; Mahler et al., 
2007).  Anatomically this area is densely populated by the MCH receptor, as 
are areas involved in olfaction and gustation (Kokkotou et al., 2001, Saito et 
al., 2001).  Therefore it was hypothesised that circulating MCH 
concentrations may be associated with habitual food intake which was 
assessed by self-reported food diary.  Nevertheless in the current study there 
were no associations between plasma MCH concentrations and total caloric 
intake or specific macronutrient intake.  Needless to say ingestive behaviours 
are more complex in humans than in rodents, the cues and drives to eat 
being influenced by many non-biological factors.  Although the results of 
interventional animal studies place MCH firmly in the neurocircuitry which 
regulates feeding behaviours, in free-living humans cognitive, emotional and 
environmental factors may over-ride pure biological input.  Whilst these initial 
results do not endorse a role for circulating MCH in appetitive behaviours in 
humans there are many more aspects of these behaviours to be explored.  
For example in the current study it was not known whether the subjects were 
in positive, negative or eu-energy balance which may have impacted on 
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circulating MCH concentrations. Additionally the inherent limitations 
associated with self-reported food intake are acknowledged (Carriquiry, 
2003), though for the purposes of this initial characterisation the self-reported 
food diary method was deemed to be adequate.  
 
5.5.6 Summary, limitations and future work  
A major outcome from this study was the establishment of a reference range 
for circulating MCH concentrations in young, healthy adults which is in broad 
agreement with the reference range derived from a larger and more diverse 
sample population described in Chapter 4. Secondly there may be an 
association between the post-prandial MCH response and the post-prandial 
insulin response which is currently tenuous in the light of the small sample 
size of the sub-groups. Thirdly despite evidence of a functional albeit possibly 
indirect link between the actions of central MCH and leptin, there appears to 
be no direct relationship between circulating MCH and leptin concentrations 
in the acute phase after feeding in this population.  So it appears that 
circulating MCH does not fluctuate in concord with other primary metabolic 
mediators but it could be that it is only up or down-regulated in response to 
some perturbation in the system.  Whereas leptin and insulin convey 
continuous metabolic information from the periphery to the CNS, MCH 
activity may only become apparent if a number of conditions are satisfied.  A 
major limitation of the current study was the cessation of blood sampling 2 
hours post-prandial. This combined with the absence of a 24-hour profile of 
circulating MCH concentrations hampers meaningful interpretation of these 
results and is a subject that should be addressed in future work;  for example 
it could be that MCH behaves as leptin post-prandially with no real effect 
being observed until several hours after feeding. In terms of energy intake 
associations were not found between circulating MCH concentrations and 
total caloric intake or macronutrient preference, however the use of weighed 
rather than estimated food diaries would have improved confidence in this 
outcome. 
A further finding was that RMR was not strongly associated with fasting MCH 
concentrations except in females whose RMR was in the normal category 
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though not in excess of 100% predicted (and in a separate study in older lean 
males whose RMR was in the same category).  A larger sample population 
needs to be examined before more robust conclusions can be drawn with 
regard to a physiological role for circulating MCH in energy expenditure in 
humans. 
An unexpected outcome of this study was that circulating MCH 
concentrations seem to be associated with lean mass rather than fat mass in 
younger adults and only in males.  The results of this study and other studies 
undertaken in this series indicate that there is some sexual dimorphism 
associated with MCH activity.  It may also be that, in young adults who are 
less likely to have a dysregulated metabolism circulating MCH may be better 
indexed to lean rather than fat mass.  
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6. The association between circulating concentrations of MCH with 
glucose and insulin in response to fasting and feeding in lean 
individuals and those with excess body fat 
 
6.1 Introduction 
In humans very little is known about the sources, targets and natural 
fluctuations of circulating and peripheral MCH.  In rodents both central and 
peripheral MCH have been implicated in glucose homeostasis (Ludwig et al., 
2001; Pereira-da-Silva et al., 2005). A recent study (Pissios et al., 2007) 
detected MCH and its receptor in both human and mice islets and in clonal β-
cell lines.  Additionally MCH k/o mice exhibited reduced β-cell mass 
compared to controls in response to high fat feeding; and exogenous MCH 
stimulated insulin secretion in cultured human and mouse islets. In a 
previous study mice over-expressing MCH demonstrated islet hyperplasia 
which was out of proportion to their mildly obese phenotype (Ludwig et al., 
2001).  If MCH stimulates β-cell activity it would be logical to investigate 
whether circulating concentrations of MCH change in the same direction as 
insulin.  Furthermore since obesity is associated with insulin resistance (Kahn 
et al., 2001) the hypothesis that subjects with normal amounts of body fat 
would exhibit a differential post-prandial MCH response to those with excess 
body fat was explored.  Therefore the aims of this study were: 
• To determine whether there is an association between circulating 
concentrations of MCH and circulating concentrations of 
glucose/insulin.  
• To examine changes in circulating MCH concentrations in the fasted 
and fed states in lean individuals and those with excess body fat. 
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6.2. Subjects and experimental protocol 
 
6.2.1 Participants 
 
Two cohorts of subjects were recruited (n=50) by methods described in 
Section 3.2.2; a) those with excess body fat and b) lean individuals.  Lean (L) 
was defined as ≤ 30.9% body fat in females and ≤ 20.9% body fat in males.  
Excess body fat (E) was defined as ≥ 31% in females and ≥ 21% in males 
(ACSM, 1996). The inclusion criterion for both males and females was that 
they should be over 40 years of age. Those on medication for chronic 
illnesses were not automatically excluded though those on medication known 
to cause hypo- or hyperglycaemia or affect metabolic rate were precluded 
from participation. Exclusion criteria for females were pregnancy, lactating or 
recently lactating (within the last 12 months).   
 
6.2.2. Pre-test 
 
Subjects received a Subject Information Sheet (Appendix 6) and completed 
an Informed Consent form (Appendix 7).  Otherwise as described in Section 
5.2.2. 
 
6.2.3 Experimental protocol 
 
Subjects were tested in a 4 hour protocol described in Section 5.2.3.  Venous 
and fingerprick blood samples were collected, treated and the plasma stored 
as described in Section 3.2.6.  Plasma samples were subsequently assayed 
for MCH, leptin and insulin as described in Section 3.2.7.   
 
6.3 Statistical analyses 
 
Linear multiple regression analysis was not used to examine relationships 
between circulating MCH concentrations, RMR and body composition 
otherwise as section 5.3. 
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6.4 Results 
6.4.1. Subject characteristics 
Males and females were of similar ages (p=0.779) and BMI (p=0.423). Ages 
ranged from 40.4 to 69.9 years.  Males were significantly taller (p<0.001), 
heavier (p<0.001) and leaner (p<0.001) than females.  Females had 
significantly greater fat mass % than males (p<0.001).  Females in the lean 
group did not differ in % fat mass from males in the excess fat group.   
Demographic and anthropometric characteristics of the study participants are 
presented in Table 6.1 below. 
Table 6.1 Demographic and anthropometric characteristics of study 
participants 
 Lean Excess body fat 
 Male  
(n = 10) 
Female  
(n =11) 
Male 
 (n = 16) 
Female  
(n = 13) 
Age (yrs)   50.6±6.4a     51.4±9.3a      51.8±7.3a      52.5±5.9a 
Height (m)   1.81±0.1a     1.64±0.1b      1.78±0.1a     1.66±0.1b 
Weight (kg)   77.7±3.9a     59.5±8.2b      89.8±11.3c      76.7±11.4a 
Fat mass (%)   12.7±3.6a     26.5±5.3b      26.5±5.3b      38.8 ± 5.4c 
Lean mass (%)   87.2±3.8a    74.2±3.6b      74.3±6.2b      61.1±5.3c 
BMI (kg/m2)   23.5±1.5a     22.1±2.4a      28.0±3.5b      28.1±4.6b 
Waist-Hip 
Ratio  
  0.83±0.1a     0.78±0.1a      0.91±0.1b      0.83±0.1a 
Mean ± SD, within a category values with different superscripts are significantly different 
from each other  (one-way between-groups ANOVA; p<0.05)  
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6.4.2 Plasma hormone concentrations 
6.4.2.1  Pre and post-prandial plasma MCH concentrations 
The four sampling timepoints were designated F=fasted; PP1=30 minutes 
after feeding; PP2=60 minutes after feeding; PP3=120 minutes after feeding. 
In all individuals plasma MCH concentrations increased after eating. Fasting 
plasma MCH concentrations were significantly lower (p<0.005) than those 
measured 1 hour and 2 hours postprandial with a large effect of size, 
multivariate partial eta squared=0.757. Female plasma MCH concentrations 
were significantly higher than fasting 2 hours post prandial (p=0.023), male 
plasma MCH concentrations were significantly higher than fasting at the 1 
hour and 2 hour sampling time-points (Table 6.2: Figure 6.1 (a): one-way 
repeated measures ANOVA; p=0.001, p=0.006 respectively).  Subjects were 
grouped by fat mass as Section 6.2.1.  There was a significant increase from 
fasting at the 1 hour and 2 hour postprandial sampling time-points in both 
groups (Table 6.2: one-way repeated measures ANOVA; p<0.05).  However 
there were no differences in plasma MCH concentrations between L and E at 
any of the sampling time-points. To further explore the effect of fat mass and 
gender on circulating MCH concentrations subjects were divided into four 
groups: male lean (ML): body fat % < 21%; male excess fat (ME): body fat % 
≥ 21%; female lean (FL): body fat % < 31%; female excess fat (FE): body fat 
% ≥ 31% (ACSM, 1996). There was no effect of gender and adiposity though 
there was a trend for increased post-prandial plasma MCH concentrations 
compared to fasting (Figure 6.1 (b): one-way between groups ANOVA; 
p>0.05).  Only subjects from whom blood samples were collected at each of 
the 4 time-points were included in the above analyses hence the change in 
subject numbers per group.  The incremental area under the curve (AUC) for 
MCH was not different between the four groups nor when grouped only by 
gender or adiposity.  
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Table 6.2: Pre and post-prandial plasma MCH concentrations in lean 
males and females and those with excess body fat 
 All 
(n=18) 
Female 
(n=8) 
Male 
(n=10) 
L 
(n=9) 
 
E 
(n=9) 
FL 
(n=4) 
FE 
(n=4) 
ML 
(n=5) 
ME 
(n=5) 
MCH 
F 
34.43 
±5.6a 
33.08 
±4.5a 
35.52 
±6.3a 
35.17 
±7.3a 
33.70 
±3.4a 
33.07 
±5.3 
33.09 
±4.5 
36.85 
±8.8 
34.19 
±2.6 
MCH2 
PP1 
38.13 
±7.7 
37.94 
±4.5 
38.28 
±9.8 
39.6 
±7.2 
36.31 
±8.9 
38.18 
±4.0 
37.71 
±5.6 
41.38 
±9.2 
 
35.19 
±10.3 
MCH3 
PP2 
40.13 
±5.7b 
37.51 
±4.0 
42.22 
±6.3b 
41.45 
±6.5b 
38.80 
±4.8b 
38.17 
±3.7 
36.85 
±4.8 
44.07 
±7.5 
40.36 
±4.8 
MCH4 
PP3 
40.22 
±4.2b 
38.87 
±2.7b 
41.29 
±5.0b 
41.7 
±4.3b 
38.75 
±3.8b 
39.93 
±2.5 
37.82 
±2.7 
43.09 
±5.2 
39.49 
±4.7 
Values with different superscripts are significantly different from each other within a group 
(one-way repeated measures ANOVA; p,0.05. Reduced n values are due to missing plasma 
samples.   
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Figure 6.1 (a): Pre- and post-prandial plasma MCH concentrations in males (n=10)  
and females (n=8)  (mean ± SEM)        All       Male         Female  p: post-prandial  
 
 
Figure 6.1 (b): Pre- and post-prandial plasma MCH concentrations in lean males and 
females and those with excess fat   (mean ± SEM)        Female lean (n=4)         Male lean 
(n=5)          Female excess fat (n=4)         Male excess fat (n=5)  p: post-prandial   
 
 
 
 
 
 
 
 
 
0 
0 
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6.4.2.2. Pre- and post-prandial plasma leptin concentrations  
In all individuals plasma leptin concentrations decreased in the acute period 
after feeding.  However there was a gender difference in the pattern of the 
post-prandial leptin response.  Female fasting plasma leptin concentrations 
were significantly higher than those measured 1 hour but not 2 hours post-
prandial (p=0.037; partial eta squared=0.687).  Male fasting plasma leptin 
concentrations had not decreased significantly by the 1 hour sampling time-
point but were significantly lower than fasting by the 2 hour post-prandial 
sampling time-point. (Figure 6.2: one-way repeated measures ANOVA; 
p=0.028, partial eta squared=0.716).   
 
Figure 6.2: Pre- and post-prandial plasma leptin concentrations (mean ± SEM)  
        All (n=17)       Male (n=9)        Female (n=8) p: post-prandial  
 
6.4.2.3 Pre- and post-prandial blood glucose and plasma insulin 
concentrations  
All individuals responded as expected following break of fast, that is, there 
was a sharp significant increase in blood glucose and plasma insulin 
concentrations which then declined over the following 2 hour period.  Mean 
post-prandial insulin concentrations were significantly higher in the excess fat 
group compared to the normal fat group (p=0.034).  Subjects were grouped 
by fat-mass as Section 6.4.2.1.  Plasma insulin concentrations were 
measured at the four sampling time-points, there were significant differences 
Chapter 6. Study 2 
79 
 
between E and L only at 30 minutes post-prandial; E had significantly higher 
plasma insulin concentrations than L (Figure 6.3: p=0.033).  This difference 
was not apparent when the groups were further sub-divided by gender as 
Section 6.4.2.1 (Figure 6.4: p>0.05).  The AUC for insulin was not different 
between FL, FE, ML or ME (one-way between-groups ANOVA; p>0.05), nor 
when grouped by gender or adiposity only. 
 
Figure 6.3: Pre- and post-prandial plasma insulin concentrations in lean individuals and 
those with excess fat (mean ± SEM)        Lean (n=9)        Excess fat (n=10) p: post-prandial    
 
Figure 6.4: Pre- and post-prandial plasma insulin concentrations in lean males and females 
and those with excess fat (mean ± SEM)        Female lean (n=4)         Male lean (n=5)       
       Female excess fat (n=4)        Male excess fat  (n=6)   p: post-prandial    
 
The AUC for glucose was not different between those with excess fat and 
lean individuals of either gender. There were no significant differences 
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between male and female pre and post blood glucose concentrations at any 
sampling time-point.  Nor were there significant differences when the data 
was grouped by fat mass or by fat mass and gender (Figure 6.5: one-way 
between-groups ANOVA; p>0.05). 
 
 
Figure 6.5: Pre- and post-prandial blood glucose concentrations in lean males and females 
and those with excess fat (mean ± SEM)        Female lean (n=8)       Male lean (n=9)        
       Female excess fat (n=11)        Male excess fat (n=13)   p: post-prandial 
 
 
6.4.2.4  Associations between pre- and post-prandial plasma MCH and leptin 
concentrations  
There were significant correlations at 2 sampling time-points 1) a negative 
correlation between fasted plasma MCH concentrations and fasted leptin 
concentrations in males with excess fat (r =-0.772, p=0.043, n=6) and 2) a 
positive correlation 30 minutes post-prandial between plasma MCH 
concentrations and plasma leptin concentrations in lean males (r =0.770, 
p=0.025, n=6). The MCH AUC was not significantly correlated with the leptin 
AUC.  
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6.4.2.5  Associations between pre- and post-prandial circulating MCH, 
glucose and insulin concentrations 
For each subject the mean MCH plasma concentration of the four sampling 
time-points was calculated and used for the analyses in the following 
sections.  The AUC for insulin was negatively correlated with mean MCH 
plasma concentrations (all individuals: r=-.485, p=0.014).  In a model in which 
mean MCH plasma concentrations, percent fat mass and waist-hip ratio were 
the predictors for the insulin AUC in standard multiple regression analysis, 
34% of the variance in the insulin AUC was explained by this model. Of the 3 
independent variables only mean plasma MCH concentrations made a 
significant unique contribution (17.2%) to the variance in the insulin AUC 
(adjusted R square =0.340; part correlation co-efficient=-0.415; p=0.021). A 
moderate but significant association was observed between the glucose AUC 
and mean MCH plasma concentrations in those with excess fat only (r=-
0.398, p=0.049).  The AUC for glucose was not significantly correlated with 
the AUC for MCH or leptin.  
6.4.2.6  Associations between pre- and post-prandial circulating leptin, 
glucose and insulin concentrations 
As Section 6.4.2.5, for each subject the mean circulating leptin, glucose and 
insulin concentrations of the four sampling time-points were calculated and 
used for the analyses in the following sections.  Thirty minutes after feeding 
there was a significant negative correlation between plasma leptin 
concentrations and blood glucose concentrations (all individuals: r=-0.345, 
p=0.049).  When split by gender the association was not upheld in males 
though was in females (r=-0.852, p<0.001), this relationship was stronger in 
lean females (r=-0.989, p=<0.001).   
Two hours after feeding there was a significant negative correlation in males 
with excess fat between plasma leptin concentrations and blood glucose 
concentrations (r=-0.714, p=0.031). All correlations for leptin are  presented 
after controlling for fat mass.  
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6.4.3 Associations between mean plasma MCH concentrations and body 
composition parameters 
There was a strong positive correlation between BMI, body weight and mean 
plasma MCH concentrations in lean females.  There was also a strong 
positive correlation between mean post-prandial plasma MCH (that is, mean 
of the 3 sampling time-points post-feeding for each individual) and body fat 
weight in lean females (Table 6.3).  
Table 6.3 Associations between mean plasma MCH concentrations with 
body composition parameters in lean males and females and those with 
excess body fat 
 Female Male 
 All 
(n=24) 
L 
(n=11) 
E 
(n=13) 
All 
(n=26) 
L 
(n=11) 
E 
(n=15) 
Fat mass  
(%) 
 
-0.099 0.370 -0.155 -0.279 -0.472 0.071 
Lean mass 
(%) 
0.099 -0.370 0.155 0.279 0.472 -0.071 
BMI (kg/m2) -0.074 0.613 
(p=0.045)* 
-0.204 -0.160 0.032 -0.034 
Body weight 
(kg) 
-0.143 0.602 
(p=0.050)* 
-0.408 -0.130 -0.058 0.013 
Fat mass 
weight (kg) 
-0.148 0.608# 
(p=0.047)* 
-0.318 -0.241 -0.391 0.071 
Lean mass 
weight (kg) 
-0.081 0.545 -0.532 0.143 0.231 -0.042 
Waist hip 
ratio 
0.068 0.347 -0.163 -0.210 -0.375 0.134 
Values represent Pearson product-moment correlations,  * significant at 0.05 level (2 tailed); 
L: lean, E: excess fat,  # mean post-prandial MCH 
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6.4.4  Associations between plasma MCH concentrations and resting 
metabolic rate  
Subjects were divided into 3 groups based on percentage of predicted RMR 
as in Section 5.6.  The groups were Low (L)= ≤89.9% predicted RMR; 
Normal (N)=90 – 99.9% predicted RMR; High (H)= ≥ 100% predicted RMR 
as Section 5.4.4.  There was a significant correlation between fasting plasma 
MCH concentrations and RMR in lean males in the N group only (r=0.781, 
p=0.038, n=7). 
 
6.5 Discussion 
 
6.5.1.  MCH response to feeding in association with circulating leptin 
concentrations 
Adiposity is associated with an impaired insulin response which is linked to 
leptin resistance and all 3 appear to be factors of aging though the cause-
effect is currently unclear (Carrascosa et al., 2009).  Since both central and 
peripheral MCH have been implicated in glucose metabolism (Ludwig et al., 
2001; Pereira-da-Silva et al., 2005; Pissios et al., 2007), and there is ample 
evidence that MCH and leptin have the capacity to both inhibit and stimulate 
each other (Huang et al., 1999; Bradley et al., 2000; Kokkotou et al., 2001; 
Bradley et al., 2002) a primary objective of this study was to describe the 
post-prandial MCH, leptin and insulin response in older individuals 
characterised as having excess fat, and thereby being more likely to have 
some degree of insulin resistance, and to compare their response with their 
leaner counterparts.  
 
In contrast to the study undertaken with 18 – 30 year olds reported in 
Chapter 5, there was a significant change in post-prandial MCH 
concentrations in both males and females.  Circulating MCH concentrations 
had risen significantly by the 1 hour sampling time-point in males and by the 
2 hour sampling time-point in females.  Body composition did not appear to 
be a factor since this increase was evident in both lean individuals and those 
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with excess fat by the 1 hour post-prandial sampling time-point and remained 
elevated until the 2 hour post-prandial sampling time-point.  Additionally, at 
least in the lean older individuals, their body fat mass, lean mass and BMI 
were similar to those of the younger group in both males and females 
(p>0.05).  Furthermore both the younger and older groups were fed the same 
meal (Section 5.2.3) therefore meal composition does not appear to be 
relevant.  Since this discrepancy does not appear to be related to body 
composition or meal content, the next question to be addressed is whether or 
not this increase could be driven by humoral factors.  First MCH 
concentrations changed in the same direction as blood glucose and plasma 
insulin and there were correlations between the insulin AUC and mean 
plasma insulin concentrations discussed in Section 6.5.2.  Secondly for the 
first time in this series of studies, a significant correlation was observed 
between plasma leptin and plasma MCH concentrations in males only.  
Specifically, after controlling for fat mass, fasted plasma MCH concentrations 
were inversely correlated with fasted plasma leptin concentrations in males 
with excess fat (r=-0.722, p=0.043), and 30 minutes post-prandial plasma 
MCH concentrations were positively correlated with plasma leptin 
concentrations in lean males only (r=0.770, p=0.025). In energy homeostasis 
hypothalamic leptin indirectly inhibits hypothalamic MCH via the NPY/AgRP 
metabolic pathway (for review see Schwartz et al., 2000), therefore the 
inverse correlation between fasting MCH and leptin would be expected if this 
effect is reflected in the periphery.  Few other studies have attempted to 
evaluate the association between circulating MCH and leptin.  In rodents no 
direct correlation was found between these two metabolic markers in lean or 
obese animals (Stricker-Krongrad et al., 2001).  In humans fasting serum 
MCH concentrations were not associated with serum leptin concentrations in 
a younger sample population (17 ± 1.7 yrs; Gavrila et al., 2005).   Nor were 
there any relationships between plasma leptin and plasma MCH in 2 
separate studies (Chapters 5 and 7).  Therefore the question must be posed 
as to why a relationship was observed in the current study but only in 2 
distinct cohorts; that is, older males with excess fat in the fasted state and 
older lean males post-prandial.  Leptin action is altered with aging and is 
characterised by increased adiposity and the development of leptin 
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resistance, however it is not known which precedes which (Carrascosa et al., 
2009).  It may be that the differential direction of the plasma MCH/plasma 
leptin relationship between those with excess fat and lean phenotypes 
(negative versus positive) is symptomatic of disruption between MCH and 
leptin signalling, in this context it is possible that MCH may be responding to 
some leptin resistant state. It must also be borne in mind that the n of the 
sub-groups was modest (males excess fat: n=9; males lean: n=9) therefore 
further substantive work is required, although the above observations support 
the sexual dimorphism which has already been reported in the MCH 
response in the current series of studies (Chapter 5) and by others (Chen et 
al., 2002; Alon and Friedman, 2006).   
At least in the acute phase after feeding plasma MCH concentrations and 
plasma leptin concentrations were moving in opposing directions, as leptin 
concentrations were decreasing, MCH concentrations were increasing 
though the leptin response was apparent earlier in females than males (1 
hour versus 2 hours post-prandial).  This is in agreement with the results 
reported in Chapter 5 but as noted there, this decrease may have been 
related to the morning nadir of leptin in circulation, and it may well be that 
plasma leptin concentrations subsequently rose which would have been in-
line with current understanding regarding the acute leptin response to feeding 
(Boden et al., 1996; Saad et al., 1998; Attoub et al.,1999). 
 
6.5.2. Post-prandial MCH response in association with the post-prandial 
glucose and insulin response 
Currently the source(s) and targets of circulating and peripherally derived 
MCH are not known though there is evidence that it may be expressed in the 
pancreas in both rodents and humans.  Results of a recent study suggest 
that MCH may be necessary for normal β-cell function and MCH has been 
shown to stimulate insulin release from βcells in vitro (Pissios et al., 2007).  
Whether or not MCH acts in a paracrine or autocrine manner within the 
pancreas or is released into the circulation is not known.  If MCH is active at 
the level of the endocrine pancreas it was hypothesised that the post-prandial 
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insulin response might be related to the post-prandial MCH response and 
could be altered in the presence of insulin resistance.  Current results 
indicate that circulating MCH concentrations are associated with the 
peripheral post-prandial insulin response. First there was an inverse 
correlation between the insulin AUC and mean plasma MCH concentrations 
(r=-.485, p=0.014) with a shared variance of 23.5%.  Secondly in a 
regression analysis where mean plasma MCH concentrations, percent fat 
mass and waist-hip ratio were predictors for the insulin AUC, mean plasma 
MCH concentrations made a significant unique contribution (17.2%) to the 
variance in the insulin AUC.  However the nature of the association can only 
be speculated upon without further investigation.  As previously noted the 
sources and targets of circulating and peripheral MCH are not currently 
known although both MCH and its receptor have been detected in human 
and mouse pancreatic islets and MCHR-1 has also been detected in a clonal 
β-cell line (Pissios et al., 2007).  It therefore seems likely that one of the 
sources of circulating MCH could be the endocrine pancreas and the inverse 
relationship between the insulin AUC and mean circulating MCH 
concentrations at least in the acute period after feeding could be indicative of 
increased MCH activity at the level of the pancreas.  At least in rodents it 
would appear that MCH modulates normal islet physiology as evidenced by 
the failure of MCH k/o mice to display the customary islet hyperplasia 
associated with high-fat feeding (Pissios et al., 2007) and the excessive islet 
hyperplasia observed in mice over-expressing MCH (Ludwig et al., 2001).  It 
is therefore entirely possible that MCH may be one of a number of 
neuropeptides which exert manifold influence at different levels of energy 
homeostasis though elucidation is ongoing regarding its specific interactions 
and pathways.   In the current series of studies it was the aim to describe the 
relationship between circulating MCH and leptin in humans, given that leptin 
is a major peripheral adiposity signal which exerts its influence at the level of 
the hypothalamus.  Apart from the aforementioned correlations between (a) 
fasting plasma MCH concentrations and leptin in males with excess fat and 
(b) post-prandial plasma MCH concentrations and leptin in lean males there 
were no other significant associations between circulating plasma MCH and 
leptin.   Insulin increases leptin production (Bradley and Cheatham, 1999; 
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Lee et al., 2006; Lee et al., 2007).  However in the current study circulating 
leptin concentrations were not significantly correlated with circulating insulin 
concentrations at any sampling time-point or between the respective AUCs.  
On the other hand there was a moderate but significant inverse association 
between the glucose AUC and mean plasma MCH concentrations in those 
with excess fat only (r=-.398, p=0.049).  In terms of the discrete sampling 
time-points there was also a moderate but significant correlation between 
blood glucose and plasma leptin 30 minutes post-prandial (r=-.345, p=0.049).  
When split by gender this association was stronger in females only (r=-.852, 
p<0.001) and in lean females the correlation was (r=-.989, p<0.001). At the 
same sampling time-point plasma MCH concentrations were positively 
correlated with plasma leptin concentrations in lean males only (r=-770, 
p=0.025). Two hours post-prandial there was a significant inverse correlation 
between blood glucose and plasma leptin in males with excess fat only (r=-
.714, p=0.031). One should exercise caution when interpreting results such 
as these in the absence of a more comprehensive depiction of the circulating 
hormonal milieu in the acute phase after feeding.  The physiological 
relevance of such outcomes should be considered. Nonetheless these 
results suggest that circulating MCH is involved in nutrient related cross-talk 
between components of energy metabolism which is differentially regulated 
in the presence of adiposity.   
At the outset of this study it was the intention to compare an older fatter 
cohort with an older leaner cohort reasoning that the more corpulent group 
would be more likely to have some degree of insulin resistance.  However 
even those displaying morphological characteristics which would incline them 
towards insulin resistance; that is a BMI of > 30kg/m2 and waist-hip ratio of > 
1.0 for men and > 0.8 for women, had fasting and 2 hr post-prandial blood 
glucose concentrations within the normal range (< 6.1mmol/l fasting, < 
7.8mmol/l 2 hrs post-prandial).  Furthermore the individual Homeostatic 
Model Assessment (HOMA) scores (Matthews et al., 1985), which is a 
mathematical model method for detecting insulin resistance, only exceeded 
2.0 in 2 individuals.   There appears to be no reference values for HOMA 
scores which represent insulin resistance, however scores in excess of 2.0 
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and 3.99 have been taken as definitive in other studies (Bakari and 
Onyemelukwe, 2005; Wahreneburg et al., 2005).  Although plasma insulin 
concentrations were significantly higher in those with excess fat than lean 
individuals 30 minutes post-prandial, the AUCs for insulin and glucose were 
not different between the excess fat and lean groups of either gender.  
Therefore it would seem that glucose homeostasis was still normal in both 
the lean group and the excess fat group, hence the hypothesis that an 
altered MCH response may have been observed in the presence of insulin 
resistance could not be further explored in the current study. 
 
6.5.3  MCH and body composition 
A further objective of this study, and one which has been attendant in the 
other studies in this series was to describe associations between circulating 
MCH and body composition in the discrete populations under scrutiny, since 
this association is differentially pertinent for each study.  In the current study 
the fundamental enquiry was highly dependent on differences in body 
composition, specifically body fat and lean mass.  As discussed in Chapters 
5 and 7, up-regulation or central infusion of MCH is strongly associated with 
adiposity in rodents and conversely ablation of functional MCH results in a 
lean phenotype accompanied by increased energy expenditure.  Conflicting 
results with regard to the association between circulating MCH and body 
composition have been found in this series of studies.  In the current study, in 
contrast to the results reported in Chapter 5 a positive correlation between 
(a) BMI, body weight and mean plasma MCH concentrations and (b) body fat 
weight and mean post-prandial MCH was observed in lean females only 
(r=0.613, p=0.045; r=0.602, p=0.05; r=0.608, r=0.047 respectively).  A high 
BMI in conjunction with a high body weight and a high body fat weight is 
indicative of adiposity.  Based on results from rodent studies those with 
increased adiposity would be expected to have higher circulating MCH 
concentrations and the current results are not in complete accord with this.  
MCH was positively associated with markers of adiposity though not with fat 
mass percentage in lean women only.  This is a further example of sexual 
dimorphism which has been previously noted in this context and curiously 
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based on the results reported here and in Chapter 5 (though not in Chapter 
7) it seems that MCH signalling may be more acute in the lean rather than in 
the obese.  Again the n was relatively modest (11) and larger studies are 
required to confirm or deny these results but the question is posed as to 
whether in some populations fat interferes with MCH signalling either directly 
or indirectly via leptin resistance or some other perturbation of the system.  
With regard to the observed sexual dimorphism relating to circulating MCH 
concentrations in the energy homeostasis context it must be noted that  
results of previous work are suggestive of a gender-related component to 
MCH physiologic function.  A body of evidence has accrued implicating an 
oestrogen-sensitive or oestrogen-dependent mechanism in the modulation of 
central MCH activity (Viale et al., 1999; Murray et al., 2000b; Mystkowski et 
al., 2000) and in the current series of studies an association between plasma 
MCH concentrations and plasma progesterone concentrations in females has 
been reported (Chapter 7).  Therefore a link between the MCH system and 
gonadal steroids is suggested .   In males there is little published work in this 
context.  In the current series of studies results of correlational analysis from 
a sub-sample of males (n=17, mean age: 38.7 ± 11.7 yrs) were consistent 
with a robust relationship between circulating MCH and circulating 
testosterone concentrations (r=0.537, p=0.026).  An indirect mechanism may 
be operative since testosterone has been reported to modulate the activity of 
other anabolic central effectors, namely NPY (Sahu et al., 1992; Urban et al., 
1993), which projects onto MCH neurones in the lateral hypothalamus. 
 Finally the other studies in this series (Chapters 5 & 7) have examined RMR 
in association with circulating MCH concentrations since the results of  
animal studies strongly suggest that the MCH system impacts on energy 
expenditure and anatomically there are several proposed mechanisms 
through which it may influence thermogenesis including suppression of the 
sympathetic nervous system (Astrand et al., 2004; Messina and Overton, 
2007)  and reduction of uncoupling protein activity in brown adipose tissue  
(Ito et al., 2003; Segal-Lieberman et al., 2003).  The conclusions derived 
from the aforementioned studies in this series are that in humans there is no 
strong association between RMR and circulating MCH concentrations.  In the 
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current study an association was observed in a sub-section of the sample 
population, that is, in lean males with an RMR of 90 – 99.9% of predicted, 
which is considered normal (r=0.781, p=0.038).  However in light of the small 
n (7), these results are reported but no inference is currently made. 
 
6.5.4 Summary, limitations and future work 
 
The main finding of this study is supportive of a role for circulating MCH in 
the acute post-prandial period in humans, as evidenced by the results of 
correlation and regression analyses between plasma MCH, leptin, insulin and 
blood glucose concentrations.  However the strength and direction of these 
inter-relationships appears to be heavily influenced by combinations of 
gender and adiposity which is not entirely unexpected given the major roles 
of these circulating factors both as conveyors of metabolic information and 
effectors. Additionally in regression analysis mean plasma MCH 
concentrations made a significant contribution to the variance in the insulin 
AUC. Nevertheless further investigative work is required to explore certain 
inconsistencies; for example the AUC for MCH was not correlated with the 
AUC for insulin though mean plasma MCH concentrations were.   A 
consistent observation in this population however was that plasma MCH 
concentrations rose in all groups post-prandial, the source of this increase is 
not known though the endocrine pancreas is a candidate. On the other hand 
fluctuations in circulating MCH concentrations may be responding to 
fluctuations in pancreatic insulin production. It should also be noted that MCH 
has many and varied physiologic functions and it is quite likely that circulating 
MCH concentrations may be responding to multiple input. It was also 
interesting to note in this and other studies in this series that circulating MCH 
concentrations seem to be associated with distinct body composition 
parameters in distinct populations and that it is associated with leaness as 
well as adiposity. It may also be that adiposity alters MCH signalling either 
directly or indirectly via insulin or leptin resistance. 
A major limitation of the current study was the failure to recruit participants 
who were overtly insulin resistant as it was the intention to describe MCH 
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activity in the presence of both dysregulated and well-regulated glucose 
metabolism.  Additionally, some problems were experienced obtaining four 
consecutive blood samples from subjects within a relatively short time period 
and this resulted in missing data which has reduced the power of the study.  
However since the missing data was missing completely at random (MCAR) 
the decision was taken to use the available data in the analyses rather than 
impute missing values. As little is known about the variance in circulating 
MCH concentrations it was thought that unnecessary bias and imprecision 
may have been introduced.  In terms of methodology, the study would have 
been improved by the use of indwelling catheters to obtain blood samples, 
this would have enabled more frequent sampling and improved data 
collection.   This option however was not available.  
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7.   To investigate changes in concentrations of circulating MCH during 
the menstrual cycle and their associations with circulating 
progesterone, leptin and metabolic rate 
 
7.1 Introduction 
Evidence resulting from a number of recent studies is supportive of an 
emergent role for central MCH in the modulation of reproductive function. 
Based largely on interventional studies with rodents and in vitro work, several 
of those studies propose a role for MCH in the hypothalamic regulation of LH 
release (Tsukamara et al., 2000; Chiocchio et al., 2001; Gallardo et al., 2004; 
Murray et al., 2006).  One recent study suggests that the MCH system is 
active at the level of GnRH; MCH has been shown to have a direct inhibitory 
effect on kisspeptin signalling which is essential for normal reproductive 
function, notably mediation of the preovulatory LH surge (Wu et al., 2009). 
There is also neuroanatomical evidence supporting a mediatory role for 
centrally expressed MCH in reproductive activity (Williamson-Hughes et al., 
2005, Ward et al., 2009).   However a potential role for circulating MCH in the 
reproductive axis has not been investigated in any other species.  Therefore 
in the first instance it was deemed important to determine if there were any  
cyclical changes in circulating MCH concentrations throughout the menstrual 
cycle in humans.  In females intra-individual variations in energy expenditure 
during the menstrual cycle have been aligned to hormonal changes 
(Solomon et al., 1982; Howe et al., 1993). Whether or not phasic changes in 
consummatory behaviours contribute to altered energy expenditure has not 
been established (Webb, 1986; Pelkman et al., 2001).  Results of rodent 
studies suggest that hypothalamic MCH has the capacity to impact strongly 
on both energy expenditure (Segal-Lieberman et al., 2006; Jeon et al., 2006) 
and ingestive behaviours (Qu et al., 1996; Ludwig et al., 2001; Marsh et al., 
2002), though the activities of circulating MCH in this context are not known, 
therefore associations between resting metabolic rate, energy intake and 
circulating MCH concentrations during different phases of the menstrual 
cycle were examined.   Since leptin is generally recognised as a key factor in 
both normal reproductive physiology and energy balance, circulating leptin 
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concentrations were also examined in relation to circulating MCH 
concentrations in an effort to determine if there was a quantifiably 
measurable relationship between these two circulating factors during the 
menstrual cycle.  Therefore the aims of this study were: 
• To track circulating MCH concentrations throughout the menstrual 
cycle in normally cycling women. 
• To describe associations between circulating MCH concentrations, 
resting metabolic rate, energy intake and body composition at different 
stages of the menstrual cycle. 
• To determine associations between circulating MCH, progesterone 
and leptin concentrations throughout the menstrual cycle. 
 
7.2 Subjects and experimental protocol 
 
7.2.1 Participants 
 
Thirty one female subjects were recruited as Section 3.2.2. Inclusion criteria 
were that they should be pre-menopausal and having a regular menstrual 
cycle.  Lactating females, recently lactating (within the last 12 months) and 
pregnant women were excluded.  Subjects who were using oral 
contraceptives were allowed to participate and their data used as controls. 
Those on chronic medication were not routinely excluded though anyone 
taking superovulatory medication or medication known to affect metabolic 
rate were not allowed to participate. Data collected by another researcher at 
the University of Westminster has been included in the current analyses. The 
researcher was Faridah Shahab (BSc (Hons) 2008/09). 
 
7.2.2 Pre-test 
 
Subjects attended an initial laboratory visit during which they were verbally 
familiarised with all experimental procedures.  Since subjects were expected 
to attend the laboratory on several occasions it was felt that that this 
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induction would limit drop-out rate.  During the initial visit subjects were 
supplied with and instructed how to use a digital clinical thermometer 
(RJ95D, Maplin, UK).  Prior to testing all subjects maintained a daily record of 
their waking oral temperature for  1 – 2 full menstrual cycles in order to 
establish when ovulation usually occurred within their monthly cycle.  This 
temperature record was also kept during the month they attended the 
laboratory for testing.  Subjects received a detailed Subject Information Sheet 
(Appendix 8) and completed an Informed Consent Form and pre-test Medical 
Screening Questionnaire as Sections (Appendices 9 & 4).  
 
7.2.3. Experimental protocol 
 
Subjects attended the laboratory four times over the course of one complete 
menstrual cycle.  The visits were timed so that subjects attended twice during 
the follicular phase (early and late) and twice during the luteal phase (early 
and late). See Figure 7.1 for schematic representation of experimental 
protocol.  Each visit subjects attended after an overnight fast.  On the first 
visit anthropometric measurements were taken as described in Section 3.2.3.  
On all visits RMR and total body fat and lean mass were measured using the 
procedures described in Sections 3.2.4 and 3.2.5.  A fasting venous blood 
sample was obtained on all visits which was collected, treated and the 
plasma samples stored as described in Section 3.2.6.  Subsequently plasma 
samples were assayed for MCH, leptin and progesterone by methods 
described in Section 3.2.7.  Subjects completed two 3-day Food Diaries (2 
consecutive weekdays and 1 weekend day (Appendix  5), one during the late 
follicular phase and one during the late luteal phases of their monthly cycle. 
The Food Diaries were anaylsed using software described in Section 5.2.2. 
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Figure 7.1: Schematic representation of the experimental protocol, in 
this example the length of the cycle is 28 days.   
 
7.3 Statistical Analyses 
 
Normality of each data set was assessed by Shapiro Wilks W test and by 
examination of Skewness and Kurtosis values. Log-transformed data were 
used where necessary.  Homogeneity of variance was determined by 
Levene’s Test for Equality of Variances. Differences between circulating 
hormone concentrations in the follicular and luteal phases of the monthly 
cycle were assessed by paired samples t-tests. Differences in circulating 
hormone concentrations between those subjects who had an ovulatory cycle 
or an anovulatory cycle were determined by independent samples t-tests and 
the non-parametric Mann-Whitney U test.  Comparisons between circulating 
hormone concentrations during the early follicular, late follicular, early luteal 
and late luteal phases of the menstrual cycle were determined by repeated 
measures design ANOVA.  Post-hoc tests were performed using Bonferroni 
adjustment for multiple comparisons.  One-way between-groups ANOVAs 
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were conducted to determine if there was an effect of BMI and body fat % on 
plasma hormone concentrations.  Post-hoc tests were performed using 
Tukey adjustment for multiple comparisons.  The effect of size (group) was 
calculated using partial eta squared or eta squared.  The guidelines for 
interpretation were those proposed by Cohen (1988).  The strength of 
relationships between variables was determined by Pearson product-moment 
correlation coefficient.  Partial correlation was used to control for 
compounding variables.  Unless otherwise stated, values are presented as 
mean ± SD or mean ±  SEM. Data were analysed using the Statistical 
Package for the Social Sciences (SPSS version 16.0 for Windows; Chicago, 
IL, US).  Statistical significance was set at p<0.05. 
 
7.4  Results 
 
7.4.1  Subject characteristics 
 
Of the 31 subjects data from 2 were excluded from the analyses since it was 
not possible to obtain blood samples from them. Another subject was 
excluded since her plasma MCH concentrations were greater than two 
standard deviations from the mean and two subjects were excluded due to 
irregularities in their menstrual cycles.  Of the remaining 26 subjects 20 were 
classified as ovulators (ov) and 6 as non-ovulators (non-ov) based on 
whether their awakening body temperature changed mid-cycle and their 
plasma progesterone concentrations.  Two of the non-ovulators were  
contraceptive pill users.  Even though an anovulatory cycle will not have a 
true luteal phase (that is, a corpus luteum will not be formed and therefore 
there will be no luteal phase increase in circulating progesterone 
concentrations), for the purposes of these analyses plasma hormone 
concentrations measured during the last 16 days of the cycle have been 
designated as luteal phase for the non-ov group.   
Demographic and anthropometric characteristics of the study participants are 
presented in Table 7.1.  There were no differences in age, height, weight, 
BMI, percent fat mass and percent lean mass between the ovulatory and 
non-ovulatory women (p>0.05).  
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Table 7.1 Demographic and anthropometric characteristics of study 
participants 
 Mean ± SD Range 
 All 
(n=26) 
Ov 
(n=20) 
Non-ov 
(n=6) 
All 
(n=26) 
Ov 
(n=20) 
Non-ov 
(n=6) 
Age  
(yrs) 
 
37.1±6.0 37.3±5.2 36.4±8.9 26.8-49.0 30.7-49.0 26.8-47.8 
Height  
(m) 
 
1.66±0.1 1.66±0.1 1.66±0.1 1.57-1.8 1.57-1.8 1.63-1.7 
Weight 
(kg) 
67.7±15.1 70.5±8.5 68.6±6.3 50.2-118.9 50.2-118.9 56.9-82.4 
Fat mass 
(%) 
29.9±8.0 29.4±8.5 31.4±6.3 16.3-49.2 16.3-49.2 23.2-38.4 
Lean 
mass (%) 
70.0±8.0 70.5±8.5 68.5±6.3 50.7-83.6 50.7-83.6 61.6-76.7 
BMI 
(kg/m2) 
24.6±5.3 24.8±5.8 25.0±2.9 18.3-40.6 18.3-40.6 21.1-28.5 
 
7.4.2 Plasma hormone concentrations 
 
7.4.2.1 Plasma MCH concentrations during the menstrual cycle  
 
Fasting plasma MCH concentrations measured during the early follicular, late 
follicular, early luteal and late luteal phases of the menstrual cycle were not 
significantly different at any of the four sampling time-points when data from 
the whole group were analysed (p=0.808); nor when the group was split 
between ovulatory (p=0.672) and non-ovulatory women (p=0.709). Mean 
plasma MCH concentrations in the follicular phase of the cycle were not 
significantly different to those in the luteal phase either in the group as a 
whole (p=0.130) or within women who did ovulate and those who did not 
(Table 7.2: ov: p=0.213; non-ov: p=0.459). There were no significant 
differences in plasma MCH concentrations between the ovulatory and non-
ovulatory women in either phase of the menstrual cycle (Table 7.2: follicular: 
p=0.125; luteal: p=0.185). However there was a non-significant trend for 
ovulatory women to have higher plasma MCH concentrations in the follicular 
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and luteal phases than non-ovulatory women (Table 7.2).  Both groups also 
appear to have higher MCH concentrations in the luteal phase than in the 
follicular phase though again this difference was not significant. Plasma MCH 
concentrations ranged from 29.2 - 61.8 pg/ml.  
Table 7.2  Plasma hormone concentrations during the follicular and 
luteal phases of the menstrual cycle in ovulatory and anovulatory 
women 
  
Mean ± SD 
 
Range over the entire 
cycle 
 All 
(n=26) 
Ov 
(n=20) 
Non-ov 
(n=6) 
Ov 
(n=26) 
Non-ov 
(n=6) 
 F L F L F L   
MCH  
(pg/ml) 
41.7 
±6.9 
43.2 
±7.3 
42.7 
±6.8 
43.9 
±7.9 
37.8 
±5.9 
39.4 
±6.6 
 
32.6–61.8 
 
29.2-48.5 
Leptin  
(ng/ml) 
11.4 
±10.9a 
12.5 
±9.6b 
11.5 
±11.8 
12.6 
±10.2 
11.3 
±8.6 
12.3 
±8.4 
 
1.8-50.3 
 
3.2-27.9 
Progesterone 
(ng/ml) 
0.5 
±0.4a 
8.1 
±5.2b 
0.5 
±0.4a 
10.0 
±3.8b 
0.3 
±0.1a 
0.5 
±0.3a 
 
0.3-16.1 
 
0.3-1.03 
F: follicular; L: luteal; within a hormone values with different superscripts are significantly 
different from each other (paired samples t-test; p<0.05) 
 
7.4.2.2 Plasma leptin concentrations during the menstrual cycle  
 
Mean plasma leptin concentrations in the follicular phase of the cycle were 
significantly lower than those in the luteal phase in all individuals (11.4 ± 10.9 
ng/ml versus 12.5 ± 9.6 ng/ml; paired samples t-test; p=0.044).  There were 
no differences in plasma leptin concentrations between the follicular and 
luteal phases either within ovulatory  and non-ovulatory women (ov: p=0.100; 
non-ov: p=0.226) or between ovulatory and non-ovulatory women (Table 7.2: 
independent samples t-test; follicular; p=0.978; luteal: p=0.914). The 
ovulatory  womens’  leptin concentrations were significantly higher in the 
early and late luteal phases of the cycle compared to the early follicular 
phase (Table 7.3: one-way repeated measures ANOVA; p=0.03; with a large 
Chapter 7. Study 3 
99 
 
effect of size, multivariate partial eta squared =0.502). Only women from 
whom blood samples were collected at each of the four sampling time-points 
were included in this analysis hence the change in subject numbers per 
group. 
 
Table 7.3  Plasma hormone concentrations during the menstrual cycle 
in ovulatory and anovulatory women  
 Mean ± SD 
 
 Ov (n = 15) 
 
Non-ov (n = 3) 
 
 
MCH 
(pg/ml) 
EF 
 
LF EL LL EF LF EL LL 
44.71 
±8.3 
 
43.01 
±8.3 
44.53 
±6.8 
45.02 
±7.5 
41.11 
±6.4 
42.09 
±6.4 
42.7 
±7.3 
38.8 
±3.6 
Leptin 
(ng/ml) 
8.73 
±6.4a 
9.84 
±7.2 a,b 
 
10.62 
±7.0b 
11.29 
±8.0b 
14.19 
±9.3 
18.10 
±10.6 
17.07 
±10.9 
15.4 
±8.4 
Prog 
(ng/ml) 
0.45 
±0.3a 
0.83 
±1.6a,b 
11.17 
±5.7c 
8.63 
±5.3c 
0.30 
±0 
 
0.30 
±0 
0.56 
±0.5 
0.30 
±0.5 
EF: early follicular, LF: late follicular, EL: early luteal, LL: late luteal, within a hormone values 
with different superscripts are significantly different from each other (one-way repeated 
measures ANOVA; p<0.05). Reduced n values are due to missing plasma samples. 
 
 
7.4.2.3 Plasma progesterone concentrations during the menstrual cycle 
 
Within ovulatory women plasma progesterone concentrations were 
significantly higher in the early and late luteal phases than in the early and 
late follicular phases of the cycle (p<0.005).  Luteal phase plasma 
progesterone concentrations in ovulatory women were also significantly 
higher than follicular and luteal phase progesterone concentrations in non-
ovulatory women (p<0.005).  There were no significant changes in plasma 
progesterone concentrations in non-ovulatory women across the cycle (Table 
7.3: p>0.005). 
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7.4.3 Associations between circulating MCH and leptin concentrations and 
BMI  
 
Subjects were divided into 3 groups according to BMI to determine whether 
there was a difference in plasma MCH or plasma leptin concentrations 
between women who were in the normal, overweight or obese BMI 
categories.  The groups were: B1= ≤ 24.9; B2= 25 – 29.9; B3= ≥ 30 kg/m2. 
MCH: There were no significant differences in mean follicular or mean luteal 
MCH concentrations between the three categories of BMI for either ovulatory 
or non-ovulatory women (data not shown).  Leptin: For both ovulatory and 
non-ovulatory women, as BMI increased circulating leptin concentrations 
increased.  In ovulatory women B3 circulating leptin concentrations were 
significantly greater than B1 and B2 (Table 7.4: p<0.005).  In non-ovulatory 
women circulating leptin concentrations were significantly greater in B2 than 
B1 (Table 7.4: p<0.005). Within the BMI categories there was a significant 
difference in the concentration of leptin between the follicular and luteal 
phase in ovulatory women in the B1 group only (Table 7.4: paired samples t-
test; p=0.002) 
 
7.4.4 Associations between circulating MCH and leptin concentrations and 
body fat and lean mass 
 
Subjects were sub-divided into 3 groups according to body composition. The 
groups were: Lean (L)= 19 – 22% fat mass; Moderately Lean (ML)= 23 – 
30% fat mass; Excess Fat (EF) ≥ 31% fat mass, (ACSM, 1996).  MCH: There 
were no significant differences in the concentrations of MCH between the 
follicular and luteal phases both within and between a category in either 
ovulatory or non-ovulatory women (results not reported).  Leptin: Ovulatory 
women in the EF group had significantly greater leptin concentrations than in 
ML and L groups (Table 7.4: p<0.005) There was a trend for greater leptin 
concentrations in EF than ML in non-ov women (Table 7.4: p=0.643). Within 
the per cent fat mass categories there was a significant difference in the 
concentrations of leptin between the follicular and luteal phases in the ML 
category in ovulatory women only (Table 7.4: p=0.035).  
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Table 7.4: Associations between circulating leptin concentrations in the 
follicular and luteal phases of the menstrual cycle with BMI and fat 
mass  
 
Ov 
 
Non-ov 
        
  BMI 
Follicular Luteal Follicular Luteal 
B1 
(n=11) 
B2 
(n=5) 
B3 
(n=3) 
B1 
(n=11) 
B2 
(n=5) 
B3 
(n=3) 
B1 
(n=3) 
B2 
(n=3) 
B3 
(n=0) 
B1 
(n=3) 
B2 
(n=3) 
B3 
(n=0) 
 
5.2±  
3.3a* 
 
12.9± 
6.7 a,b 
 
32.0± 
15.8c 
 
7.8±  
4.9a* 
 
15.1± 
5.5a,b 
 
28.8± 
14.2c 
 
6.5± 
3.0a 
 
18.1± 
8.2b 
 
n/a 
 
5.7± 
3.1a 
 
16.9± 
9.1b 
 
n/a 
 
        
    Fat Mass 
 
L 
(n=4) 
ML 
(n=7) 
EF 
(n=8) 
L 
(n=4) 
ML 
(n=8) 
EF 
(n=8) 
L 
(n=0) 
ML 
(n=2) 
EF 
(n=4) 
L 
(n=0) 
ML 
(n=2) 
EF 
(n=4) 
 
3.5±  
1.2a 
 
4.9±  
2.3a,b* 
 
21.2± 
12.8c 
 
5.9±  
3.0a 
 
8.0±  
4.7a,b* 
 
21.1± 
10.5c 
 
n/a 
 
3.9± 
1.06 
 
15.0± 
8.4 
 
n/a 
 
4.9± 
1.5 
 
16.0± 
7.9 
B1 : ≤ 24.9; B2: 25 – 29.9; B3: ≥ 30 kg/m2;   L: lean, ML: moderately lean, EF: excess fat. 
Leptin concentrations are expressed as mean ± SD (ng/ml); within ov or non-ov groups 
values with different superscripts are significantly different from each other  (one-way 
between-groups ANOVA; p<0.05); within ov or non-ov groups between follicular and luteal 
phases values with * are significantly different from each other (paired samples t-test; 
p<0.05). Reduced n values are due to missing plasma samples. 
 
7.4.5 Associations between circulating MCH, leptin and progesterone 
concentrations during the menstrual cycle  
 
There was a significant negative association between early luteal MCH 
concentrations and early luteal progesterone concentrations in ovulating 
women (Table 7.5: r =-0.533, p=0.023). There were no other significant 
associations between concentrations of any of the hormones examined at 
any of the sampling time-points in either the ov or the non-ov group.  
However there was a trend for an inverse relationship between MCH and 
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leptin, higher concentrations of MCH were associated with lower 
concentrations of leptin. There were no significant associations between 
plasma leptin and plasma progesterone at any of the sampling timepoints 
(data not shown).  
 
Table 7.5: Bivariate analyses:  Correlations between plasma MCH, leptin 
and progesterone during the menstrual cycle (ov women)  
 MCH (EF) MCH (LF) MCH (EL) MCH (LL) 
LEP (EF) (n=19) -0.103 
(p=0.685) 
- - - 
LEP (LF) (n=17) - -0.175 
(p=0.502) 
- - 
LEP (EL) (n=18) - - -0.155 
(p=0.539) 
- 
LEP (LL) (n=19) - - - 0.014 
(p=0.955) 
PROG (EF) (n=19) 0.030 
(p=0.902) 
- - - 
PROG (LF) (n=18) - -0.334 
(p=0.176) 
- - 
PROG (EL) (n=18) - - -0.533 
(p=0.023)* 
- 
PROG (LL) (n=19) - - - 0.057 
(p=0.818) 
Values represent Pearson product-moment correlations, *significant at 0.05 level,  LEP: 
leptin, PROG: progesterone, EF: early follicular, LF: late follicular, EL: early luteal, LL: late 
luteal. Reduced n value is due to missing plasma samples. 
 
7.4.6  Associations between circulating MCH and leptin concentrations and 
body composition parameters 
 
For each woman the mean MCH and leptin concentrations over her 
menstrual cycle were calculated and used for the following analyses (Table 
7.6: Figs 7.1(a) & 7.1(b).   Whilst there were no significant associations 
between mean circulating MCH and body composition parameters there were 
trends for inverse relationships between % fat mass, BMI and body weight 
with circulating plasma MCH concentrations.  By comparison there were 
strong significant positive relationships between circulating leptin 
concentrations and the same body composition parameters.  However when 
associations between the body composition parameters and plasma MCH 
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concentrations measured at each of the four sampling time-points were 
examined there were significant correlations between % body fat mass, % 
body lean mass and late follicular MCH in women with excess fat only (r=-
0.733, p=0.038; r=0.733, p=0.038 respectively; n=8).  
 
Table 7.6 Associations between mean circulating MCH and leptin 
concentrations and body composition parameters 
 MCH 
(n=26) 
Leptin 
(n=26) 
Fat mass (%) -0.207 (p=0.310) 0.554 (p=0.003)** 
Lean mass (%) 0.207 (p=0.310) 0-.554 (p=0.003)** 
Fat mass (kg) -0.224 (p=0.271) 0.530 (p=0.005)** 
Lean mass (kg) -0.114 (p=0.580) 0.145 (p=0.480) 
BMI (kg/m2) -0.234 (p=0.250) 0.519 (p=0.007)** 
Body weight (kg) -0.201(p=0.325) 0.431 (p=0.028)* 
Values represent Pearson product-moment correlations, * significant at 0.05 level (2 tailed)  
** significant at 0.01 level (2 tailed)   
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Figure 7.1(a): Correlation between menstrual cycle mean circulating MCH concentrations 
and body fat mass % (Pearson product-moment correlation, r=-0.270, p=0.310, n=26)  
 
Figure 7.1(b): Correlation between menstrual cycle mean circulating leptin concentrations 
and body fat mass % (Pearson product-moment correlation, r=0.556, p=0.003, n=26) 
 
7.4.7 Circulating MCH concentrations and resting metabolic rate 
 
Resting metabolic rates (RMR) were compared during the early follicular, late 
follicular, early luteal and late luteal phases of the menstrual cycle.  When the 
whole group was analysed RMR measured in the late follicular phase 
(absolute values kcal/day) was significantly lower (1274.9 kcal/day) than 
RMR measured in the late luteal phase (1328.1 kcal/day ) (one-way repeated 
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measures ANOVA: p=0.001; with a large effect of size, multivariate partial 
eta squared=0.613).  When ovulatory and non-ovulatory women were 
grouped separately there were no significant differences in RMR at any 
sampling time-point in non-ovulatory women however there were significant 
differences in RMR in the ovulatory women.  Late follicular RMR was 
significantly lower than early though not late luteal RMR (Table 7.7: one-way 
repeated measures ANOVA; p=0.037; with a large effect of size, multivariate 
partial eta squared=0.603).  There were no significant differences between 
ov RMR and non-ov RMR in any phase of the menstrual cycle. 
 
Table 7.7: RMR (kcal/day) in ovulatory and anovulatory women during 
the menstrual cycle 
EF LF EL LL 
Ov 
(n=19) 
Non-ov 
(n=5) 
Ov 
(n=19) 
Non-ov 
(n=5) 
Ov 
(n=19) 
Non-ov 
(n=5) 
Ov 
(n=19) 
Non-ov 
(n=5) 
1283 
±143a,b 
1348  
±214 
1287  
±139a 
1406 
±176 
1320 
±141b 
1382 
±185 
1326 
±150a,b 
1441 
±173 
 EF: early follicular, LF: late follicular,  EL: early luteal, LL: late luteal. Within the ovulatory 
group values with different superscripts are significantly different from each other (one-way 
repeated measures ANOVA, p<0.05). Reduced n values are due to missing plasma 
samples.  
There were no associations between plasma MCH concentrations and RMR 
when analyses were performed for the four sampling time-points during the 
menstrual cycle, neither in the group as a whole nor within ovulatory or non-
ovulatory women. 
 
7.4.7.1 Associations between circulating MCH, leptin, progesterone and RMR 
during the menstrual cycle in ovulatory women (n = 18)  
 
Ovulatory women were divided into 2 groups based on their % predicted 
RMR. Predicted RMR (kcal/day) was calculated as the mean of the Harris-
Benedict and Fleisch equations as Section 5.4.4.  A RMR of ± 10% predicted 
is considered normal (McKardle et al., 2001). Therefore the groups were N 
(normal)= ≥ 90% predicted; L (low)= ≤ 89.9% predicted. MCH: There were no 
strong associations between plasma MCH concentrations and RMR in either 
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group at any of the four sampling time-points in the menstrual cycle Leptin: 
There were no significant correlations between plasma leptin concentrations 
and RMR after controlling for fat mass. Progesterone: There were no 
significant correlations between RMR and plasma progesterone 
concentrations in either group in any phase of the menstrual cycle  
 
7.4.8  Associations between plasma MCH concentrations, energy intake and 
RMR 
 
Twenty-four 3-day food diaries kept by 12 ovulatory women were analysed.  
Each woman kept one diary in the follicular phase and one in the luteal 
phase of her cycle.  There were no differences in caloric (kcal/day or kcal per 
kg/bodyweight/day) or percent macronutrient intake between the follicular 
and luteal phases of the cycle (p>0.05).  Neither were there significant 
correlations between fasting plasma MCH concentrations and caloric or 
percent macronutrient intake in either phase of the cycle (Pearson product-
moment correlation; p>0.05).  Energy intake was not associated with RMR 
(absolute values) in either phase of the cycle.   
 
7.5  Discussion 
 
7.5.1 Circulating MCH concentrations during the menstrual cycle 
Although all subjects had regular menstrual cycles both ovulatory and 
anovulatory females were included in the study in order to compare the MCH 
response in the presence/absence of progesterone.  This was deemed an 
important distinction since if MCH plays a role in normal reproductive function 
it would be expected that circulating concentrations of the hormone would 
differ between ovulatory and anovulatory cycles.  If fluctuations of peripheral 
MCH conform to those of central MCH in the rodent (Gallardo et al., 2004), 
then it would be expected that there would be a difference in circulating MCH 
concentrations between the follicular and luteal phases of the menstrual 
cycle.  
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Plasma MCH concentrations at four phases of the menstrual cycle, namely: 
early follicular, late follicular, early luteal and late luteal were measured in 
both ovulatory and anovulatory women and there appears to be no significant 
changes in circulating MCH which may be demarcated by phases of the 
menstrual cycle. There was however a non-significant trend for plasma MCH 
concentrations to be higher in ovulatory women compared to anovulatory 
women and for luteal concentrations to be higher than follicular 
concentrations in both.  This is in contrast to the behaviour of other metabolic 
markers of energy homeostasis such as leptin.  Considerable disparity in 
circulating leptin concentrations in different phases of the menstrual cycle 
have been reported; commonly luteal phase concentrations being higher than 
follicular phase concentrations (Hardie et al., 1997; Paolisso et al., 1999; 
Ludwig et al., 2000; Geisthovel et al., 2004).  The findings reported herein 
are in broad agreement with these results.  Although plasma leptin 
concentrations were not significantly different in any phase of the menstrual 
cycle between ovulatory and anovulatory women, plasma leptin 
concentrations were significantly lower in the early follicular phase compared 
to the early and late luteal phases in ovulatory women only.  This 
discrepancy between ovulatory and anovulatory women should be treated 
with caution since a full data set for only 3 subjects in the anovulatory group 
was available for analysis.  In energy homeostasis central leptin antagonises 
the actions of MCH via the anabolic NPY/AgRP metabolic pathway (for 
review see Schwartz et al., 2000). In the reproductive axis there is some 
evidence that MCH may act collaboratively with leptin in mediating the LH 
surge (Murray et al., 2000c). However few studies have elucidated the nature 
of the relationship between leptin and MCH in the periphery.  The only other 
study to date to measure circulating MCH concentrations in humans found no 
significant associations between fasting plasma leptin and MCH 
concentrations (Gavrila et al., 2005).  In the current study there were no 
significant correlations between fasting plasma MCH concentrations and 
plasma leptin concentrations in any phase of the menstrual cycle. However 
there was a trend for inverse correlations between circulating MCH and leptin 
which is in line with the reported suppression of hypothalamic MCH activity 
by leptin.  
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7.5.2 MCH and RMR 
 
As discussed in Chapter 5 central MCH appears have a profound influence 
on energy expenditure at least in rodents.  Variations in energy expenditure 
have been observed during the human menstrual cycle (Solomon et al., 
1982; Webb, 1986; Bisdee et al., 1989; Meijer et al., 1992; Henry et al., 
2003).  Elevated RMR in the luteal phase has been attributed to the 
thermogenic effect of progesterone.  Therefore a key objective of the current 
enquiry was to establish whether or not there were significant associations 
between cyclic RMR and circulating concentrations of MCH in healthy 
women.  In agreement with previous work there were significantly higher 
RMR values  in the luteal phase of the cycle compared to the follicular phase 
(kcal/day).  When ovulatory and anovulatory women were grouped together 
late follicular RMR was significantly lower than late luteal though not early 
luteal RMR.  When analysed separately anovulatory women did not display 
significant fluctuations in RMR over the cycle but in ovulatory women RMR 
was significantly higher in the early luteal phase than in the late follicular 
phase.  The apparent delayed rise in luteal RMR in the whole group 
compared to the earlier elevated luteal RMR in the ovulatory women was 
likely due to the masking effects of decreased early luteal RMR in non-
ovulatory women. 
 
Circulating MCH concentrations do not appear to be aligned to RMR since 
there were no significant associations between RMR and plasma MCH 
concentrations when analyses were performed at the four sampling time-
points in the whole group or within ovulatory and anovulatory women. Nor 
were there significant associations between RMR and plasma MCH 
concentrations at any sampling time-point in those with either a normal or low 
metabolic rate.  However whilst there was no direct association between 
RMR and plasma MCH concentrations in the luteal phase, there was a 
significant inverse correlation (r=-0.533, p=0.023) between plasma MCH and 
plasma progesterone concentrations in the early luteal phase of the cycle in 
ovulatory women only. Given the acknowledged thermoregulatory actions of 
both MCH and progesterone, which are in opposing directions this finding is 
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unsurprising, though it is suggestive of a signalling pathway between MCH 
and gonadal steroids.  
 
7.5.3  MCH, body composition and BMI 
 
There is a wealth of evidence documenting the contribution of MCH to the 
obese phenotype and conversely the phenomena of the lean phenotype 
characteristic of MCH or MCHR-1 k/o rodents.  Reduced adiposity, increased 
lean mass and reduced body weight accompanied by either hyper- or 
hypophagia have been reported in genetically modified animals or those to 
whom an MCHR-1 antagonist has been administered (Chen et al., 2002; 
Marsh et al., 2002; Mashiko et al., 2005; Bjursell et al., 2006; Kowalski et al., 
2006).  Increased body mass and adiposity have been observed following 
MCH infusion or up-regulation of MCH expression (Ludwig et al., 2001; 
Gomori et al,. 2002).  Interestingly MCH induced food consumption appears 
to be related to the hedonic aspects of feeding which was discussed in 
Chapter 5.  In humans a phasic change in food intake has been observed, 
specifically a reduction in food intake in the ovulatory period followed by a 
rise in the luteal phase (Lyons et al., 1989; Paolisso et al., 1999). Therefore 
since MCH plays a key role in systemic energy balance it would seem logical 
to investigate whether or not circulating MCH concentrations were associated 
with anthropomorphic dimensions or caloric intake.   
 
There were no significant correlations between percent body fat mass, 
percent body lean mass, fat mass weight (kg), lean mass weight (kg) BMI or 
body weight (kg) and mean plasma MCH over one entire cycle.  This was in 
contrast to plasma leptin which was strongly associated with all of the above 
parameters with the exception of lean body mass weight (Table 7.6).  There 
was however an inverse association between percent fat mass and 
circulating MCH concentrations measured in the late follicular phase of the 
cycle in women with excess fat only (r=-0.733, p=0.038, n=8).  The 
association between circulating MCH concentrations and certain body 
composition parameters in discrete sub-groups of the sample population has 
been a recurrent phenomenon throughout this series of studies.  It seems 
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that circulating MCH concentrations are altered in the presence of adiposity 
or leanness which is gender specific in a given population.  However by 
definition the sample sizes of the sub-groups were small therefore inferential 
caution must be exercised.  It is tempting to speculate that there may be a 
relationship with oestrogenic activities. In rodents endogenous oestradiol 
appears to suppress MCH activity during the oestrous phase of the 
reproductive cycle which could be said to correspond to the follicular phase in 
humans since it is a period of high circulating oestrogen. In the current study 
there was a trend, though non-significant, for follicular phase circulating MCH 
concentrations to be lower than those in the luteal phase. Whether or not this 
was partly due to oestrogenic inhibition is a subject for further investigation.  
Furthermore although not significant, MCH correlations were in the inverse 
direction to leptin, that is, correlations between percent fat mass, BMI, body 
weight and plasma MCH were negative, whilst correlations between percent 
lean mass and plasma MCH were positive.  
 
The impact of BMI and body composition on circulating MCH concentrations 
was explored.  Subjects were divided into 3 groups based on BMI categories 
which are widely accepted as representing normal weight, overweight or 
obese individuals.  There were no differences in circulating MCH 
concentrations between women in any of the categories, in either the 
follicular or luteal phases, and no differences between ovulatory or 
anovulatory women.  Since BMI does not represent adiposity per se, women 
were also grouped into 3 body composition categories based on the ASCM’s 
classification of a lean, moderately lean and excess fat phenotype.  In this 
paradigm body composition does not appear to impact on circulating MCH 
concentrations, no differences being found between any category in either 
phase of the cycle and no differences between ovulatory and anovulatory 
women.  As expected circulating leptin concentrations increased in line with 
increased adiposity and BMI in both ovulatory and anovulatory women; the 
increases were not statistically significant in the anovulatory women but the 
small sample size was likely a factor.  Leptin concentrations were also 
significantly higher in the luteal phase compared to the follicular phase in 
women in the normal BMI category and in the moderately lean category, 
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which did not appear to be related to fluctuations in percent fat mass or body 
weight.  
 
7.5.4  MCH, energy intake and RMR 
In rodents hypothalamic MCH has the capacity to impact strongly on feeding 
behaviours, this subject was also discussed in Chapter 5.  Briefly 
pharmacologically or genetically altered availability of hypothalamic MCH 
induces significant changes in consummatory behaviour.  Generally 
increased availability of hypothalamic MCH resulted in hyper-phagia (Qu et 
al., 1996; Ludwig et al., 2001) whilst hyper- or hypophagia may be induced 
by decreased availability of hypothalamic MCH depending on the rodent 
model (Chen et al., 2002; Kowalski et al., 2006).  In normally cycling pre-
menopausal women evidence suggests that energy intake is strongly 
influenced by ovarian hormones.  In an analysis of 37 groups of women, 27 
of the groups exhibited increased energy intake in the luteal compared to the 
follicular phase of the cycle.  A non-significant tendency for increased luteal 
phase energy intake was observed in a further 7 groups (Dye and Blundell, 
1997).  It has been hypothesised that an interaction between circulating 
oestrogen and progesterone post-ovulation is responsible for the altered 
ingestive behaviours (for review see Davidsen et al., 2007).  An apparent 
increased preference for carbohydrates (Bowen et al., 1990; Cross et al., 
2001; Martini et al., 2004) or fats (Tarasuk et al., 1991; Johnson et al., 1995) 
in the luteal phase has been reported in a number of studies. However in the 
current study although data from ovulatory women exclusively were 
analysed, no differences were observed either in energy intake or 
macronutrient composition of the diet between the follicular and luteal 
phases.  Nor were there any associations between energy intake and RMR 
(absolute values). There are several factors which are thought to contribute 
to the variation in phasic energy expenditure in women including hormonal 
(Solomon et al., 1982; Howe et al., 1993) and sympathetic nervous system 
activity (Day et al., 2005). The contribution of energy intake though a feasible 
candidate has not been well defined.  There appear to be few studies in 
which energy intake and expenditure have been measured in the same 
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women (Davidsen et al., 2007). A previous study reported increased luteal 
phase energy intake and energy expenditure which were not related 
(Pelkman et al., 2001). In the current study energy intake and expenditure 
were not aligned in either study. Curiously though mean caloric intake 
(absolute and per kg bodyweight) were almost identical between the 2 
phases.  This brings into question the validity of self-reported estimated food 
diaries; difficulties associated with this type of nutritional tool are 
acknowledged (Kaczowski et al., 2000). 
 
7.5.5 Summary, limitations and future work 
 
The main finding of this study was that fasting plasma MCH concentrations 
remain relatively stable over the course of a normal menstrual cycle. There 
was very little difference in circulating MCH concentrations between women 
who ovulated and those who did not apart from in the early luteal phase of 
the cycle when plasma MCH concentrations were inversely correlated with 
plasma progesterone concentrations in ovulatory women.  Superficially this 
finding may be interpreted as a disassociation between MCH and female 
reproductive function in the periphery.  However it must be said that in this 
study plasma MCH was measured at only 4 time-points over an entire cycle, 
nothing is known about secretion or clearance rates, or whether MCH is 
secreted in a pulsatile or continuous manner. Additionally all samples were 
obtained from fasted subjects between 08.00 – 10.00am.  In a separate study 
in this series plasma MCH concentrations increased post-prandial, therefore 
it is entirely possible that, since only fasting samples were obtained, temporal 
fluctuations may have been missed. In rodents MCH expression follows a 
diurnal pattern, nothing is known in this regard in humans and would be a 
subject for future work. 
 
With regard to metabolic rate it would appear there are no strong 
associations between RMR and plasma MCH concentrations in either phase 
of the cycle either in ovulatory or anovulatory women.  Therefore it would 
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seem that plasma MCH does not strongly reflect energy expenditure in the 
periphery. 
 
Throughout this study the actions of circulating MCH have been compared to 
those of circulating leptin, which having a dominant role in both energy 
homeostasis and reproductive function might be considered a yardstick for 
MCH activity in the periphery.  However in the current study there were no 
significant associations between plasma MCH and plasma leptin during the 
menstrual cycle.  Fluctuations in circulating MCH were not reflected in 
fluctuations in circulating leptin although there was a consistent trend for 
negative MCH correlations to be matched by positive leptin correlations both 
within the contexts of body composition and RMR.  With regard to body 
composition it seems that circulating MCH does not convey information 
relating to fuel stores and availability in the same manner that leptin does, 
though again perhaps the use of fasting plasma samples was in some way 
restrictive since in a separate study we found significant associations 
between certain body composition parameters and post-prandial MCH 
concentrations. 
 
A principal limitation of this study was the imbalance in sample size between 
ovulatory and anovulatory women.  The small sample size of the anovulatory 
group (n=6) made comparisons and conclusions regarding disparities 
between the groups difficult.  Except in the case of the 2 women who were 
contraceptive pill users, it was not possible to confirm whether women were 
having ovulatory or anovulatory cycles until testing was complete.  Although 
the sample size was comparable to and in some cases larger than previous 
work in this area, it was disappointing to have to exclude 5 subjects (on the 
grounds of various anomalies) from what was initially an adequate though 
relatively modest sample size.  Further work with larger sample sizes is 
required.  Additionally as noted above, the use of fasting plasma samples 
only may have limited the scope of the study. 
 
Clearly the capacity for further work with circulating MCH is enormous, this 
initial characterisation of MCH activity in the menstrual cycle instigates many 
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questions. Based on the results of this study it would seem that a potential 
relationship between circulating MCH and oestrogen in human females would 
be worthy of investigation. The current results indicate that one cannot make 
assumptions regarding the activities of circulating MCH based on knowledge 
of hypothalamic MCH activity.   Whilst circulating MCH does not appear to be 
overtly reactive in the menstrual cycle, it could be that circulating MCH 
behaves in a manner more subtle than this initial investigation has been able 
to detect.  
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8.  Synthesis of Findings 
 
This series of studies was designed to describe normal patterns and 
fluctuations of circulating MCH as a prelude towards exploring the 
physiological relevance of circulating MCH in humans.  To this end it was 
necessary to develop and validate a specific, reliable and sensitive means of 
measuring circulating MCH concentrations since previous work by others has 
failed to realise this objective.  The enhanced sensitivity of the RIA permits 
measurement of minute quantities of product in blood and is commonly used 
for the quantification of hormone and non-hormone proteins, drugs, 
metabolites, viral agents and other substances found in very low 
concentrations. Before exploratory work with human subjects could 
commence the assay had to be satisfactorily validated.  As described in 
Chapter 4 the validation procedure was undertaken to identify optimal 
conditions for the operation of the RIA and potential sources of variation in 
the results.  Once the validation procedure was satisfactorily completed 
sample populations were recruited.  
 
Chapter 5 describes the first study with human subjects although 
concomitantly data was being collected which is presented in Chapter 4.  
During data collection for Chapter 5 all procedures which were subsequently 
used in Chapters 6 and 7 and concomitantly in Chapter 4 were refined and 
standardised.  There were common parameters which were examined in 
Chapters 5, 6 and 7; specifically 1) the association between circulating MCH 
concentrations and body composition parameters; 2) the association 
between circulating MCH and leptin concentrations 3) the association 
between circulating MCH concentrations and RMR.  Although subjects were 
drawn from 3 entirely different populations these factors were relevant to the 
aims of each study.   Additionally in Chapters 5 and 6 the MCH post-prandial 
response to feeding was explored therefore associations between circulating 
MCH, glucose and insulin were examined.  Energy intake in association with 
MCH was examined in Chapters 5 & 7.  This approach was helpful in 
detecting emergent trends or patterns. 
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Once all the data had been reconciled there were both consistencies and 
inconsistences throughout this series of studies.   
 
8.1  Consistent trends: 
 
8.1 1 Circulating MCH  
 
Although there were slight differences in the calculated reference ranges of 
circulating MCH (± 2 SD from mean) between the four groups examined the 
lower and upper limits were 19.4 – 62.38 pg/ml, therefore 95% of all subjects 
tested would be expected to have had circulating MCH concentrations within 
this range although there were 2 subjects with excessively high values.  
There were no differences between male and female circulating MCH 
concentrations in any sample population.  This was in broad agreement with 
the results of the only other study to measure circulating MCH in humans 
who reported a gender difference which lost significance after adjusting for 
certain variables (Gavrila et al., 2005). However although there were no 
gender differences in absolute MCH concentrations there were sexually 
dimorphic patterns of association throughout the studies. 
  
8.1.2  Post-prandial MCH response in association with circulating glucose 
and insulin concentrations 
 
The results of Chapters 5 and 6 are supportive of a post-prandial relationship 
between circulating MCH, glucose and insulin. In the older cohort there was a 
negative relationship between the incremental area under the curve (AUC) 
for insulin and mean circulating MCH concentrations (all individuals).  In 
regression analysis mean circulating MCH concentrations made a significant 
unique contribution to the variance in the insulin AUC.  In the younger cohort 
there was a positive relationship between the respective AUC’s for insulin 
and MCH as well as with the insulin AUC and mean circulating MCH 
concentrations but only in individuals with excess fat.  There was also a 
negative association between the respective AUC’s for glucose and MCH but 
in males only.  As discussed in Chapter 6 there is evidence to suggest that 
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MCH may be active at the level of the endocrine pancreas and may be 
involved in insulin production (Pissios et al., 2007).  The results presented 
here are the first to suggest that circulating MCH may have a role in this 
paradigm in humans. The differential direction of the relationships between 
circulating MCH and insulin between the different cohorts could be the result 
of well regulated or dysregulated glucose metabolism in younger/older 
leaner/fatter individuals.      
 
8.1.3 MCH and RMR 
 
The results of the RMR analyses are in broad agreement across Chapters 5, 
6 and 7 in that there were no robust relationships between circulating MCH 
concentrations and RMR in any of the sample populations.  In rodents 
hypothalamic MCH has the capacity to strongly impact on energy 
expenditure and there are several proposed mechanisms through which it 
may act including modulation of autonomic nervous system activity (Astrand 
et al., 2004; Messina and Overton, 2007) and uncoupling protein expression 
(Ito et al., 2003; Segal-Lieberman et al., 2003).  Hence it was hypothesised 
that this effect would be reflected in the periphery, however no such 
associations were observed except in 2 small cohorts.   In Chapter 5 
circulating MCH concentrations were negatively associated with RMR in 
females with normal but not ≥ 100% predicted RMR and in Chapter 6 the 
same parameters were positively associated in lean males.  However the 
sample sizes were small (n = 8 & 7 respectively) and larger sample sizes are 
required in order to verify or deny whether circulating MCH concentrations 
are aligned to energy expenditure within a specific range of RMR.  In Chapter 
7 there were no associations between RMR and circulating MCH at any of 
the sampling time-points during the menstrual cycle.  Although RMR was 
significantly higher in the luteal phase than in the follicular phase circulating 
MCH did not change significantly over the cycle.  So it would appear that in 
humans any association between energy expenditure and MCH is not readily 
detectable by plasma content.  
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8.1.4  MCH, energy intake and RMR 
 
In the studies reported in Chapters 5 and 7 subjects kept food diaries 
immediately prior to testing (Chapter 5) and during the test period (Chapter 
7). Intervention studies with rodents clearly demonstrate that increased or 
decreased availability of hypothalamic MCH can alter consummatory 
behaviours.  Since to date the best substantiated role for MCH is in energy 
homeostasis it was hypothesised that differences in energy or specific 
macronutrient intake may be reflected in circulating MCH concentrations in 
humans.  However there were no associations between circulating MCH 
concentrations and energy or specific macronutrient intake in either study.  
Nor was there a phasic change in energy intake in the study reported in 
Chapter 7; this is contrary to the results of a sizeable proportion of earlier 
work where a luteal phase increase in energy intake has been reported.  In 
the current study the nutritional tool was the estimated self-reported food 
diary which although has inherent limitations was deemed to be sensitive 
enough to detect trends or patterns.  However in this instance there were 
none.  In free-living humans, consummatory behaviours are far more 
complex than in rodents and the results herein demonstrate that more 
sophisticated techniques would be required in order to pursue this line of 
enquiry.  Energy intake was not aligned to RMR in either study. 
 
8.2 Inconsistencies between studies: 
 
8.2.1  Circulating MCH and leptin concentrations 
 
Throughout this series of studies circulating MCH and leptin concentrations 
have been compared.  In the widely subscribed to lipostatic model of energy 
homeostasis (for review see Woods, 2005), leptin inhibits the anabolic 
pathway through which MCH operates.  There is also evidence that leptin 
and MCH may interact in the periphery; for example the MCH receptor has 
been detected on rodent adipocytes (Bradley and Mansfield, 2002).  Leptin’s 
dual roles in energy homeostasis and the reproductive axis have been well-
researched and are well-defined, and since emerging evidence suggests that 
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MCH has similar dual roles, a common objective of this series of studies was 
to detect any relationships between circulating MCH and leptin in different 
human populations.  There were no consistent significant associations 
between circulating MCH and leptin concentrations in the studies described 
in Chapters 5 and 7.  In Chapter 6 there was an association at two discrete 
sampling time-points, that is fasting and 30 minutes post-prandial.  However 
these associations were only observed in sub-groups of the population.  
Fasting plasma MCH and leptin concentrations were negatively associated in 
males with excess fat only  and 30 minutes post-prandial the association was 
positive in lean males only.  Throughout this series of studies some sexual 
dimorphism has been observed in the MCH response though the question is 
raised as to why this outcome was not observed in males in Chapter 5.  As 
discussed in Chapter 6 some disruption between MCH and leptin signalling in 
the older cohort may be responsible since the observed correlations were in 
the opposite direction between lean individuals and those with excess fat    
Again the sample sizes were small (n=7) and larger scale enquiry is required.   
However there was a trend for circulating MCH and leptin concentrations to 
be inversely correlated which, whilst non-significant was consistent across all 
the studies. 
 
8.2.2 Circulating MCH concentrations and body composition parameters 
 
This element of the enquiry produced significant associations between 
circulating MCH concentrations and body composition parameters in all four 
human studies.  However these associations were between different sub-
groups of the populations and different body composition parameters in each 
study (Table 8.1). 
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Table 8.1  Summary of correlational analysis between circulating MCH 
concentrations and body composition parameters reported in Chapters 
4, 5 6 and 7  
 BMI 
(kg/m2) 
Body 
weight (kg) 
Fat  mass 
(%) 
Lean 
mass (%) 
Fat mass 
(kg) 
Lean mass 
(kg) 
Female 
(EF) 
 
r=-0.368 
p=0.018* 
(n=41) 
 
 
r=-0.360 
p=0.021* 
(n=41) 
 
 
r=-0.733 
p=0.038* 
(n=8) 
 
r=0.733 
p=0.038* 
(n=8) 
 
 
 
 
 
 
Male 
(EF) 
 
r=0.472 
p=0.003** 
(n=38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female 
(L) 
 
r=0.613 
p=0.045* 
(n=11) 
 
 
r=0.602 
p=0.050* 
(n=11) 
 
 
 
 
 
 
 
r=0.608 
p=0.047* 
(n=11) 
 
 
 
Male  
(A) 
 
r=0.230 
p=0.030* 
(n=90) 
r=0.662 
p=0.037* 
(n=11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
r=0.639 
p=0.034* 
(n=11) 
Values represent Pearson-product moment correlations, ** significant at 0.01 level (2 tailed)  
* significant at 0.05 level (2 tailed)    Chapter 4  Chapter 5  Chapter 6  Chapter 7 (late 
follicular phase only) EF: Excess fat; L: Lean; A: All   
Significant results only reported.  
 
The association between circulating MCH concentrations and BMI in four 
sub-groups and also between MCH and body weight in 2 sub-groups is 
somewhat curious since, as discussed in Chapter 4, although superficially 
BMI and body weight may be taken as markers of adiposity, there are 
substantial non-adipose components to both measurements.  However in 
Chapters 5 and 6 there are corroborative associations between MCH and 
lean mass or fat mass (percent or absolute) which indicate circulating MCH 
may be considered a marker of adiposity or leanness in different populations.  
For example in Chapter 6 a positive correlation between mean plasma MCH 
concentrations and BMI, body weight and fat mass weight in females 
designated as lean was observed.  There were no such associations in 
Chapter 5, although mean fat mass percentage, lean mass percentage and 
BMI were almost identical between the females in Chapter 5 and lean 
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females in Chapter 6, the difference in mean age was approximately 20 
years.  In Chapter 5 the associations between circulating MCH 
concentrations and body composition parameters were in males and 
appeared to be indexed to leanness rather than adiposity.  Therefore it would 
seem that MCH activity in the periphery has both age and gender-related 
components.  The two major peripheral adiposity signals; leptin and insulin 
are processed differently in males and females, female brains being more 
sensitive to leptin and male brains being more sensitive to insulin. In terms of 
body fat, leptin correlates better with total body fat in females and insulin 
correlates better with total body fat in males (Clegg et al., 2003, Woods et al., 
2003).  It could be that MCH also displays a sexually dimorphic sensitivity 
which correlates better with lean mass in males or fat mass in females.    
 
8.2.3 Circulating MCH and leptin post-prandial response  
 
In the studies reported in Chapters 5 and 6 subjects consumed identical 
breakfasts (Section 5.2.3).  Blood samples were then collected at 30, 60 and 
120 mins post-prandial.  In Chapter 6 both males and females demonstrated 
a significant increase from baseline in circulating MCH concentrations.  This 
was accompanied by a significant decline in circulating leptin concentrations.  
In Chapter 5 there was a non-significant increase in circulating MCH 
concentrations post-prandial in females though in males there was a non-
significant dip.  In agreement with Chapter 6 circulating leptin concentrations 
declined significantly.  Whether or not the post-ingestive leptin response was 
related to the meal, MCH concentrations or the morning nadir of leptin 
requires qualification.  There were no associations between circulating MCH 
and leptin concentrations at any of the four sampling time-points and the 
respective  AUC’s were not related.  The discrepancy between the MCH 
response to feeding between the two groups may be the result of an 
exaggerated MCH response in the older group which could have become 
apparent in the younger group over a longer time-course.  The final sampling 
time-point was 2 hours post-prandial.  Currently a 24 hour profile for 
circulating MCH has not been established and is a subject which invites 
further enquiry. 
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8.3  Circulating MCH concentrations during the menstrual cycle 
The study reported in Chapter 7 was somewhat distinct from those reported 
in previous chapters since, although common parameters were measured, 
subjects attended the laboratory on four separate occasions and circulating 
MCH concentrations were tracked over the course of one menstrual cycle.  
Comparisons of the common parameters are reported above.  The results of 
this chapter indicate that circulating MCH concentrations remain relatively 
stable over the course of the menstrual cycle though an association between 
circulating MCH concentrations and circulating progesterone concentrations 
in the luteal phase are suggestive of MCH input.  However it must be 
admitted that the data derived from four distinct sampling time-points can be 
limited.  If as is suspected, MCH acts in a subtle manner it may be prone to 
fluctuations that were missed by the time-course of these observations.  
Based on these results it is therefore recommended that future investigation 
should utilise more frequent sampling which is tightly aligned to the 
individual’s menstrual cycle. 
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9.   Conclusion 
 
The results reported herein are the first to examine normal circulating MCH 
concentrations in humans.  An important outcome of this study was the 
demonstration that circulating MCH can be reliably and quantifiably 
measured in humans by means of a relatively inexpensive, simple 
radioimmunoassay. The pharmaceutical industry is currently very interested 
in developing MCHR-1 antagonists not only for obesity pharmacotherapy but 
as a co-therapeutic for anxiety and mood related disorders; however much of 
the evidence supporting the efficacy of MCH antagonism in such paradigms 
is derived from animal models.  Nothing is known about the role of circulating 
MCH in humans hence the quantification of MCH in human plasma will be 
important in assessing the systemic consequences of deletion of functional 
MCH.  Moreover the RIA will be constructive in establishing whether or not 
MCH may be used as a specific biomarker. Reference ranges for circulating 
MCH concentrations have also been established, the upper and lower limits 
across all four groups were 19.4 – 62.4 pg/ml. Although no robust 
physiological effect of MCH was observed some trends have emerged which 
are worthy of further investigation.  First the MCH post-prandial response 
particularly in relation to insulin; current results are supportive of a role for 
circulating MCH in glucose homeostasis in humans, which is in agreement 
with the findings of research with animal models.  Secondly these results  
indicate that circulating MCH concentrations are aligned in some way to body 
composition and further investigation would serve to delineate that 
relationship. Thirdly although no strong associations were observed between 
energy expenditure, energy intake and circulating MCH concentrations, other 
researchers should not be dissuaded from pursuing this line of enquiry since 
it is suspected that there are subtle mechanisms involved which may become 
apparent under further investigation. Overall it would seem that circulating 
MCH concentrations are not overtly reactive but there appears to be some 
differential regulation in the presence of a combination of gender and 
adiposity which is variable depending on the population under examination. 
Since one of the key roles of MCH is in energy homeostasis it would be 
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expected that its expression is in a permanent state of flux and this initial 
characterisation may be used as an index for future investigators. 
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10.  Recommendations for future work 
 
Based on the outcomes of the studies described in this thesis in addition to 
the points raised above, the following recommendations are made: 
1) It is important that a 24 hour profile of circulating MCH is established to 
lend contextual relevance to results such as those reported herein. 
2)  An association was observed between circulating MCH concentrations 
and circulating progesterone concentrations.  It seems likely that 
circulating MCH concentrations may also interact with oestrogen and this 
line of enquiry should be pursued in order to further delineate the 
physiological relevance of MCH in human reproductive function. 
3) Evidence derived from rodent studies indicates that MCH may be        
involved in peripheral lipid metabolism; this subject has never been 
explored in humans and should logically be addressed given its  
emergent role in peripheral glucose homeostasis.  Associations between 
circulating MCH, lipoproteins and triglycerides would serve to further 
understanding of the metabolic repertoire of circulating MCH. 
4) The MCH RIA described herein requires minimal sample  preparation, is 
simple to perform and has the capacity for high through-put.  Its utilisation 
will facilitate further research into the  physiological role of circulating MCH 
by other laboratories. 
5) Future investigators should consider the use of indwelling catheters rather 
than venepuncture for the collection of blood samples.  This would 
increase points of observation and enable a more temporally flexible 
method of data collection. 
6) Finally an interesting new area which would lend itself to this type of 
investigation would be to examine circulating MCH concentrations in 
association with circulating cortisol concentrations since there is an 
accruing body of evidence which implicates MCH in the stress axis which 
is also aligned to nutritional status and reproductive function.
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Please tick relevant box: 
 
 Undergraduate    Postgraduate    PhD Student    Staff  
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Section 2 – to be completed when applicable 
 
Please note that all applicants with a supervisor(s) must ensure that the supervisor signs the 
declaration. All staff must obtain the signature of their Dean of School, or School Research 
Director, as appropriate.  
 
 
 
2.1 Supervisor Details 
 
Name:  Dr Joanne Murray 
 
 
Email:  J.F.Murray@wmin.ac.uk 
School/Department:  Human and Health 
Sciences 
 
Telephone Number: 0207 911 5000 ex 
5366 
 
Declaration: 
 
In accordance with the University’s Code of Practice Governing the Ethical Conduct of 
Investigation, Demonstrations, Research and Experiments, I agree that the applicant named 
in 1.2 above should submit their proposal to the Ethics Committee for consideration. 
 
Signed: 
 
 
Date: 
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Section 3 
 
 
 
3.1 Does your work relate to any of the following areas? Please tick box 
 
 Human Participants in Health and Community settings  
 
 Work with prescription drugs 
 
 Work involving foetal tissue 
 
 Drug Studies on human participants  
 
 Pre-marketing drug trials  
 
3.2 Are you proposing work using participants from any of the following categories? 
Please tick box:  
 
 Prisoners sectioned under the Mental Health Act 
 
 Prisoners or arrestees 
 
 Persons with severe mental illness 
 
 Persons with learning difficulties or brain damage 
 
 Persons with a reduced level of consciousness  
 
3.3 Any work where a qualified clinical person is required to: 
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 Be responsible for all work carried out 
 
 Be in attendance when certain procedures are carried out 
 
 Ensure that facilities for emergency medical care are at hand  
 
If you have ticked one or more boxes in Section 3, please contact your supervisor and 
discuss sending your proposal for external approval. More information can be found at:  
 
www.wmin.ac.uk/page-3380  
 
In addition, please complete this form up to Section 3, sign the declaration in Section 11 and 
send it to:  
 
Carl Hornsey 
Assistant Registrar (Student Information) 
Academic Registrar’s Department 
University of Westminster 
115 New Cavendish Street 
London W1W 6UW 
 
 
If you have not ticked any boxes in Section 3, please continue to Section 4 
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Section 4 
 
 
 
4.1 Is your work related to any of the following areas? Please tick relevant box: 
 
 Any work involving patients 
 
 Non-clinical work involving bodily fluids 
 
 Administering of a non-food substance 
 
 Work with children 
 
 Deception of participants – Possibly Study 3 option (c) 
 
 Data not already in the public domain that bears on the issues of criminality 
 
 Work which requires participants to reveal medical history  
 
If you have ticked one or more boxes in Section 4, your proposal will need approval from 
the University Ethics Committee – please continue to fill out the rest of this form giving as 
much detail as possible.  
 
If you have not ticked any boxes in Section 3 or Section 4, your work does not require 
approval by the University Ethics Committee. Please refer to the University of 
Westminster ‘Code of Practice Governing the Ethical Conduct of Investigations, 
Demonstrations, Research and Experiments’ and consult with your supervisor.  
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Section 5  
 
 
 
5.1 Please provide a brief description of your proposed work below: 
 
MCH is known to have multiple physiological effects including modulation of energy balance, 
reproductive function and more complex behaviours such as stress response, anxiety and 
depression.  Despite this very little is known about circulating MCH in human populations.  
The initial objective of this study will be to determine the pattern of release of circulating 
human MCH.  Depending on the results of the initial characterisation, further studies will 
examine the pattern of circulating MCH in response to interventions such as specific food 
intake, exercise and stress.   
 
Specifically the objectives of the research will be as follows: 
 
Study 1 : To investigate the pattern of circulating MCH throughout the normal 
               menstrual cycle 
Study 2 : To determine whether there is a diurnal rhythm of circulating MCH, to determine 
               whether there is any correlation between circulating MCH concentrations and 
               plasma cortisol, to determine post-prandial effects on circulating MCH   
               concentrations 
Study 3 : To investigate the pattern of circulating MCH concentrations in response to food 
               intake/exercise/stress  
 
 
 
 
 
5.2 What are the specific aims of the work you plan to carry out? 
 
The relationship between reproductive function and nutritional status is well established, 
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though the mechanisms involved are complex and incompletely understood. In particular this 
investigation will examine the dual roles of MCH in the modulation of energy balance and 
reproductive function.  Specifically whether or not circulating concentrations of MCH mediate 
either or both of its food intake/metabolic and reproductive functions and to determine 
whether MCH provides a link between nutritional status and fertility.  Also to explore 
associations between biochemical markers of stress and circulating MCH since stress 
affects both reproductive function and eating behaviours. 
 
MCH is an orexigenic neuropeptide (stimulates eating).  Manipulation of the availability of 
MCH has been shown to decrease food intake, body weight and fat mass and to increase 
energy expenditure. The potentially therapeutic value of MCH antagonists in the treatment of 
human obesity is currently being taken seriously by both the scientific community and the 
pharmaceutical industry.  Clearly there are clinical implications for the treatment of 
under/overnutrition syndromes and related fertility.  The incidence of obesity in many 
Western countries is currently endemic and its many associated afflictions such as Type II 
diabetes, metabolic syndrome, hypertension, heart attack, stroke, some cancers, as well as 
fertility problems impose a huge burden on the community as well as considerable personal 
distress to the individual.   
 
This research aims to further the understanding of the mechanisms which link energy 
balance to reproductive function and how they are integrated and regulated.  An 
understanding of the natural fluctuations of circulating MCH and pattern of expression in 
various peripheral tissues will enhance understanding of how its actions relate to particular 
reproductive and metabolic behaviours and the nutritional management of anovulation.   
 
 
 
 
5.3 Please outline the design and methodology of your work  
 
A series of 3 consecutive studies using different cohorts of volunteers (n.b. some volunteers 
may take part in more than one study), will be performed in which blood samples will be 
collected and assayed for MCH, leptin, glucose, insulin, appropriate reproductive hormones, 
appropriate biochemical markers and possibly other metabolically active molecules.  Prior to 
commencement of the main studies a pilot study will be performed in order to determine inter 
and intra-subject variations of plasma MCH concentrations since (to our knowledge) no such 
data exists.  The reliability and reproducibility of the assay will also be assessed using data 
from the pilot study. 
NOTE 1 :  Written informed consent will be obtained from all participants prior to participation 
(pilot and main studies, copies attached). 
NOTE 2 : All of the studies will be undertaken in the human performance laboratory at the 
University of Westminster.   Since some subjects will be expected to spend several hours in 
the laboratory (maximum 24 hours), every effort will be made to ensure they are relaxed, 
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comfortable and reassured for the duration of their stay. 
NOTE 3 :  Prior to participation in any study volunteers will be required to give a finger prick 
blood sample to screen for anaemia (haematocrit count).  Any subject with a haematocrit 
count outside of the normal range will not be allowed to participate 
Pilot study 
Ten male and ten female volunteers will be recruited by various methods including 
advertisements in local press, radio, family planning clinics, polyclinic and posters.  Female 
subjects will be pre-menopausal, non-oral contraceptive using women aged 18 – 30yrs, body 
mass index (BMI) 19 – 25.   Males will be aged 18 – 30yrs, BMI 19 – 25.  Those on 
medication for chronic illnesses, lactating females, those who have been lactating within the 
last 12 months and pregnant women will be excluded.  Female subjects should have regular 
menstrual cycles of normal length (26 – 30 days).  The study will be undertaken in the 
human performance laboratory at the University of Westminster.  Subjects will be expected 
to attend in the morning after an over-night fast.  On arrival resting energy expenditure will 
be measured via Delta-trac calorimeter. Subjects will be required to wear a ventilated hood 
attached to a metabolic cart (Delta-trac). Some subjects may find wearing the hood slightly 
unsettling at first and a subject-specific period of acclimatisation will be allowed. 
Measurements will then be taken continuously whilst the subject reclines prone for a period 
of one hour.  It is known that MCH affects metabolic energy expenditure based on rodent 
models.  On completion of the energy expenditure measurements an indwelling intravenous 
catheter will be inserted into a forearm vein by a trained phlebotomist.  After a 30 minute 
recovery period, the 1st blood sample will be withdrawn.  A standard controlled meal will then 
be consumed by subjects (mixed macronutrient composition) 15 minutes after 1st blood 
sampling.  Blood plasma will then be sampled at 15 minute intervals over the next 2 hours to 
determine changes in plasma MCH concentrations in response to feeding and to determine if 
there is a relationship between the post-prandial glucose and insulin response and 
circulating MCH concentrations.  Subjects will then be served a standard controlled mid-day 
meal (mixed macronutrient composition). Two further post-prandial samples will be 
withdrawn at 2 hours and 4 hours post-feeding.   The first of these samples will be dispensed 
into 3 vacutainers containing different anti-coagulants to assess the effect of these anti-
coagulants on plasma MCH concentrations. Over the study period the total volume of blood 
drawn is not expected to exceed 250ml. Note : This is a relatively small amount of blood 
compared to 470ml, the amount normally donated to the National Blood Service. Subjects 
will be expected to attend for a total of no more than 9 hours.  During this period fat mass will 
be measured by Air Displacement Plethysmography (ADP).  During this procedure subjects 
sit comfortably in a sealed chamber (Bodpod) for 1 minute, whilst body volume is estimated 
by measuring the amount of air displaced by the subjects body.  Subjects will also complete 
a questionnaire to assess their stress/anxiety levels since there are conflicting reports on the 
effects of MCH administration/MCH receptor antagonists on anxiety/stress in rodents.  
Summary : Aims of Pilot Study as follows : 
1. To validate the MCH assay developed by researchers at University of Westminster 
2. To determine the range of plasma MCH concentrations which will inform how many 
subjects will be required in the main studies 
3. To detect any obvious relationships between MCH and BMI, fat mass, resting 
energy expenditure, plasma cortisol, glucose, insulin concentrations and gender 
Study 1 
Objective :  To investigate the pattern of circulating MCH throughout the normal 
menstrual cycle 
Design : Observational Study 
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Female volunteers will be recruited as above.  Sample size will be calculated using the 
results of the pilot study in conjunction with a standard sampling equation.  
Exclusion/inclusion criteria will be as Pilot Study above.  Subjects will be asked to keep a 
menstrual diary for 3 full cycles prior to attendance at the laboratory, this will include 
recording daily morning resting shell temperature (taken orally). Thermometers to be 
supplied by the University of Westminster.  Subjects will attend a minimum of 3, maximum of 
6 occasions during one full menstrual cycle.  The 1st occasion should be during menses 
(days 1 – 3 menstrual cycle).  At each visit a blood sample will be withdrawn (on arrival 
between 08.00 – 10.00am) from a forearm vein by a trained phlebotomist.  No more than 
15ml will be withdrawn during each visit. Each subsequent visit will be at agreed times 
between subject and researchers according to the individual subject’s self-described 
menstrual cycle.  Ideally each subject will attend (in addition to during menses): at least once 
in late follicular phase, peri-ovulatory stage; once in early to mid-luteal phase; and once in 
late luteal phase.  Blood samples will be assayed for the appropriate hormones and 
metabolically active molecules as above (see below for assay details).  Additionally during 2 
of the visits resting energy expenditure will be measured by Delta-trac metabolic cart as 
above, on these occasions subjects will attend for no longer than  a 2 hour period, on visits 
when blood plasma only is sampled subjects will attend for no longer than a 30 minute 
period. Core temperature will be measured tympanically on each visit before blood sampling.  
Assays : 
1. In-house MCH assay validated by researchers at University of Westminster 
2. In-house steroid assay (radioimmunoassay) 
3. Commercial kits will be obtained to assay for insulin, glucose, cortisol 
(radioimmunoassy or ELISA) 
Study 2 
Objectives :  
• To determine whether there is a diurnal rhythm of circulating MCH 
• To determine whether there is any correlation between circulating MCH levels 
and plasma cortisol 
• To determine post-prandial effects on circulating MCH levels 
Design : Observational Study 
Male and female volunteers will be recruited as above.  Sample size will be calculated as 
Study 1.  Inclusion/exclusion criteria will be as Pilot study and Study 1 above. Male and 
female subjects will be age and BMI matched.  Female subjects will be required to attend on 
Day 2 of their menstrual cycle for a period of 24 hours. Matched male subjects will be 
required to attend on a mutually agreed date with researchers for a period of 24 hours.  
Subjects will be expected to arrive between 08.00am – 10.00am. On arrival an indwelling 
intravenous catheter will be inserted into a forearm vein by a trained phlebotomist.  After a 
30 min recovery period blood plasma sampling will be initiated hourly except for in the 2 hour 
period after meals when sampling will be every 15 minutes.  During the 24 hour period no 
more than 300ml blood plasma will be withdrawn by a trained phlebomist.   Again less than 
the amount normally donated to the National Blood Service (470ml). Subjects will be free to 
move around and will be encouraged to take exercise using on-site exercise equipment in 
the morning or late afternoon within defined time slots.  Exercise intensity should not exceed 
that which would elicit a heart rate of more than 60% age-related maximum. Sleeping will be 
encouraged between 11.00pm and 07.00am and not permitted at other times.  During the 
night the intravenous tubing will be extended beyond a screen so that blood samples can be 
withdrawn with minimum disturbance to the subject.  On awakening resting energy 
expenditure will be measured by Delta-trac metabolic cart as described in Pilot Study.  Over 
the 24 hour period subjects will be served standardised meals at set times.  Eating between 
meals will not be permitted but water may be consumed ad libitum, non-caffeinated drinks 
will also be available at set times.  During the day fat mass will be assessed by Air 
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Displacement Plethysmography (ADP) as Pilot Study. Subjects will be encouraged to keep 
an activity diary during their stay at the laboratory.  They will also complete a stress/anxiety 
questionnaire(s). Blood samples will be assayed for hormones and appropriate metabolically 
active molecules as Study 1 above. 
Study 3 
Objective :  To investigate the circulating MCH levels in response to food 
intake/exercise/stress  
Study Design :  Intervention study 
Male and/or female volunteers (depending on results of Studies 1 and 2) will be recruited as 
above.  Sample size will be calculated as Studies 1 and 2.  Inclusion/exclusion criteria to be 
defined. Male and female subjects will be age and BMI matched.  The study will be 
performed in the human performance laboratory at the University of Westminster and 
subjects may be required to attend the laboratory a number of times.  The study design will 
be somewhat dependent upon results of the Pilot Study and Studies 1 and 2 and in 
conjunction with the in vitro rodent studies which will be running concurrently.  The latter 
studies aim to identify factors regulating the pattern of secretion of MCH.  The human studies 
aim to assess the applicability of these regulatory factors to human populations.  Study 3 will 
be designed to determine the role of yet to be determined variables in the secretion of MCH.  
These variables could include any one of or a combination of the following 1) food 
intake/macronutrient content of food, 2) energy expenditure, 3) stress.  Depending on the 
final study design the following procedures in relation to the variables above may be 
implemented : 
(a)   Food intake/macronutrient content of food : Subjects will attend the laboratory a 
maximum of 3 times, minimum once for (a) 12 hour period(s) and consume 3 equicaloric 
single meals consisting of a) carbohydrate, b) protein and c) lipid at 4 hourly intervals in 
randomised order.  Subjects will be cannulated on arrival as Pilot Study and Study 2, blood 
samples will be withdrawn at 15 minutes intervals for the 1st 2 hours post-feeding, then 
hourly for 2 hours post-feeding. No more than 150ml of blood plasma will be withdrawn over 
the study period. Samples will be assayed for glucose, insulin and other appropriate 
biochemical markers to determine post-prandial plasma MCH response to single meals. 
(b)  Physical exercise :  Subjects will attend the laboratory on no more than 4 occasions for a 
period of no more than 4 hours each visit.  On Visit 1 aerobic fitness will be assessed by the 
Astrand sub-maximal cycle test.  Subjects will be required to review and sign “Informed 
Consent” forms and complete “pre-test Medical Questionnaire” forms (copies attached) prior 
to testing. The Astrand test is a sub-maximal aerobic test of no more than 9 minutes 
duration.  It is performed on a cycle ergometer and subjects’ heart rates are monitored (by 
Polar heart rate monitor) and recorded at 60 second intervals.   The load on the cycle 
ergometer will be manipulated so that the subject reaches a steady state heart rate (no more 
than 10 beats per minute difference between minutes 5 and 6) at not more than 75% age-
predicted maximum heart rate.  An estimation of maximal oxygen consumption (VO2max) 
may then be derived by nomogram.  The subject may feel slightly breathless but healthy 
subjects should feel no discomfort since maximal exertion is not required.  On subsequent 
visits subjects will be cannulated as above and a blood sample (5ml) will be withdrawn from 
a forearm vein by a trained phlebotomist on arrival.  Subjects will then perform physical 
activity on a stationary cycle or treadmill for a period of no longer than 20 minutes.  The 
intensity at which the subject will exercise will be randomised and prescribed by different 
percentages of Heart Rate Reserve (HRR).  This is a method of prescribing exercise 
intensity which corresponds approximately to maximal oxygen consumption (VO2max).  The 
American College of Sports Medicine recommends exercising at intensities ranging from 40 
– 50%HRR to 85%HRR several times per week for the attainment/maintenance of 
cardiorespiratory fitness.  An intensity of 40 – 50% HRR is at the lower end of the range and 
is considered mild to moderate.  Subjects will be randomised to perform 1 bout of exercise 
(either mild, moderate or higher intensity) at each visit within the HRR range above.  Less 
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aerobically fit individuals or those unused to regular exercise will not be expected to exercise 
at higher intensities. After the exercise period a further blood sample will be withdrawn (5ml).  
Subjects will then perform a 5 minute cool down.  Subjects will remain in the laboratory for a 
further 2 hours and 2 further hourly blood samples will be taken.  No more than 40ml blood 
will be withdrawn in total. 
(c)   Stress :  The final study design (sample size, gender, inclusion/exclusion criteria) will be 
partly contingent on results from Studies 1 and 2.  However it is envisaged that subjects will 
attend the laboratory on 2 occasions (S1 Protocol and S2 Protocol)) in the early afternoon at 
least 2 weeks between visits.  Subjects will be instructed not to have consumed food or drink 
(except water) or to have done strenuous exercise for at least one hour prior to their visit to 
the laboratory. S1 Protocol will proceed as follows : On arrival subjects will be fitted with an 
indwelling intravenous catheter as Study 2.  A blood sample will be withdrawn immediately 
after which samples will be withdrawn at intervals of 30 minutes until commencement of the 
stress challenge.  After a 30 minute recovery period subjects will complete (a) stress/anxiety 
questionnaire(s) then be encouraged to relax for one hour. Subjects will then participate in a 
controlled psychosocial stress challenge (modified version of Trier Social Stress Test). This 
test is a widely used standardized laboratory stress protocol which reliably invokes a strong 
cortisol stress response in humans.  During the challenge subjects will be asked to present a 
short oral presentation to 2 researchers on a pre-determined subject. Subjects will be 
informed that their performance (both audio and visual) will be recorded by video camera.  
Subjects will be given a short time to prepare before presentation.  They will also be asked to 
complete a mental arithmetic task.  After the task subjects will be fully debriefed that they in 
fact were not recorded. The duration of the challenge is 65 minutes which includes 10 
minutes relaxation time, 10 minutes preparation time, 10 minutes task performance and 35 
minutes recovery period (debriefed). During the challenge blood will be sampled 
approximately every 10 minutes.  After completion of the challenge subjects will remain in 
the laboratory for a further 2 hours and 2 further hourly blood samples will be taken.  
Subjects are expected to attend the laboratory for a period of not more than 5 hours.  During 
S2  Protocol subjects will cannulated as above and blood sampling initiated immediately, 
then at 30 minute intervals for the next 5 hours.  Subjects will complete the stress/anxiety 
questionnaire(s) as above but will not take part in the stress challenge. The order in which 
subjects undertake either S1 Protocol or S2 Protocol will be randomized thereby subjects will 
act as their own controls (pattern of cortisol release). This will also ensure collection of 
maximum data if subjects fail to return for their second session.  In total no more than 150ml 
of blood will be withdrawn.  Blood samples will be assayed for MCH, cortisol and possibly 
other metabolically active molecules.   
 
 
 
5.4 
 
Start Date:  January 2007 
 
 
Estimated duration of work:  3 years 
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5.5 If your work is a multi-centred study, please provide details of any other 
organisations involved    N/A 
 
Contact Name 
 
 
Contact Name 
 
 
Address 
 
 
Address 
 
 
Telephone Number 
 
 
Telephone Number 
 
 
 
Please provide a copy of any agreement between the organisations  
 
 
 
Section 6 
 
 
 
6.1 Describe any potential physical/emotional discomforts to participants in the 
investigation:  
Where multiple blood samples are to be obtained an indwelling intravenous catheter will be 
placed in a forearm vein by a trained phlebotomist. The level of discomfort will be no more 
than that normally associated with giving a blood sample in a clinical setting i.e. a slight sting 
upon entry of the needle.  It is possible some subjects may experience minor bruising around 
the point of entry.  This method is less likely to cause tissue damage than the withdrawal of 
multiple samples. Where single blood samples are required the sample (no more than 15ml 
on each occasion) will be withdrawn from a forearm vein by a trained phlebotomist. The level 
of discomfort is expected to be transient as per cannulation above.   
Participants may be required to undertake physical activity which may be somewhat  
physically challenging but not expected to cause discomfort to healthy individuals.   
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During the psychosocial stress challenge (Trier Social Stress Test) subjects may experience 
subjective feelings of stress and anxiety in varying degrees during the first part of the 
challenge (approximately 20 minutes).   
 
 
6.2 Aside from 6.1 above, describe potential hazards which may be suffered by the 
participants? Please give details of any measures taken e.g. COSH, Risk Assessment 
etc.   No additional potential hazards envisaged to participants.  Risk assessment will take 
the form of a medical screening questionnaire (copy attached), any contra-indications would 
become evident at this point and the participant would not be allowed to participate. 
 
 
 
 
 
6.3 Outline the degree to which these risks are balanced against potential benefits  
 
N/A – no risks envisaged 
 
 
 
 
 
6.4 What criteria will be employed for deciding the end point at which: 
 
a) the investigation will stop because of unjustifiable further risk? 
b) one method is declared the preferred option and the investigation terminates? 
 
a) No risks envisaged to participants 
b) There will be no comparison of methodologies therefore not relevant 
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6.5 What monitoring mechanisms will be in place to decide when participants should 
be withdrawn from the research? 
 
Subjects will be advised that they are free to terminate participation in the research at any 
time without personal disadvantage.  If any subject complains of feeling unwell during 
participation in the research they will be withdrawn from the study and medical advice 
sought, it is not anticipated that any ill effect would be the consequence of participation in the 
study.  
 
 
 
 
6.6 What procedures and subsequent observations are to be made on participants for 
the purpose of detecting any complication arising from the investigation? 
 
No complications are expected to arise from the taking of blood samples by a trained 
phlebotomist or by healthy subjects performing physical exercise of individually-prescribed 
intensity. 
 
 
 
6.7 Do participants have any previous or existing professional relationship with the 
investigator? 
 
Possibly, students, staff and researchers from the University of Westminster may volunteer 
to participate in the studies 
 
If yes, please explain the circumstances: 
 
 
 
 
Section 7 – Consent of Applicants  
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7.1 What type of consent will you seek? 
 
 Written (including email)  
 
 Verbal only 
 
 Not applicable (please give justification below as to why consent is not applicable)  
 
 
 
 
 
 
7.2 How and where will you make contact with the participant(s) in order to obtain 
consent? 
 
Copies of “Informed Consent Form and Information Sheet” (pilot and main studies, copies 
attached) will be forwarded to participants at least one week prior to date of initial 
participation.  Completed forms will be returned to researchers on the initial day of 
participation  
 
 
 
 
7.3 Is there a subject information sheet? 
 
 Yes (Please enclose a copy with this application)  in addition to the above a separate   
“Subject Information Sheet” is attached for each study 
 No 
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7.4 Is parental consent required? 
 
 Yes 
 
 No 
  
 
 
Section 8 – Confidentiality of Information  
 
 
 
8.1 Will the sharing of information be communicated to others working on the project? 
 
 Yes (Please attach a copy of the Participant Confidentiality Code of Practice which will  
       be used)   Copy attached 
 
 No 
 
 
 
 
 
 
8.2 Will the work include: 
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 Named participants 
 
 Participants whose names have been separately coded 
 
 Unnamed participants 
 
 
 
 
8.3 Where will locked files of investigation material be stored? 
 
All data files will be coded and stored in a locked filing cabinet in a lockable room at the 
University of Westminster  
 
 
 
8.4 If the investigation involves storage of computerised data which might enable the 
participant it be identified, please name the investigator in charge of Computer 
System Security for the investigation? 
 
N/A – a handwritten list of coded names will be kept in the locked filing cabinet as above.  
Each subject will be allocated a code and all samples and data will be identified only by 
code.  A photocopy of the handwritten list will be kept in a locked cabinet in the office of Dr 
Joanne Murray at the University of Westminster, therefore there will be no computerised 
record which may identify participants. 
 
 
 
 
8.5 Does the investigation and any planned publication include the use of 
photographs or videos either of individuals or tissues? 
 
Tissues           Yes      No  
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Individuals       Yes                  No  
 
If yes to either of these, please provide a copy of the consent form which participants will be 
asked to sign for this purpose. 
 
 
 
Section 9 - Finance 
 
 
 
9.1 Will expenses be paid to participants? 
 
 Yes (If yes, how much?)  Travel expenses within Greater London (public transport only) 
 
 No 
 
 
 
9.2 Will a reward over and above expenses be made to participants? 
 
 Yes (If yes, please give more details) 
 
 No 
 
 
 
9.3 Is this study initiated/sponsored by a pharmaceutical or other industrial company? 
 
 Yes (If yes, what is the name of the company?) 
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 No 
 
 
 
9.4 Detail any financial or other direct interest to you or to your department arising 
from this study. 
 
 
N/A 
 
 
9.5 Will this project increase work/cost to any other Department or School? 
 
 Yes (If yes, obtain and include the name and signature of the relevant Dean(s) of  
       School(s) concerned: 
 
Name Signature 
 
 
 
 
 
 
 
 
 No -  The study costs will be covered by the applicants (Jane Naufahu) School of   
Bioscience Scholarship award, University of Westminster 
 
 
 
 160 
 
Section 10 – Insurance  
 
 
 
10.1 Are manufacturers providing insurance cover? 
 
 Yes (If yes, please enclose a letter confirming insurance cover, including the names of 
all  
        covered) 
 
 No  
 
 
 
10.2 Are all of the investigators employees or students of the University of 
Westminster? 
 
 Yes 
 
 No  
 
If no, please provide evidence of insurance cover, including: 
• list of all people involved in the investigation 
• details of the form this cover will take 
 
 
 
10.3 Does the investigation involve the use of equipment or medicines? 
 
 Yes 
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 No 
 
If yes, please give details of manufacturer’s indemnity:   
 
Statement of Cover attached 
 
 
 
 
 
10.4 Does the investigation involve the use of equipment or medicines which are 
manufactured on site but are not covered by insurance? 
 
 Yes 
 
 No 
 
If yes, appropriate insurance cover must be arranged and written confirmation of such cover 
must be attached 
 
 
 
 
 
Section 11 – Declaration – this Section must be completed by all applicants 
 
 
 
Please Read and Sign 
The information I have given on this form is true and to the best of my knowledge 
correct: 
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Signed: 
 
Date: 
 
Send the completed form to: 
 
Carl Hornsey 
Assistant Registrar (Student Information) 
Academic Registrar’s Department 
University of Westminster 
115 New Cavendish Street 
London W1W 6UW 
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Appendix 2  Informed Consent Form Study 1 
INFORMED CONSENT FORM AND INFORMATION SHEET 
 
PILOT STUDY FOR   The project entitled “Investigating the anti-obesogenic effects 
and potential links to fertility of the neuropeptide, melanin-concentrating hormone 
(MCH) ” 
Thank you for showing an interest in this pilot study.  Please read all the information 
carefully.  Think about whether or not you want to take part.  I will contact you again to ask 
about your decision. 
If you decide to take part you will be asked to sign this form. 
You do not have to take part.  If you decide that you do not want to participate, there will be 
no disadvantage to you. 
Melanin-concentrating hormone (MCH) is a recently discovered molecule known to be 
active in the control of eating behaviours, energy expenditure and in reproductive function.  
Recently pharmaceutical companies have become interested in its potential as an anti-obesity 
treatment since manipulation of the availability of MCH has been shown to decrease food 
intake and increase energy expenditure.   MCH also affects many aspects of female 
reproduction and hence fertility status.  It is known that MCH circulates in the human blood 
system but little is known about what regulates its activities.  
The main aim of the pilot study is to derive data which will inform the normal range of blood 
concentrations of the hormone, melanin-concentrating hormone (MCH) in healthy men and 
women in order to design further studies.   
If you agree to take part you will be required to attend the human performance laboratory at 
the University of Westminster. You will arrive at an agreed time in the morning and will stay 
for a period of approximately 4 hours. Your stay will involve the following procedures: 
 
• On arrival your resting energy expenditure will be measured.  This involves relaxing 
on a bed for about 40 minutes wearing a ventilated hood whilst measurements are 
taken, you will not feel any physical discomfort from this procedure. 
 
• Four blood samples (2 from each arm) will be taken by a trained phlebotomist at 
intervals during the morning.  No more than 50ml of blood will be withdrawn in 
total.  (Note: this is a relatively small amount of blood compared to 470ml normally 
withdrawn during blood donation).  You may also be required to give some finger-
prick blood samples (one or two drops of blood per sample). 
 
• You will be served one meal of mixed macronutrient composition after energy 
expenditure has been taken in the morning. 
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• Your total body fat and lean mass will be measured via “Bodpod”.  During this 
procedure you sit comfortably in a chamber for one minute. 
 
• You will complete a stress/anxiety questionnaire to assess your stress levels. 
 
Risks and discomfort 
The risks to yourself are minimal. You will be required to give blood samples a number of 
times over the morning as indicated above. A trained phlebotomist will take all samples.  
You may experience a slight stinging sensation exactly like giving a regular blood sample in 
a clinical setting, after that you should feel no further discomfort.  Some volunteers may also 
experience minor bruising around the point of entry.  A momentary pricking sensation may 
be experienced when the finger-prick samples are taken.  
Safety 
You will complete a medical questionnaire prior to taking part to identify any health related 
reasons why you may not participate.  You will be informed if you are deemed unsuitable to 
participate.  Blood samples will be taken only by a trained phlebotomist. 
 
Injury 
In the unlikely event you are injured during the testing and have questions about your 
treatment you should contact Jane Naufahu, who will be present and who will liaise with the 
appropriate medical service. 
 
Benefits 
 
Your resting energy expenditure will be measured and your basal metabolic rate (BMR) will 
be calculated.  BMR indicates how many calories your body requires per day for basic 
functioning of your vital organs. This is useful if you are interested in maintaining a healthy 
body weight. Additionally your total body fat and lean mass will be accurately measured and 
categorised.  
 
Your stress hormone levels will be measured and you may be asked to complete a 
stress/anxiety questionnaire, results of these tests are useful for anyone interested in 
identifying personal stress levels.  Note: results of these tests are not intended to 
identify/evaluate specific life stressors such as jobs or relationships.   
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You can change your mind and decide not to take part at any time.  If you decide to stop, you 
do not have to give any reasons for your decision, and you will be placed at no disadvantage 
whatsoever. 
What information will be collected, how it will be used 
Your age, height, weight, fat mass and resting energy expenditure will be recorded. Blood 
concentrations of MCH, glucose, insulin, cortisol, reproductive hormones and possibly other 
biochemical markers and metabolically active molecules will established.  All or any 
combination of these can be detected in a single blood sample, it is not necessary to take 
separate blood samples.  The reason for taking multiple samples will be to look for changes 
in blood levels of these metabolically active molecules over time or in response to an 
intervention such as eating a meal.  
The results will be stored in a locked container and accessed only by researchers involved in 
the study.  All samples and data files will be coded and participants will not be identifiable.  
The results of the final project may be published, but the information will not be linked to 
any specific person.  A copy of your results (excluding blood parameters) will be given to 
you if you ask for them.  Please note your blood will only be screened for hormones, 
biochemical markers and metabolically active molecules as above.  It will not be screened 
for clinical disease or medical conditions. 
You can ask questions about the pilot study at any time.  Please contact Jane Naufahu at the 
testing session or telephone 0207 911 5000 ext 2830, e:mail jane@cavresearch.org 
Statement by subject: 
• I have volunteered to take part in this project 
• I know I can stop taking part an any time without being disadvantaged 
• I am satisfied that the results will be stored securely 
• I know that the results of the main project may be published 
• I am aware of any possible risks and discomfort 
• I agree to inform the researcher immediately if I am in pain, or if I feel 
uncomfortable 
• I have had the chance to ask questions 
• I know that I will not receive any money for taking part 
 
I have read this form and I understand it.  I agree to take part in the pilot study for the project 
titled “Investigating the anti-obesogenic effects and potential links to fertility of the 
neuropeptide, melanin-concentrating hormone (MCH)” 
Signed (Subject) :      Date : 
 
 
Signed (Witness) :     Date : 
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Appendix 3  Subject Information Sheet Study 1 
SUBJECT INFORMATION SHEET 
Study 1 
How do I prepare for the visit to the laboratory? 
 
Location 
All research will be conducted in the Human Performance Laboratory (4th 
floor), University of Westminster, 115 New Cavendish Street, London W1W 
6UW   
 
What to bring 
• Signed Informed Consent Form 
• Food diary 
• Swimwear 
• Something to occupy you during short rest periods e.g. reading 
material, ipod, laptop 
 
General Preparation 
You will be required to keep a food diary for three days prior to the visit.  This 
will be emailed to you and you simply fill in what you eat and how much of it. 
You will also be required to complete an initial medical screening 
questionnaire.   
In the laboratory 
You will be expected to arrive in the laboratory in the morning having eaten 
or drunk nothing since the night before and will spend approximately 4 hours 
in the laboratory.  On arrival your resting energy expenditure will be 
measured. This involves relaxing on a bed for about 40 minutes wearing a 
ventilated hood whilst measurements are taken, you will not feel any physical 
discomfort from this procedure.    
Afterwards a blood sample will be taken from a forearm vein by a trained 
phlebotomist, this is the same procedure as giving a regular blood sample in 
a clinical setting. You may feel a slight sting as the sample is taken.  Some 
volunteers may experience minor bruising around the point of entry.  
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You will be served a breakfast of mixed macronutrient content in the morning 
after your resting energy expenditure has been measured. Although the meal 
will be of controlled content your personal preferences will be taken into 
account. 
 
After breakfast 3 more blood samples will be taken over the next 2 hours. 
Therefore a total of 4 blood samples (2 from each arm) will be taken over the 
course of the morning.  No more than 50ml of blood will be withdrawn in total, 
this is a comparatively small amount compared 470ml of blood which is 
normal given when donating blood and is easily tolerated by healthy people.  
In addition we will take some small finger-prick blood samples, this involves 
one or two drops of blood being withdrawn from a fingertip, again you may 
feel a slight sting as the sample is taken.  
 
Your total body fat and lean mass will be also be measured by a procedure 
where you sit in a chamber for 2 – 3 minutes.  During this procedure you 
should wear swimwear or underwear.  This procedure measures the amount 
of air displaced by your body in the chamber and is quite comfortable.   
 
You will also complete a stress/anxiety questionnaire to assess your stress 
levels. 
Thank you for your co-operation, by agreeing to take part you will help to 
inform the normal range of blood concentrations of melanin-concentrating 
hormone (MCH) in healthy men and women.  This is important since (to our 
knowledge) no such data exists and it is essential that researchers are 
equipped with such knowledge in order to design further studies.   Currently 
very little is known about circulating MCH in humans though MCH is known 
to affect food intake, energy expenditure and reproductive function.  The 
results of the pilot study will help researchers design experiments which will 
examine whether or not circulating concentrations of MCH mediate its 
multiple functions and whether MCH provides a link between nutritional 
status and fertility.    
 
Also you will get an accurate assessment of your basal metabolic rate 
(minimum number of calories you need per day for basic functioning of your 
vital organs), This is useful if you are interested in maintaining a healthy body 
weight. Additionally your total body fat and lean mass will be accurately 
measured and categorised.  You will also receive the results of your stress 
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questionnaire which is useful for anyone interested in identifying personal 
stress levels. 
 
 
Thank you once again for your interest, if you would like to be involved 
please email jane@cavresearch.org to arrange a mutually convenient date 
for the testing. 
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Appendix 4  Medical Screening Questionnaire 
MEDICAL SCREENING QUESTIONNAIRE 
 
The information obtained in this form will be kept as CONFIDENTIAL. Only the researchers 
related to the above named project may have access to the information. 
 
All sections are to be completed by the participant. 
 
 
 
Participant’s Surname (Miss/ Ms/ Mrs): __________________________________________ 
 
First name:___________________________________________ 
 
Date of Birth: _______________________________ 
 
Address: _____________________________________________________ 
 
 ________________________________________________________ 
 
 ________________________________________Postcode:_________________ 
 
Contact Tel. No:_________________________ (Home)  
 
  ________________________(Office) 
 
Mobile No: ____________________________ 
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Medical History 
 
Have you suffered any of the following conditions at any time?  
(Please tick the appropriate column. If ‘Yes’ please give some details.) 
 
 No Yes Details 
Rheumatic or scarlet 
fever 
   
Heart trouble or murmur    
Heart Palpitations    
High Blood Pressure    
Heart Attack    
Chest pain/Angina    
Stroke    
Disease of arteries or 
veins 
   
Haemophilia    
Fainting or blackout    
Epilepsy    
Lung or bronchial 
disease 
   
Asthma    
Hay fever    
Anaemia    
Diabetes    
Thyroid Disease    
Any other medical 
conditions not mentioned 
above 
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Having normal or regular 
periods 
   
Currently pregnant or 
breast feeding 
   
 
 
Current Medication  
 
State the name and dosage of any drugs or medicines including ORAL CONTRACEPTIVES 
that you are taking regularly. 
 
Drug/ Oral 
contraceptives Dose Time of last dose 
   
   
   
   
 
 
Signed : ______________________________________________ 
 
Name : ______________________________________________ 
 
Date: ______________________________________________ 
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Appendix 5  Food Diary 
 
3-DAY FOOD DIARY 
 
Dear Participant, 
The purpose of the food diary is to find your average daily calorie intake and the 
percentage of calories obtained from protein carbohydrate and fat.  
 
Directions for Using the Food Diary 
1. Do not specifically alter your diet during the period you keep this diary. 
2. Keep your food diary current. List foods immediately after they are eaten. 
Please print all entries. 
3. Record only one food item per line on the record sheet 
4. Record amounts in household measures, e.g. ounces, tablespoons, cups, slices 
or units, as in one cup non-fat milk, two slices of wheat toast, or one raw apple 
5. Include the method that was used to prepare the food item, e.g. fresh, frozen, 
stewed, fried, baked, canned, broiled, raw, or braised, also any oils or fats used 
in preparation. 
6. For canned foods, include the liquid in which it was canned, e.g. sliced peaches 
in heavy syrup, fruit cocktail in light syrup, or tuna in water. 
7. Remember to record the amounts of visible fats (oils, butter, salad dressings, 
margarine, etc) you eat or use in cooking. 
8. Remember to record drinks and indicate whether diet or non-diet version. 
 
9. It would be useful if you could also keep the labels or cut out the ingredients 
listed on any packaging to give in with the food diary. 
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Name:  
 
Day 1: Date:  
 
Time 
 
Food Item and Method of Preparation Amount Eaten 
Breakfast   
   
   
   
   
   
   
   
   
Mid Morning   
   
   
   
   
Lunch   
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Tea   
   
   
   
Evening Meal   
   
   
   
   
   
   
   
   
Evening Snack   
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Name:  
 
Day 2: Date:  
 
Time 
 
Food Item and Method of Preparation Amount Eaten 
Breakfast   
   
   
   
   
   
   
   
   
Mid Morning   
   
   
   
   
Lunch   
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Tea   
   
   
   
Evening Meal   
   
   
   
   
   
   
   
   
Evening Snack   
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Name:  
 
Day 3: Date:  
 
Time 
 
Food Item and Method of Preparation Amount Eaten 
Breakfast   
   
   
   
   
   
   
   
   
Mid Morning   
   
   
   
   
Lunch   
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Tea   
   
   
   
Evening Meal   
   
   
   
   
   
   
   
   
Evening Snack   
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Appendix 6  Subject Information Sheet Study 2 
SUBJECT INFORMATION SHEET 
Study 2 
How do I prepare for the visit to the laboratory? 
 
Location 
All research will be conducted in the Human Performance Laboratory (4th 
floor), University of Westminster, 115 New Cavendish Street, London W1W 
6UW   
 
What to bring 
• Signed Informed Consent Form 
• Food diary 
• Something to occupy you during short rest periods e.g. reading 
material, ipod, laptop 
 
General Preparation 
You will be required to keep a food diary for three days prior to the visit.  This 
will be emailed to you and you simply fill in what you eat and how much of it.  
You will also be required to complete an initial medical screening 
questionnaire.  Anyone whose medical screening questionnaire results 
indicate that they should not be involved will not be allowed to participate in 
the main study.   
 
In the laboratory 
You will be expected to arrive in the laboratory in the morning having eaten 
or drunk nothing except water before you arrive that morning and will spend 
approximately 4 hours in the laboratory.  On arrival your resting energy 
expenditure will be measured. This involves relaxing on a bed for about 40 
minutes wearing a ventilated hood whilst measurements are taken, you will 
not feel any physical discomfort from this procedure.    
 
Afterwards a blood sample will be taken from a forearm vein by a trained 
phlebotomist, this is the same procedure as giving a regular blood sample in 
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a clinical setting. You may feel a slight sting as the sample is taken.  Some 
volunteers may experience minor bruising around the point of entry.  
 
You will be served a breakfast of mixed macronutrient content in the morning 
after your resting energy expenditure has been measured.  Although the 
meal will be of controlled content your personal preferences will be taken into 
account. 
 
After breakfast we will ask you for 3 more blood samples spaced out over 2 
hours. Therefore a total of 4 blood samples (2 from each arm) will be taken 
over the course of the morning.  No more than 50ml of blood will be 
withdrawn in total, this is a comparatively small amount compared to 470ml 
of blood which is normal given when donating blood and is easily tolerated by 
healthy people.  In addition we will ask you for some small finger-prick blood 
samples, this involves one or two drops of blood being withdrawn from a 
fingertip, again you may feel a slight sting as the sample is taken.  
 
Your total body fat and lean mass will be also be measured by a procedure 
where you sit in a chamber for 2 – 3 minutes.  During this procedure you 
should wear swimwear or underwear.  This procedure measures the amount 
of air displaced by your body in the chamber and is quite comfortable.   
 
You will also complete some stress/anxiety questionnaires to assess your 
stress levels. 
 
Thank you for your co-operation, by agreeing to take part you will help to 
inform the normal range of blood concentrations of melanin-concentrating 
hormone (MCH) in men and women.  Currently very little is known about 
circulating MCH in humans though MCH is known to affect food intake, 
energy expenditure and reproductive function.  The results of this study will 
help researchers determine whether or not circulating concentrations of MCH 
mediate its multiple functions and particularly the role of MCH in energy 
balance, nutritional status and blood glucose levels   
 
Also you will get an accurate assessment of your basal metabolic rate 
(minimum number of calories you need per day for basic functioning of your 
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vital organs), This is useful if you are interested in maintaining a healthy body 
weight. Additionally your total body fat and lean mass will be accurately 
measured and categorised.  You will also receive the results of your stress 
questionnaire which is useful for anyone interested in identifying personal 
stress levels. 
 
Thank you once again for your interest, if you would like to be involved 
please email jane@cavresearch.org to arrange a mutually convenient date 
for the testing. 
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Appendix 7  Informed Conent Form Study 2 
 
INFORMED CONSENT FORM AND INFORMATION SHEET 
 
FOR   The project entitled “Investigating the anti-obesogenic effects and 
potential links to fertility of the neuropeptide, melanin-concentrating hormone 
(MCH) ” 
Thank you for showing an interest in this study.  Please read all the information 
carefully.  Think about whether or not you want to take part.  I will contact you again 
to ask about your decision. 
If you decide to take part you will be asked to sign this form. 
You do not have to take part.  If you decide that you do not want to participate, there 
will be no disadvantage to you. 
Melanin-concentrating hormone (MCH) is a recently discovered molecule known to 
be active in the control of eating behaviours, energy expenditure and in reproductive 
function.  Recently pharmaceutical companies have become interested in its potential 
as an anti-obesity treatment since manipulation of the availability of MCH has been 
shown to decrease food intake and increase energy expenditure.   MCH also affects 
many aspects of female reproduction and hence fertility status.  It is known that 
MCH circulates in the human blood system but little is known about what regulates 
its activities.  
The main aim of this study is to derive data which will inform the normal range of 
blood concentrations of the hormone, melanin-concentrating hormone (MCH) in men 
and women over the age of 40 particularly with regard to its correlation with blood 
glucose levels.   
If you agree to take part you will be required to attend the human performance 
laboratory at the University of Westminster. You will arrive at an agreed time in the 
morning and will stay for a period of approximately 4 hours. Your stay will involve 
the following procedures: 
 
• On arrival your resting energy expenditure will be measured.  This involves 
relaxing on a bed for about 40 minutes wearing a ventilated hood whilst 
measurements are taken, you will not feel any physical discomfort from this 
procedure. 
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• Four blood samples (2 from each arm) will be taken by a trained phlebotomist 
at intervals during the morning.  No more than 50ml of blood will be 
withdrawn in total.  (Note: this is a relatively small amount of blood 
compared to 470ml normally withdrawn during blood donation).  You will 
also be required to give some finger-prick blood samples (one or two drops of 
blood per sample). 
 
• You will be served one meal of mixed macronutrient composition after 
energy expenditure has been taken in the morning. 
 
• Your total body fat and lean mass will be measured via “Bodpod”.  During 
this procedure you sit comfortably in a chamber for about two minutes. 
 
• You will complete a stress/anxiety questionnaire to assess your stress levels. 
 
Risks and discomfort 
The risks to yourself are minimal. You will be required to give blood samples a 
number of times over the morning as indicated above. A trained phlebotomist will 
take all samples.  You may experience a slight stinging sensation exactly like giving 
a regular blood sample in a clinical setting, after that you should feel no further 
discomfort.  Some volunteers may also experience minor bruising around the point of 
entry.  A momentary pricking sensation may be experienced when the finger-prick 
samples are taken.  
Safety 
You will complete a medical questionnaire prior to taking part to identify any health 
related reasons why you may not participate.  You will be informed if you are 
deemed unsuitable to participate.  Blood samples will be taken only by a trained 
phlebotomist. 
Injury 
In the unlikely event you are injured during the testing and have questions about your 
treatment you should contact Jane Naufahu, who will be present and who will liaise 
with the appropriate medical service. 
Benefits 
Your resting energy expenditure will be measured and your basal metabolic rate 
(BMR) will be calculated.  BMR indicates how many calories your body requires per 
day for basic functioning of your vital organs. This is useful if you are interested in 
maintaining a healthy body weight. Additionally your total body fat and lean mass 
will be accurately measured and categorised.  
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Your stress hormone levels will be measured and you may be asked to complete a 
stress/anxiety questionnaire, results of these tests are useful for anyone interested in 
identifying personal stress levels.  Note: results of these tests are not intended to 
identify/evaluate specific life stressors such as jobs or relationships.   
You can change your mind and decide not to take part at any time.  If you decide to 
stop, you do not have to give any reasons for your decision, and you will be placed at 
no disadvantage whatsoever. 
What information will be collected, how it will be used 
Your age, height, weight, fat mass and resting energy expenditure will be recorded. 
Blood concentrations of MCH, glucose, insulin, cortisol, reproductive hormones and 
possibly other biochemical markers and metabolically active molecules will be 
established.  All or any combination of these can be detected in a single blood 
sample, it is not necessary to take separate blood samples.  The reason for taking 
multiple samples will be to look for changes in blood levels of these metabolically 
active molecules over time or in response to an intervention such as eating a meal.  
 
The results will be stored in a locked container and accessed only by researchers 
involved in the study.  All samples and data files will be coded and participants will 
not be identifiable.  
 
The results of the final project may be published, but the information will not be 
linked to any specific person.  A copy of your results (excluding blood parameters) 
will be given to you.  Please note your blood will only be screened for hormones, 
biochemical markers and metabolically active molecules as above.  It will not be 
screened for clinical disease or medical conditions. 
 
You can ask questions about the pilot study at any time.  Please contact Jane 
Naufahu at the testing session or e:mail jane@cavresearch.org 
 
Statement by subject: 
 
• I have volunteered to take part in this project 
• I know I can stop taking part an any time without being disadvantaged 
• I am satisfied that the results will be stored securely 
 185 
 
• I know that the results of the main project may be published 
• I am aware of any possible risks and discomfort 
• I agree to inform the researcher immediately if I am in pain, or if I feel 
uncomfortable 
• I have had the chance to ask questions 
• I know that I will not receive any money for taking part 
 
I have read this form and I understand it.  I agree to take part in this study for the 
project titled “Investigating the anti-obesogenic effects and potential links to 
fertility of the neuropeptide, melanin-concentrating hormone (MCH)” 
 
Signed (Subject) :      Date : 
 
 
Signed (Witness) :     Date : 
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Appendix 8  Subject Information Sheet Study 3 
SUBJECT INFORMATION SHEET 
Study 3 
How do I prepare for the visits to the laboratory? 
 
Location 
All research will be conducted in the Human Performance Laboratory (4th 
floor), University of Westminster, 115 New Cavendish Street, London W1W 
6UW   
 
What to bring 
• Signed Informed Consent Form 
• Food diaries 
• Swim suit or close fitting underwear 
 
General Preparation  
You will be required to take your temperature at the same time every morning 
and record it on a record sheet provided for a 1 – 3 weeks depending on 
where you are in your cycle. 
You will also be required to keep two 3 day food diaries (each diary 2 
weekdays and one weekend day).  These will be provided and you simply fill 
in what you eat and how much of it.  You will also be required to complete an 
initial medical screening questionnaire.  Anyone whose medical screening 
questionnaire results indicate that they should not be involved will not be 
allowed to participate in the main study.  
Four dates will be booked for you to come in to the laboratory at around 
09.00 am each visit. The first visit will be during the early follicular phase, the 
second will be 2/3 days before the expected day of ovulation, the third will be 
2/3 days after ovulation and the fourth and final visit will be during the late 
luteal phase of your monthly cycle.  You should also carry on keeping your 
temperature diary during this month. 
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In the laboratory 
 
You should arrive in the laboratory in the morning having eaten or drunk 
nothing except water before you arrive that morning and will spend 
approximately 1 hour in the laboratory.  On arrival your resting energy 
expenditure will be measured. This involves relaxing on a bed for about 40 
minutes wearing a ventilated hood whilst measurements are taken, you will 
not feel any physical discomfort from this procedure.    
 
Your total body fat and lean mass will be also be measured by a very 
accurate procedure where you sit in a chamber for 2 – 3 minutes.  During this 
procedure you should wear swimwear or underwear.  This procedure 
measures the amount of air displaced by your body in the chamber and is 
quite comfortable.   
 
Afterwards a small blood sample will be taken from a forearm vein by a 
trained phlebotomist, this is the same procedure as giving a regular blood 
sample in a clinical setting. You may feel a slight sting as the sample is 
taken.  Some volunteers may experience minor bruising around the point of 
entry.  No more than 10ml of blood will be taken (about 2 tsps).  
 
We will also provide a light breakfast after your measurements have been 
taken.  
 
Also you will get an accurate assessment of your basal metabolic rate 
(minimum number of calories you need per day for basic functioning of your 
vital organs), This is useful if you are interested in maintaining a healthy body 
weight. Additionally your total body fat and lean mass will be accurately 
measured and categorised.  Your body mass index and waist/hip ratio will 
also be calculated. 
 
Thank you for your co-operation, by agreeing to take part you will help to 
inform the normal range of blood concentrations of melanin-concentrating 
hormone (MCH) in women at different stages of their menstrual cycle.  
Currently very little is known about circulating MCH in humans though MCH 
is known to affect food intake, energy expenditure and reproductive function.  
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The results of this study will help researchers determine whether or not there 
is any association between circulating MCH concentrations throughout the 
menstrual cycle, body fat mass and metabolic rate and hence whether MCH 
plays a role in the integration of energy balance with the reproductive axis. 
 
All data obtained will be confidential. 
 
Thank you once again for your interest, if you would like to be involved 
please email jane@cavresearch.org to arrange a mutually convenient date 
you to collect your thermometer, food diaries and other relevant information. 
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Appendix 9  Informed Consent Form Study 3 
INFORMED CONSENT FORM AND INFORMATION SHEET 
STUDY FOR   The project entitled “Investigating the anti-obesogenic effects 
and potential links to fertility of the neuropeptide, melanin-concentrating 
hormone (MCH) ” 
Thank you for showing an interest in this study.  Please read all the information 
carefully.  Think about whether or not you want to take part.  I will contact you again 
to ask about your decision. 
If you decide to take part you will be asked to sign this form. 
You do not have to take part.  If you decide that you do not want to participate, there 
will be no disadvantage to you. 
Melanin-concentrating hormone (MCH) is a recently discovered molecule known to 
be active in the control of eating behaviours, energy expenditure and in reproductive 
function.  Recently pharmaceutical companies have become interested in its potential 
as an anti-obesity treatment since manipulation of the availability of MCH has been 
shown to decrease food intake and increase energy expenditure.   MCH also affects 
many aspects of female reproduction and hence fertility status.  It is known that 
MCH circulates in the human blood system but little is known about what regulates 
its activities.  
The main aim of the study is to derive data which will inform the normal range of 
blood concentrations of the hormone, melanin-concentrating hormone (MCH) in 
healthy women throughout their menstrual cycle.   
If you agree to take part you will be required to attend the human performance 
laboratory at the University of Westminster. You will arrive at an agreed time in the 
morning and will stay for a period of approximately 1 hour 4 times during your 
menstrual cycle. Your stay will involve the following procedures: 
• On arrival your resting energy expenditure will be measured.  This involves 
relaxing on a bed for about 40 minutes wearing a ventilated hood whilst 
measurements are taken, you will not feel any physical discomfort from this 
procedure. 
 
• A blood sample will be taken by a trained phlebotomist.  No more than 10ml 
(about 2tsp) of blood will be withdrawn each visit.   
 
• Your total body fat and lean mass will be measured via “Bodpod”.  During 
this procedure you sit comfortably in a chamber for one minute. 
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Risks and discomfort 
The risks to yourself are minimal. You will be required to give a blood sample on 
each visit as indicated above. A trained phlebotomist will take all samples.  You may 
experience a slight stinging sensation exactly like giving a regular blood sample in a 
clinical setting, after that you should feel no further discomfort.  Some volunteers 
may also experience minor bruising around the point of entry.   
 
Safety 
You will complete a medical questionnaire prior to taking part to identify any health 
related reasons why you may not participate.  You will be informed if you are 
deemed unsuitable to participate.  Blood samples will be taken only by a trained 
phlebotomist. 
Injury 
In the unlikely event you are injured during the testing and have questions about your 
treatment you should contact Jane Naufahu, who will be present and who will liaise 
with the appropriate medical service. 
Benefits 
Your resting energy expenditure will be measured and your basal metabolic rate 
(BMR) will be calculated.  BMR indicates how many calories your body requires per 
day for basic functioning of your vital organs. This is useful if you are interested in 
maintaining a healthy body weight. Additionally your total body fat and lean mass 
will be accurately measured and categorised.  
 
You can change your mind and decide not to take part at any time.  If you decide to 
stop, you do not have to give any reasons for your decision, and you will be placed at 
no disadvantage whatsoever. 
What information will be collected, how it will be used 
Your age, height, weight, fat mass and resting energy expenditure will be recorded. 
Blood concentrations of MCH, insulin, cortisol, reproductive hormones and possibly 
other biochemical markers and metabolically active molecules will established.  All 
or any combination of these can be detected in a single blood sample, it is not 
necessary to take separate blood samples.    
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The results will be stored in a locked container and accessed only by researchers 
involved in the study.  All samples and data files will be coded and participants will 
not be identifiable.  
The results of the final project may be published, but the information will not be 
linked to any specific person.  A copy of your results (excluding blood parameters) 
will be given to you if you ask for them.  Please note your blood will only be 
screened for hormones, biochemical markers and metabolically active molecules as 
above.  It will not be screened for clinical disease or medical conditions. 
You can ask questions about the study at any time.  Please contact Jane Naufahu at 
the testing session or e:mail jane@cavresearch.org 
Statement by subject: 
 
• I have volunteered to take part in this project 
• I know I can stop taking part an any time without being disadvantaged 
• I am satisfied that the results will be stored securely 
• I know that the results of the main project may be published 
• I am aware of any possible risks and discomfort 
• I agree to inform the researcher immediately if I am in pain, or if I feel 
uncomfortable 
• I have had the chance to ask questions 
• I know that I will not receive any money for taking part 
 
I have read this form and I understand it.  I agree to take part in the pilot study for the 
project titled “Investigating the anti-obesogenic effects and potential links to 
fertility of the neuropeptide, melanin-concentrating hormone (MCH)” 
 
Signed (Subject) :      Date : 
 
 
Signed (Witness) :     Date : 
 
 
 
 
